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Abstract
The incidence of venous and arterial thromboembolic events (VTEs/ATEs) varies greatly
by cancer type and age, with increased risk in the elderly. Very little research has been
reported specific to elderly kidney cancer patients. Retrospective cohort analyses of
Medicare patients, 11,463 with and 11,463 without kidney cancer, between 2003 and
2010 were conducted to compare incidence rates of VTEs/ATEs in cancer patients with
matched noncancer patients and to assess independent risk factors for VTEs in cancer
patients. The advanced epidemiology triangle was the theoretical framework used to
interpret the association between incident events and other factors. Using Cox
proportional hazard regression, the first 2 research questions examined whether the
incidence rates of VTEs/ATEs were higher in kidney cancer patients than noncancer
patients; the third research question assessed which factors were associated with VTEs
after kidney cancer diagnosis. In the year prior to index date, cancer patients had higher
incidence rates of VTEs than noncancer patients; the incidence rate of myocardial
infarction was higher in cancer patients than noncancer patients for patients with a history
of cardiovascular disease. Elderly kidney cancer patients with transitional cell tumors had
lower rates of pulmonary embolism and ischemic stroke compared to patients with clear
cell tumors. Recent history of VTE and Charlson comorbidity score were strong
predictors of VTE after cancer diagnosis. These results can lead to positive social change
by helping healthcare providers to determine who may benefit from closer observation or
prophylaxis to prevent or minimize morbidity from these thromboembolic events, thus
improving health and quality of life for elderly kidney cancer patients.
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Chapter 1: Introduction to the Study
Introduction
Cancer patients are at increased risk of thromboembolic events, a group of serious
conditions caused by a blockage of a vein or artery by a blood clot (Blom, Doggen,
Osanto, & Rosendaal, 2005; Sallah, Wan, & Nguyen, 2002; Walker, Card, West, Crooks,
& Grainge, 2013; White et al., 2005). Venous thromboembolic events (VTEs) and arterial
thromboembolic events (ATEs) in cancer patients can cause serious complications and
reduce survival (Agnelli et al., 2006; Chew, Wun, Harvey, Zhou, & White, 2006;
Sørensen, Mellemkjaer, Olsen, & Baron, 2000; Svoboda, Poprach, Dobes, Kiss, &
Vyzula, 2012; Yeh & Bickford, 2009; Zhang et al., 2007). Cancer cells and tumors
increase the risk for thromboembolic events through effects on blood vessels and blood
flow, tissue necrosis, and cellular changes which promote clotting (Kuderer, Ortel, &
Francis, 2009; Previtali, Bucciarelli, Passamonti, & Martinelli, 2011). Cancer-directed
surgery also increases the risk of thromboembolic events, however the risk appears to
vary by surgery type and the risk may be decreased through prophylactic therapy (Agnelli
et al., 2006; Blom et al., 2006; Hall et al., 2009; Khorana et al., 2008; National
Comprehensive Cancer Network [NCCN], 2015; Previtali et al., 2011; Sallah, Wan, &
Nguyen, 2002). Surgery increases the risk for thromboembolic events through increased
tissue factor expression and increased coagulation from immobilization and inactivity
(Previtali et al., 2011). Chemotherapy and targeted therapies increase the risk for
thromboembolic events by increasing tissue factor expression and reducing natural
anticoagulant proteins in the bloodstream (Previtali et al., 2011).
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Two of the factors which affect the incidence and risk of ATEs and VTEs in
cancer patients are tumor type and patient age (Blom et al., 2006; Chew et al., 2006;
Connelly-Frost, Shantakumar, Kobayashi, Li, & Li, 2013; Khorana & Connolly, 2009;
NCCN, 2015; Piccirillo et al., 2008; Scappaticci et al., 2007; Walker et al., 2013). Age,
gender, and calendar year adjusted incidence rates of VTEs per 1,000 person-years varied
from 1.3 to 23 depending on the tumor site, with a rate of 4.7 for kidney cancer patients
(Walker et al., 2013). Incidence rates of ATEs for kidney cancer patients were not
identified in the literature, however an incidence proportion of 1.3% was reported based
on clinical trial studies of patients treated with sunitinib or sorafenib chemotherapies for
advanced or metastatic renal cell carcinoma (the most common type of kidney cancer)
(Choueiri, Schutz, Je, Rosenberg, & Bellmunt, 2010). Kidney cancer is one of the 10
most common newly diagnosed cancers in U.S. men and women, with more than 60,000
new cases of kidney cancer diagnosed each year (American Cancer Society, 2015). In
spite of the significant numbers of kidney cancer patients, information on VTEs and
ATEs in kidney cancer patients is sparse.
The risk of VTEs in cancer patients also varies by other factors including cancer
stage, receipt of chemotherapy, cardiovascular surgeries, history of a VTE or
cardiovascular disease, and placement of a central venous catheter (Alcalay et al., 2006;
Blom et al., 2005; Chew, Wun, Harvey, Zhou, & White, 2007; Connelly-Frost et al.,
2013; Moore et al., 2011; Sallah, Wan, & Nguyen, 2002). Possible other risk factors are
tumor histology and receipt of cancer-directed surgery (Alcalay et al., 2006; Blom,
Osanto, & Rosendaal, 2004; Chew et al., 2007).
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There is little published information about the incidence of ATEs and VTEs or the
risk factors for VTEs in kidney cancer patients, even less so in elderly kidney cancer
patients (Chew et al., 2006; Hall, Andersen, Krumholz, & Gross, 2009; Smith et al.,
2014). Information specific to kidney cancer may aid patients and healthcare providers in
assessing the likelihood of VTEs and ATEs in this population. Accurate risk assessments
are important for determining if close patient observation or prophylactic treatments are
warranted (NCCN, 2015; Walker et al., 2013).
Studies specific to elderly cancer patients are important because the elderly are a
growing number of cancer patients and have age-related issues which impact care,
morbidity and mortality (International Society of Geriatric Oncology, 2011; NCCN,
2015; Repetto et al., 2003). The probability of developing cancer increases with
increasing age (American Cancer Society, 2015). Age has also been identified as a risk
factor for VTEs in some cancer patients, but not consistently (Agnelli et al., 2006;
Alcalay et al., 2006; Chew et al., 2006, 2007; Moore et al., 2011). As the United States
population age distribution shifts towards greater proportions of elderly persons and life
expectancy increases, the number of elderly cancer patients continues to increase and
remains as a significant public health and medical issue (International Society of
Geriatric Oncology, 2011; Repetto et al., 2003). Elderly patients are affected by issues
which may impact their outcomes more so than younger patients including less
participation or eligibility for clinical trials (which hinders knowledge of optimal
treatments), patient and provider beliefs, functional status, comorbidities and risk of drug
interactions, and cognitive functions (International Society of Geriatric Oncology, 2011;
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NCCN, 2015; Repetto et al., 2003). A comprehensive study of the incidence of selected
ATEs and VTEs and risk factors for these VTEs in elderly kidney cancer patients may
improve understanding of the disease burden and risks in this at risk population.
This chapter begins with an overview of kidney cancer, including its
epidemiology, histology groups, staging, and treatment, followed by a summary of
published literature on VTEs and ATEs in elderly kidney cancer patients. This chapter
also contains a statement of the research problem, the purpose of the study, and a listing
of the descriptive analyses, research questions and their corresponding hypotheses. A
description of the theoretical framework of the study, the nature of the study, and terms
used in this study are presented. The next section assesses the study assumptions, scope,
delimitations, and limitations. This chapter ends with the study significance and a
summary of the chapter.
Background
Epidemiology of Kidney Cancer
It is estimated that over 60,000 people in the United States were newly diagnosed
with kidney cancer in 2015 (American Cancer Society, 2015). Kidney cancer is the
seventh most commonly diagnosed cancer in men and tenth most common in women
(American Cancer Society, 2015). More than 90% of all kidney cancers in adults are
renal cell carcinomas (RCC) (National Cancer Institute, 2010; Surveillance,
Epidemiology, and End Results [SEER] Program, 2012). Renal cell carcinomas are
malignant tumors that grow in the lining of kidney tubules (National Cancer Institute,
2013; SEER, 2012). Another 7% to 10% of kidney cancers are transitional cell cancers
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which arise in the renal pelvis and have different histology, survival and staging than
RCC (American Joint Committee on Cancer [AJCC], 2002; SEER, 2012). Established
risk factors for kidney cancer include smoking tobacco, obesity, and hypertension
(American Cancer Society, 2015; DeCastro & McKiernan, 2008; Ljungberg et al., 2011;
National Cancer Institute, 2010; Weikert & Ljungberg, 2010). The risk of kidney cancer
is also higher in patients with a family history of kidney cancer, end-stage renal disease
(ESRD) or chronic renal failure, or mutations in the von Hippel-Lindau (VHL) gene (von
Hippel Lindau syndrome), c-met proto-oncogene, fumarate hydratase gene, or folliculin
tumor-suppressor gene (American Cancer Society, 2015; Ljungberg et al., 2011; National
Cancer Institute, 2010; Weikert & Ljungberg, 2010). Evidence is inconsistent regarding
an association between kidney cancer and occupational exposures to chemicals or
carcinogenic metals (Ljungberg et al., 2011).
Kidney cancer predominantly affects the elderly and men. The median age of U.S.
kidney cancer patients diagnosed from 2007 to 2011 is 64 years old for all patients, 63
years for men, 65 years for women, 64 for Whites, and 61 for Blacks (Howlader et al.,
2014). During that same period, kidney cancer incidence rates for patients diagnosed at
65 years of age or older were 91.7 cases per 100,000 for men, 45.0 for women, 66.8 for
Whites, and 73.8 for Blacks, respectively (Howlader et al., 2014). At each age group, the
incidence rates for men were about two-fold the rate for women.
The age-standardized incidence rates of kidney cancer in the United States
increased 2% to 3% between 1975 to 2008, followed by an annual percent change of
approximately -1.0 from 2008 to 2011 (Howlader et al., 2014). More frequent use of
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abdominal imaging over time is hypothesized to be part of the reason for the increase in
incidence; however it does not fully explain the trend (American Cancer Society, 2013;
Tyson et al., 2013).
Kidney cancer is a public health burden, especially in the elderly population
(American Cancer Society, 2015; Howlader et al., 2014). Within the kidney cancer
patient population, there are differences in incidence and survival by age, race, gender,
and stage. Better understanding of the risks of VTEs and ATEs within these
subpopulations is a start to improving patient care and adding to geriatric oncology
knowledge.
Types of kidney cancer. The majority (90% or more) of kidney cancer tumors
are RCC and the remainder are primarily transitional cell tumors of the renal pelvis (7%
to 10%) (National Cancer Institute, 2010; SEER, 2012). Transitional cell tumors are a
different histologic tumor type than RCC. Renal cell carcinoma is further divided into
four main histology groups of clear cell, papillary, chromophobe, and other (Kovacs et
al., 1997). In elderly kidney cancer patients, clear cell RCC is the most common group.
Table 1 shows the definitions by ICD-O morphology code for each type of RCC and the
proportions estimated in kidney cancer patients 60 years of age or older at diagnosis
based on data from Keegan et al. (2012) and Olshan et al. (2013).
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Table 1
Proportion of RCC Histology Groups in Elderly Kidney Cancer Patients
ICD-O Histology Codes
Clear Cell
Papillary
Chromophobe
Other

Proportion in Kidney Cancer
Patients aged 60 or older
79% - 82%
9% - 13%
4% - 5%
3%- 5%

8310, 8312
8260
8317, 8270
All RCC codes except 8310,
8312, 8317, 8260, and 8270
Note. Proportions of each histology type were based on data in Keegan et al. (2012) and
Olshan et al. (2012).
Both studies of RCC patients used the SEER cancer registry data (Keegan et al.,
2012; Olshan et al., 2013) but used different populations, different time periods and
reported different age groups. Keegan et al. (2012) analyzed patients diagnosed with
RCC between 2000 and 2005 in the SEER registries who underwent nephrectomy during
the first course of treatment. The study by Olshan et al. (2013) included patients with
clear cell, papillary or chromophobe RCC diagnosed in the SEER registry areas between
2000 and 2009.
The majority of kidney cancers are RCC (National Cancer Institute, 2010; SEER,
2012). Renal cell carcinoma can be further classified into four main histology groups
(Kovacs et al., 1997). Histology group can impact patient prognosis (Keegan et al., 2012;
Patard et al., 2005). As discussed further below, differences in incidence rates of VTEs
by histology group has been noted in some tumors but not others (Alcalay et al., 2006;
Blom et al., 2004; Chew et al., 2007, 2008). This study was the first known study to
assess whether the incidence rates of VTEs and ATEs in kidney cancer patients differ by
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histology group. It also assessed whether histology type is a risk factor for VTEs in
kidney cancer patients.
Kidney cancer staging. Cancer staging is used to inform the healthcare provider
about the extent of disease, as well as determine the type of treatment and patient
prognosis (SEER, 2012). The main two staging systems used are the SEER summary
stage and the staging system by the American Joint Committee on Cancer (AJCC)
(SEER, 2012). Summary stage has five main groups which are (a) in situ, (b) localized,
(c) regionalized, (d) distant, and (e) unknown (SEER, 2012). The main disadvantage of
using the summary staging system is that the categories are very broad and may contain a
wide variation of tumors (SEER, 2012). The AJCC staging system is a more detailed
system defined by a combination of three components based on tumor size or
invasiveness (T), whether tumor cells are present in regional lymph nodes (N), and
whether the tumor has metastasized to distant sites (M) (AJCC, 2002; SEER, 2012).
There are several editions of the AJCC cancer staging system, and the 6th edition was
designed to use with cancer cases diagnosed from 2003 to 2009.
There are four stages for kidney cancer (excluding tumors of the renal pelvis) by
the AJCC staging algorithm (a) Stage I, (b) Stage II, (c) Stage III, and (d) stage IV
(AJCC, 2002). Stage I is defined by a tumor of 7 centimeters or less which is confined to
the kidney, no regional lymph node metastases, and no distant metastases (AJCC, 2002).
Stage II is defined by a tumor of greater than 7 centimeters which is confined to the
kidney, no regional lymph node metastases, and no distant metastases (AJCC, 2002).
Stage III is defined by a tumor with no distant metastases but which (a) extends beyond
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the kidney into veins or fatty tissue around the kidney, or (b) had metastases in a single
regional lymph node (AJCC, 2002). Stage IV is defined by extension of the tumor
beyond the veins and fatty tissues around the kidney, metastases in more than one
regional lymph node, or distant metastases (AJCC, 2002).
The AJCC staging system (sixth edition) of renal pelvis tumors is defined as
follows. Stage I, II, and III tumors do not have any regional lymph node metastasis or
distant metastasis (AJCC, 2002). These stages are distinguished by tumor extension.
Stage I tumors have extended into the subepithelial connective tissue; Stage II tumors
have extended the muscularis; and Stage III tumors have extended beyond the muscularis
into peripelvic fat or the renal parenchyma (AJCC, 2002, p. 330). Stage IV tumors are
defined by either (a) tumor extension into adjacent organs or into the perinephric fat, (b)
any regional lymph node metastasis, or (c) distant metastasis (AJCC, 2002). AJCC stage
instead summary stage was used to define stage in this study as the AJCC staging system
is more detailed and clinically relevant.
VTEs and ATEs in elderly kidney cancer patients. The medical dictionary
defines a thromboembolism as “the blocking of a blood vessel by a particle that has
broken away from a blood clot at its site of formation” (MedlinePlus, 2014). According
to the Centers for Disease Control and Prevention (CDC), the blockage or blood clot can
occur in the vein (venous thromboembolism) or in an artery (arterial thromboembolism)
(CDC, 2014). Two major types of VTEs are deep vein thrombosis (DVT) and pulmonary
embolism (PE). Arterial thromboembolic events in arteries of the heart or brain include
ischemic stroke, transient ischemic attack, heart attack, and other cardiovascular

10
complications (CDC, 2014; MedlinePlus, 2014). Venous and arterial thromboembolic
events may result in patient death, organ damage, or other serious health conditions
(CDC, 2014; MedlinePlus, 2014).
The risk factors for VTEs in cancer patients include age, cancer treatment (e.g.,
surgery, chemotherapy, immunotherapy), cancer site, history of VTE/ATE and
cardiovascular conditions, comorbidities, cancer stage, histology group, major surgeries,
hospitalizations, central venous catheter, and clinical factors (Blom et al., 2006;
Connelly-Frost et al., 2013; Khorana & Connolly, 2009; NCCN, 2015). Comorbidities
can be assessed individually or by a comorbidity index. The Charlson comorbidity index
was originally developed to predict mortality in hospitalized patients due to comorbid
conditions, and then adapted for predicting other adverse outcomes in hospitalized
patients (Klabunde, Potosky, Legler, & Warren, 2000). The comorbidity index has been
expanded and tested on inpatient and outpatient claims databases, and used for predicting
other outcomes in patients including thromboembolic events (Doyle, et al., 2005;
Klabunde, Legler, Warren, Baldwin, & Schrag, 2007; Smith et al., 2014).
Incidence rates of VTEs in kidney cancer patients were found in two published
articles, with other articles reporting cumulative incidence (Agnelli et al., 2006; Blom et
al., 2006; Chew et al., 2006; Walker et al., 2013). Only one of the articles presented
incidence rates by age group, and the incidence rate for VTEs for kidney cancer patients
age 60 years or older at diagnosis was 14 per 1,000 person-years (95% CI 10 - 18)
(Walker et al., 2013). The studies varied in incidence measure reported and duration of
follow-up after cancer diagnosis. Another study reported incidence rates of VTEs in
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elderly RCC patients (Connelly-Frost et al., 2013). The study of RCC patients aged 65
years or older at diagnosis and who had Medicare coverage reported incidence rates per
1,000 person-years of 32.2 (95% CI 29.1-35.7) and 108.2 (95% CI 101.6-115.2) for DVT
in the year prior and year after RCC diagnosis, respectively (Connelly-Frost et al., 2013).
The incidence rates for pulmonary embolism were 8.0 (95% CI 6.5-9.8) and 30.0 (95%
CI 26.6-33.7), for the same two respective periods relative to RCC diagnosis (ConnellyFrost et al., 2013). The incidence rates for the grouping of other VTEs were 23.7 (95% CI
21.1-26.7) and 49.0 (95% CI 44.6-53.7), in the year prior and year after RCC diagnosis
respectively (Connelly-Frost et al., 2013). Incidence rates by RCC histology group were
not reported by Connelly-Frost et al. (2013).
Incidence rates of ATEs were not found in the published literature, but cumulative
incidence was found in cancer patients treated with chemotherapy. The incidence for
myocardial infarction ranged from 0.2% to 2.9% depending on the treatment and patient
population (Bayer HealthCare Pharmaceuticals, 2013; GlaxoSmithKline, 2014; Moore et
al., 2011). Other studies reported incidence of ATEs as a group and the results ranged
from 1.3% to 3.8% for chemotherapy-treated patients of all ages, varying by treatment
and study population (Choueiri et al. 2010; Scappaticci et al., 2007). A pooled analysis of
clinical trial data reported an incidence of ATEs in patients age 65 years or older as 2.5%
in control patients and 7.1% in bevacizumab-treated patients (Scappaticci et al., 2007). In
the patients 65 years or older, the incidence of ATE was 2.6% and 4.4% in controls and
treated patients without a history of ATE, respectively, and 2.2% and 17.9% with a
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history of ATE in the controls and bevacizumab-treated patients respectively (Scappaticci
et al., 2007).
Summary
In summary, elderly kidney cancer patients are at increased risk of VTEs and
ATEs which can increase mortality and cause other health problems (Blom et al., 2006;
CDC, 2014; Connelly-Frost et al., 2013; Khorana & Connolly, 2009; MedlinePlus, 2014;
NCCN, 2015). Incidence measures for VTEs in kidney cancer patients are available in
the literature for VTEs but they are not consistent, and incidence of ATEs in kidney
cancer patients is limited to clinical trial data from a specific subset of kidney cancer
patients. The evidence of risk of VTEs and ATEs in elderly kidney patients is based
mostly on studies of other tumor types and patients of all ages (Blom et al., 2005, 2006;
Connelly-Frost et al., 2013; Sallah, Wan, & Nguyen, 2002; White et al., 2005).
I sought to address this gap in the knowledge of VTE and ATE incidence rates
and the risk factors for VTEs specific to a recent cohort of elderly kidney cancer patients
with Medicare coverage using population-based data. Having the information for this
specific population on the incidence and risk factors for thromboembolic events can aid
healthcare providers and patients in making informed decisions about the patients’ risks
for VTEs and ATEs, and thus improve both patient outcomes and patient care.
Problem Statement
Despite the risk of morbidity and mortality from VTEs and ATEs in cancer
patients, in depth analyses of incidence rates and risk factors for these conditions have
not been conducted in elderly kidney cancer patients. Incidence rates of VTEs and ATEs
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in cancer patients vary widely by type of cancer and patient age, however very little
published information is available specifically about elderly kidney cancer patients
(Connelly-Frost et al., 2013; Hall et al., 2009; Walker et al., 2013).
Most studies of the risk factors for VTEs are based on studies of other cancers,
multiple tumor types with small numbers of kidney cancer patients, or are not specific to
the elderly (Chew et al., 2006; Hall et al., 2009). No studies were found for the risk
factors for ATEs in elderly kidney cancer patients, with the only evidence reported from
clinical trial data in a subset of patients on specific treatments (Choueiri et al., 2010). The
problem is that incidence rates of VTEs and ATES for elderly kidney cancer patients
(ages 65 years or older at diagnosis) are not readily available in the literature, much less
incidence rates by histology group, patient, or other tumor characteristics. There is also a
lack of evaluation of risk factors for VTEs in elderly kidney cancer patients.
Understanding the incidence of VTEs and ATEs in elderly kidney cancer patients
can help health care providers assess the need for prophylactic treatments or additional
observation. Information on whether there are differences for subpopulations within these
patients may be of assistance for patient care as well.
Purpose of the Study
This was a quantitative, retrospective cohort study. The entire cohort consisted of
elderly patients with Medicare coverage who resided in the SEER registry areas. The
outcomes of interest were VTEs and ATEs, and the exposure status was determined as
follows: patients diagnosed with incident kidney cancer from 2004 to 2009 were exposed
and those who did not have a cancer diagnosis of any type at any point in the database
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were unexposed. The study-specific aims were to (a) estimate the incidence rates of VTEs
and ATEs that elderly kidney cancer patients with Medicare coverage have in the year
prior to cancer diagnosis and in the year after diagnosis; (b) estimate the incidence
proportions of VTEs and ATEs by discrete, mutually exclusive time periods after
diagnosis; (c) compare the incidence rates of VTEs and ATEs occurring in the 12 months
before diagnosis in cancer patients to a matched noncancer Medicare population during
the same timeframe; (d) compare the incidence rates of VTEs and ATEs occurring in the
follow-up period after diagnosis in cancer patients to a matched noncancer Medicare
population during the same timeframe; and (e) assess the independent risk factors for
each VTE and ATE in cancer patients after cancer diagnosis. The analyses for the first
two aims and the last aim only used the exposed patients in the cohort (i.e., the kidney
cancer patients). For the first aim, I estimated the incidence rates of VTEs and ATEs
overall and according to factors including age group, gender, race, histology group,
treatment, and year of diagnosis. For the third and fourth aims, I conducted a matched
cohort study using all of the exposed patients and a random sample of the unexposed
patients from the cohort. The unexposed patients (the noncancer patients) were matched
to the exposed patients on age at index date, gender, race, SEER registry area, and
duration of follow-up. The index dates for the exposed patients were the month and year
of kidney cancer diagnosis. The index date for the unexposed patients was assigned the
same as the corresponding exposed patient.
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Descriptive Analyses, Research Questions, and Hypotheses
There are two parts to this study, one descriptive and the other analytic. The
descriptive part of the study calculated the incidence rates, overall and by patient and
tumor characteristics, of VTEs and ATEs in elderly kidney cancer patients in the followup period after index date. Also described was the timing of new events by presentation
of the incidence proportions for VTEs and ATEs in discrete time intervals after index
date. The analytic part of the study had two types of analyses. The first set of analyses
used a matched cohort study to compare the incidence rates of VTEs and ATEs in the
exposed patients (kidney cancer patients) to a matched noncancer comparison group in
the year prior to the index date and compares the incidence rates in the follow-up period
after the index date. The second analysis, conducted only in the exposed patients (elderly
kidney cancer patients), was to quantify independent predictors of time to incident VTEs
in this population.
Descriptive Analysis 1
The first descriptive analysis involved the calculation of the incidence rates of
individual VTEs and of ATEs in elderly kidney cancer patients over the 12 months before
index date (kidney cancer diagnosis) and in the follow-up period after index date. For
each of the prespecified patient and tumor characteristics, the incidence rates of VTEs
and ATEs are also presented by age group, race, gender, history of VTE/ATE, history of
cardiovascular disease, AJCC stage, treatment by immunotherapy, treatment by
nephrectomy, treatment by chemotherapy or targeted therapy, histology group, Charlson
Comorbidity Index, SEER registry region, and year of diagnosis.
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Descriptive Analysis 2
For this analysis, the proportion of elderly kidney cancer patients who
experienced incident VTEs and incident ATEs in discrete, mutually exclusive time
periods during follow-up (0 to 90 days, 91 to 180 days, 181 to 270 days, and 271 to 365
days) after index date were calculated. The incidence proportions were calculated for
each VTE and ATE of interest.
Research Question 1
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly
exposed (kidney cancer) patients 12 months before index date compare to a matched
unexposed (noncancer) Medicare population during the same 12-month timeframe?
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are
statistically significantly greater in the exposed patients than in the unexposed patients.
H01: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the year prior to the index date in the exposed patients and in the matched
unexposed patients.
Research Question 2
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in
elderly exposed (kidney cancer) patients after index date compare to a matched
unexposed (noncancer) Medicare population during the same timeframe?
HA2: In the follow-up period after the index date, the incidence rates of VTEs or
of ATEs are statistically significantly greater in the exposed patients than in the
unexposed patients.

17
H02: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the period after index date in the exposed patients and in the matched
unexposed patients.
Research Question 3
Research Question 3: In the follow-up period after kidney cancer diagnosis, what
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE,
or OTE)?
HA3: No factors are statistically significantly associated with the time to newly
diagnosed VTEs in the period after kidney cancer diagnosis.
H03: Tumor histology and other factors are statistically significantly associated
with the time to newly diagnosed VTEs after kidney cancer diagnosis.
For each question, a Cox proportional hazard model was used to identify
independent predictors for each outcome. The outcome was time to the occurrence of the
first VTE or ATE after kidney cancer diagnosis or duration of follow-up. The potential
predictors included in the initial (full) model were age at diagnosis, race, gender,
diabetes, atherosclerosis, varicose veins, cardiovascular surgery, central venous catheter,
kidney disease, history of VTE, history of cardiovascular disease, AJCC stage, treatment
type (immunotherapy, nephrectomy, chemotherapy), histology group, SEER registry
region, and year of diagnosis. Independent variables which were statistically significant
at the 0.05 level were retained in the final model. The final model included any variables
identified as confounders or effect measure modifiers (EMMs). As incident ATEs were
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expected to be rarer than incident VTEs, assessment of independent risk factors for ATEs
in elderly kidney cancer patients was not included in this research question.
Theoretical Framework
A visual representation of the proposed theoretical framework is presented in
Figure 1. This theoretical framework used the advanced epidemiology triangle to
interpret the association between incident VTEs and ATEs with causative factors,
environment and lifestyle factors, and population characteristics (Merrill, 2009). While
the traditional epidemiology triangle is primarily used for modeling infectious disease
transmission, the advanced epidemiology triangle is adapted for use with chronic
diseases, injuries, and other conditions (Merrill, 2009). The factors which make up the
traditional epidemiology triangle are host, agent, and environment, whereas the factors in
the advanced triangle are population, causative factors, and environmental factors
(Merrill, 2009). In the advanced model, environmental factors include behavioral,
cultural, physiological and ecological elements (Merrill, 2009). The interaction of time
with these factors is also taken into account.
The dependent variable, the outcomes, were incident ATEs and VTEs. The
potentially confounding and effect measure modifying variables were identified from the
literature and only variables which were included in this study were presented on the
framework (Earp & Ennett, 1991). Patient factors and cancer-specific factors can directly
impact the likelihood of a patient having a VTE, and indirectly through effects on which
RCC treatments (e.g., chemotherapy and targeted therapies, nephrectomy, and
immunotherapy) a patient receives, cardiovascular surgery or placement of a central
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venous catheter. The patient factors (age, gender, SEER registry region of
diagnosis/residence, and comorbidities) and cancer-specific factors (year of diagnosis,
cancer stage, tumor histology, and cancer treatments) were selected based on previous
studies of risk factors for VTEs and ATEs (Blom et al., 2006; Chew et al., 2006;
Connelly-Frost et al., 2013; Geraci, Escalante, Freeman, & Goodwin, 2005; Khorana &
Connolly, 2009; NCCN, 2015). Placement of a central venous catheter and
cardiovascular surgery were selected based on studies that found them to be predictive
factors for VTEs in cancer patients (Connelly-Frost et al., 2013; Khorana & Connolly,
2009). Additional detail on the theoretical framework was discussed in Chapter 2.
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Causative factors (Kidney Cancer)
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immunotherapy, targeted therapies,
nephrectomy)
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Cardiovascular surgery
Central Venous Catheter

Figure 1. Theoretical model of the association between population, causative, and
environmental factors related to thromboembolic events.
Nature of the Study
This study was a quantitative, retrospective cohort study. The cohort consisted of
Medicare beneficiaries. The exposure was kidney cancer while the outcome was the
occurrence of a venous or arterial thromboembolic event. The data source utilized was
the linked SEER-Medicare database. The study population was patients diagnosed with
kidney cancer between 2004 and 2009 (exposed) and, for Research Questions 1 and 2, a
noncancer comparison group (unexposed) matched to the kidney cancer patients on
gender, age, race, SEER registry region, and duration of follow-up after the index date.
Each matched unexposed patient was assigned an index date of the month and year of the
corresponding kidney cancer patient’s diagnosis. The kidney cancer patients were
restricted to patients 65 years of age or older, diagnosed between the years of 2004 and
2009, and whose kidney cancer was the patient’s first malignancy. Age 66 years and 11
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months was the effective minimum age as the patients in the cohort were be required to
have two years of Medicare Part A and B coverage and no Medicare managed care plan
participation prior to and including the month and year of the index date. Duration of
follow-up was calculated as the number of months from index date until patient does not
have both Parts A and B coverage, participates in a managed care plan, dies, or December
31, 2010. Follow-up time for the unexposed patient was truncated to the same amount of
time as the corresponding kidney cancer patient.
In order to describe the risk of VTEs and ATEs in kidney cancer patients and in a
noncancer comparison group, incidence rates and incidence proportions were calculated.
Tables of the incidence rates overall and stratified by patient and tumor characteristics
were generated. Cox proportional hazards regression analyses were used to model
whether the incidence of VTEs and the incidence of ATEs are more likely in kidney
cancer patients than the matched comparison group for each time period. Modeling the
risk factors for each VTE in kidney cancer patients and estimating the relative risk of
VTE after kidney cancer diagnosis used Cox proportional hazards regression analyses.
Unadjusted Kaplan-Meier curves of time to VTE or ATE were generated overall and
stratified by patient and tumor characteristics. Log rank tests were used to determine
whether differences in the time-to-event curves are statistically significant. All analyses
were conducted using SAS 9.3 software (SAS Institute Inc., Cary, NC, USA).
This methodology is consistent with that used by Connelly-Frost et al. (2013) to
estimate incidence of VTEs and ATEs in RCC patients, calculate relative risk estimates
of VTEs and ATEs, compare the risk of VTEs and ATEs in RCC patients to a matched
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noncancer comparison group. The incidence rate calculation is also consistent with
Walker et al. (2013). Additionally models of relative risk and risk factors for VTEs and
ATEs were assessed as an overall group and also using the CCI and histology group as
potential risk factors, which provided results more easily comparable with other studies
in other cancer types (Alcalay et al., 2006; Chew et al., 2007).
Definitions
Arterial thromboembolism: A thromboembolism which occurs in an artery (CDC,
2014; MedlinePlus, 2014). For this study, the ATEs to be examined are acute myocardial
infarction and ischemic stroke.
Cancer-directed treatment: Treatment given with the purpose of destroying,
removing, or controlling malignant or metastatic tumor cells. Palliative care and
diagnostic tests are excluded (SEER, 2012).
Chemotherapy: Pharmaceutical drugs which kill cancer cells (National Cancer
Institute, 2013).
Comorbidity: Any condition, acute or chronic, other than the disease of interest
(Klabunde, Warren, & Legler, 2002).
Elderly: The elderly are defined as persons 65 years of age or older, as 65 has
been considered the retirement age in the United States and it is the earliest age U.S.
residents without ESRD or certain disabilities are eligible for the Medicare program
(Centers for Medicare & Medicaid Services [CMS], 2013; Ohio State University
Extension, 2004).
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Exposed: The exposed population in the cohort consisted of patients with an
incident diagnosis of kidney cancer between 2004 and 2009.
History of cardiovascular disease: A diagnosis code for a myocardial infarction,
ischemic stroke, new onset congestive heart failure, angina or transient ischemic attack in
the 12 months before the period of interest (Connelly-Frost et al., 2013).
Immunotherapy: A type of biologic therapy which affects the immune system in
order to treat diseases (National Cancer Institute, 2013). Types of immunotherapies
include cytokines and monoclonal antibodies (National Cancer Institute, 2013).
Localized tumors: Tumors which are confined to the tissue or organ from which it
originated (National Cancer Institute, 2013).
Metastasis: Cancer cells have spread to parts of the body outside the tissue or
organ from which it originated (National Cancer Institute, 2013).
Nephrectomy: Surgery which removes part or the entire kidney (National Cancer
Institute, 2010).
Palliative care: Treatments given to treat symptoms, treatment-related side
effects, or otherwise improve patient quality of life (National Cancer Institute, 2013;
SEER, 2012).
Pediatric: Related to children (National Cancer Institute, 2013). Children are
considered any person of age 18 years or younger.
Resectable: A tumor which can be removed surgically (National Cancer Institute,
2013).
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Stage (cancer): Cancer grouping based on the extent to which the cancer has
spread from the tissue or organ from which it originated (SEER, 2012). Factors which go
into staging include the primary tumor site, tumor size or thickness, extension or
metastases beyond the primary site, and presence of metastases in regional lymph nodes
(SEER, 2012).
Systemic therapy: Drugs which travel through the blood stream to affect cells in
various parts of the body (National Cancer Institute, 2013).
Targeted therapy: Anticancer drugs which interrupt cancer cell growth and tumor
spread. Different types of targeted therapies attack cells with different characteristics by
targeting specific cellular molecules. (National Cancer Institute, 2013).
Thromboembolism: A blood vessel blockage caused by a portion of a blood clot
which originated in another site (MedlinePlus, 2014).
Tumor: A mass caused by abnormal cell growth. Tumors are also known as
neoplasms. (National Cancer Institute, 2013).
Unexposed: The exposed population in the cohort consisted of patients who did
not have a cancer diagnosis in the SEER registry data at any time.
Venous thromboembolism: A thromboembolism which occurs in a vein (CDC,
2014; MedlinePlus, 2014). The VTEs to be examined in this study are deep venous
thrombosis, pulmonary embolism, and other thromboembolic events.
Assumptions
The following assumptions were made for this study: (a) all clinically relevant
diagnoses were captured in the diagnosis and procedure codes, (b) receipt of cancer-
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directed treatments were processed by Medicare and thus captured in the data, (c) the
date of cancer diagnosis was accurate, and (d) date of death was correctly identified. The
first assumption is a limitation of administrative claims data (Klabunde, Warren, &
Legler, 2002) which is discussed further in the limitations section below. The diagnoses
of interest to this study (i.e., VTEs and ATEs) are serious conditions which should meet
the criteria of being clinically relevant. The second assumption is specific to the SEERMedicare database, as only claims processed by Medicare are included in the database
(Applied Research Program, 2013). Nephrectomy, and intravenous immunotherapy and
chemotherapy administered inpatient or outpatient settings which are covered by
Medicare for kidney cancer patients should be captured. Studies have validated the
SEER-Medicare data for assessing receipt of chemotherapy (Lund et al., 2013; Warren et
al., 2002b). However, many of the targeted chemotherapy drugs for RCC approved in the
past decade are given orally, do not have an IV equivalent, and thus may not be captured
as they would be billed as prescription drugs. With the passage of the Medicare
Modernization Act of 2003, prescription drug coverage (hereafter referred to as Part D)
was an available option for Medicare participants beginning January 1, 2006 (CMS,
2013). Oral chemotherapy drugs may be captured in the HCPCS codes or in the
prescription drug event file containing Part D data using National Drug Code (NDC)
codes (Applied Research Program, 2013). The Part D data released with the SEERMedicare data released in 2013 covers years 2007 to 2010 (Applied Research Program,
2013), which overlaps with half (2007 to 2009) of my study period. Part D is optional, so
the data only includes claims for patients who have Part D coverage. Oral targeted
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therapies are the primary therapy for Stage IV or advanced RCC (NCCN, 2015).
Restricting to 2010 kidney cancer patients, 12% or less of Stage III patients age 60 years
of age or older had chemotherapy in the first course of treatment (National Cancer Data
Base, 2013). For Stage IV patients, 52% of patients age 60 to 69 years of age at diagnosis
had chemotherapy in the first course of treatment and the proportion declined to 29% of
patients 80 to 89 years of age, and 8% for patients 90 years of age or older (National
Cancer Data Base, 2013). It was not possible to determine how many patients received
oral drugs as part of the chemotherapy treatments. Treatments which are paid for by the
patient during a prescription plan coverage gap are also not captured (CMS, n.d.).
SEER data is considered a high-quality cancer data source and there was
approximately 90% agreement on the date of cancer diagnosis whether using the SEER
data or Medicare claims data (Applied Research Program, 2013; SEER, 2013). The
fourth assumption is necessary for correctly calculating duration of follow-up, and 96%
of the dates of death have been validated in the Medicare enrollment file (Asper, 2012).
Scope and Delimitations
The population included elderly kidney cancer patients with Medicare (both parts
A and B) coverage, who had no participation in Medicare Managed care plans in the two
years prior to kidney cancer diagnosis or during follow-up, whose kidney cancer was
their first diagnosed cancer, and who were 65 years of age or older at diagnosis.
Continuous Medicare coverage with parts A and B and exclusion of patients in Managed
Medicare plans prior to index date and during patient follow-up are required to reduce the
likelihood of missing claims (e.g., treatments, comorbidities, and other information) for
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the study patients (Asper & Mann, 2011). The proportion of Medicare enrollees
participating in a managed care plan ranged from 13% to 25% between 1998 and 2010
(Asper & Mann, 2011). Although people may be eligible for Medicare coverage starting
at age 65 (excluding people with coverage at earlier ages due to disability or end-stage
renal disease), so that there are two years of data including the month of index date for
each patient prior to kidney cancer diagnosis (index date) the study population needs to
be at least 66 years and 11 months of age to be eligible. Patients at risk for a VTE or ATE
during each period (the year prior to diagnosis/ index date or the year after
diagnosis/index date) were defined as patients who did not have a diagnosis for the VTE
or ATE in the year prior to the period of interest. Thus, a second year prior to the
diagnosis/index date was necessary for identifying incident events in the first year prior
to that date.
Duration of follow-up was calculated from the month after the index date until
loss of Parts A and B of Medicare coverage, participation in a Medicare managed care
plan, death, or December 31, 2010. Patients who died or were lost to follow-up in the
same month of index date (i.e., duration of follow-up is zero full months) were excluded.
Thus, the study population had at least 1 month of follow-up. No other minimum amount
of follow-up was required so as not to introduce survival bias into the study.
Additionally, follow-up for matched unexposed patients were truncated at the same
duration as the corresponding kidney cancer patient.
Patients with other cancers diagnosed in the same month as or prior to the kidney
cancer diagnosis were excluded also. This was so that the pharmaceutical and surgical
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therapies captured were for treatment of the kidney cancer and not another cancer type.
Additionally, restricting to patients without other cancers helped ensure that the study
findings in the exposed patients were due to the exposure (kidney cancer) and not other
exposures. Thus, the results of this study are generalizable to elderly Medicare patients
newly diagnosed with kidney cancer, which have both parts A and B of Medicare
coverage, and who do not participate in a managed care plan.
Limitations
Some potential limitations arise from the use of SEER-Medicare, an
administrative claim database. Administrative claims are designed for billing and
reimbursement purposes, thus reimbursement rates may influence which diagnoses and
procedures are listed and how they are listed (Klabunde, Warren, & Legler, 2002).
Another limitation is that the claims file may not contain all of the diagnosis or procedure
codes from a health care interaction. Only claims processed through Medicare are
captured. Care which took place at Veterans Administration, was billed to an insurance
program other than Medicare, or was paid for out-of-pocket are being captured in the
database (Applied Research Program, 2013). The Medicare claims databases have a
predefined number of variables to capture the diagnosis or procedure codes; for example
the outpatient claims dataset had 10 diagnosis codes variables prior to 2010, but 25
variables for 2010 and later (Applied Research Program, 2013). As such, some conditions
may be underreported because there are not enough positions for them to be included in
the file. Conditions which exist but are not considered clinically relevant may not be
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listed as a diagnosis code (Klabunde et al., 2002). This is a limitation with any
administrative claim database.
Another limitation of using administrative claims is that severity of comorbidity is
difficult or impossible to measure (Geraci et al., 2005). Lab data are not contained in the
database, thus serum levels of bilirubin (high levels are a contraindication for
temsirolimus) cannot be ascertained. Severity of condition could not be assessed in this
study, and presence or absence of VTE, comorbidity and procedures were reported based
on ICD-9-CM diagnosis codes, ICD-9-CM procedure codes, or HCPCS procedure codes.
However, SEER-Medicare database also has advantages over use of other data
sources. One such benefit is the generalizability of the database because the source
population is large and population-based. In addition, several validation studies have
been conducted using the database to assess its usefulness and appropriateness for various
purposes including identification of chemotherapy (Lund et al., 2013; Warren et al.,
2002b) and comorbidities (Klabunde et al., 2000; Klabunde et al., 2002).
Significance
This project was significant for several reasons. First, it quantified the rates of
VTEs and ATEs and the risk of VTEs in a group of kidney cancer patients for whom
there is not a lot of information (elderly patients with Medicare coverage) and assessed
whether the incidence rates of thromboembolic events differed from the rates in a
matched, noncancer comparison group. Information on incident conditions post-diagnosis
can aid in interpreting clinical trial or post-marketing drug safety profiles and identify
areas where standards of care for patients can be improved (FDA, 2011).
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Secondly, the assessment of the association between time to incident VTEs and
ATEs and potential independent risk factors can aid in the understanding of patient risk
for VTEs and ATEs among elderly kidney cancer patients with Medicare coverage. New
contributions of this study are the assessment of histology group as a potential risk factor
and use of AJCC stage instead of summary stage. Histology group had not been assessed
as a risk factor for VTEs or ATEs in kidney cancer patients, however it was found as a
risk factor for VTEs in patients with other tumor types (Blom et al., 2004; Chew et al.,
2007, 2008). The results of this study contributed to positive social change by quantifying
the incidence and risk of VTEs and ATEs for this population. Increased understanding of
the patient risk for VTEs and ATEs may improve patient care and prognosis. The
understanding may help inform healthcare providers as to which patients may benefit
from additional observation or prophylactic treatments to prevent thromboembolic
events.
Summary
VTEs and ATEs are serious conditions for which elderly cancer patients are at
higher risk than the general population (Connelly-Frost et al., 2013; Khorana &
Connolly, 2009; NCCN, 2015). Although the risk of VTE and ATE varies by cancer type,
information on the risk and risk factors in elderly kidney cancer patients is sparse (Blom
et al., 2006; Connelly-Frost et al., 2013). Therefore, tumor type-specific assessment of
the risks and outcomes in the patient population can help health-care providers and
patients make treatment decisions and understand potential outcomes. This retrospective
cohort study sought to address gaps in the literature by calculating incidence rates in an
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elderly kidney cancer population, comparing incidence rates in kidney cancer patients to
a matched, noncancer comparison group, and assessing risk factors for incident VTEs and
ATEs in elderly kidney cancer patients. Chapter 2 presents the literature search
methodology and a review of the literature for incidence rates of VTEs and ATEs and
risk factors for VTEs in elderly kidney cancer patients. The chapter concludes with a
summary of the literature and discussion of the contribution of the current study.
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Chapter 2: Literature Review
Introduction
This review of the literature provides background information on the incidence
and risk of ATEs and VTEs in elderly kidney cancer patients. Most of the publications
citing the increased risk for thromboembolism events in cancer patients are based on
multiple cancers (which included approximately 0% to 3% kidney cancers), assessed
outcomes as a grouping instead of individual thromboembolic events, and included adult
patients of all ages without results presented stratified by elderly and nonelderly (Agnelli
et al., 2006; Blom et al., 2006; Hall et al., 2009; Khorana et al., 2008; Sallah et al., 2002).
Other studies which included kidney cancer patients included patients diagnosed more
than a decade ago (e.g., 2003 or earlier) or focused on specific groups of patients such as
clinical trial participants who received a specific treatments (Connelly-Frost et al., 2013;
Hurwitz et al., 2011; Svoboda, Poprach, Dobes, Kiss, & Vyzula, 2012). The problem is
that evidence on ATEs and VTEs in elderly kidney cancer patients is not available from a
recent population-based data source which reflects the incidence rates of ATEs and VTEs
in this population or assesses the risk factors for the conditions in this population
(Connelly-Frost et al., 2013; Khorana, Kuderer, Culakova, Lyman, & Francis, 2008).
Thus this quantitative study analyzed kidney cancer patients diagnosed between 2004 and
2009 and a matched, noncancer cohort during the same period in order to ascertain the
incidence of ATEs and VTEs before and after kidney cancer diagnosis, compare the
incidence rates in kidney cancer patients to a comparable group of noncancer patients,
and assess independent risk factors for VTEs in elderly kidney cancer patients.
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Only one study was found which published incidence rates of VTEs and assessed
risk factors for VTEs in elderly RCC cancer patients diagnosed between 1991 and 2003
(Connelly-Frost et al., 2013). Other studies reported incidence rates or cumulative
incidence of VTEs in kidney cancer patients of all ages (Blom et al., 2006; Chew et al.,
2006; Walker et al., 2013). No similar study of ATEs in kidney cancer patients was
identified in the published literature.
This chapter details the strategy utilized in search engines to identify the current
literature reviewed for this study. The next section discusses in depth the theoretical
framework of this study that was introduced in chapter one. The published literature on
ATEs and VTEs in elderly kidney cancer patients was exhaustively reviewed in regards
to study methodology and variables. The chapter ends with a summary of the published
literature and transition to the methods chapter.
Literature Search Strategy
Searches for peer-reviewed literature were conducted in the Scopus electronic
multidisciplinary database. The Scopus database contains abstracts and citations from
more than 20,000 peer-reviewed journals, 6 million conference papers, and articles-inpress from almost 4,000 journals (Elsevier, 2014). The search criteria and numbers of
articles found during the search on September 29, 2015 are found in Table 2. The asterisk
directs Scopus to search for words containing the characters prior to asterisk plus any
variation of characters which appear in place of the asterisk. The Scopus search was
restricted to results in journal articles, English language, and published between January
2003 and September 2015. A total of 355 abstracts were reviewed to identify relevant
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articles. Reviews were included in the initial search and the reference lists of all studies
pulled were searched for additional relevant articles, including those with information on
other cancer types. In addition, the title and abstracts of publications which cited the
articles selected for review in this chapter were also examined for locating additional
relevant articles. Searches of the primary authors’ other publications also yielded articles
including in this literature review. Case studies and studies focusing on pediatric
populations were excluded.
Table 2
Scopus Search Criteria and Results
Search Terms
Row 1
Row 2
Row 3
Row 4

(“kidney cancer” or “renal cell carcinoma”) and ("pulmonary
embolism" or "deep venous thrombosis" or “venous
thromboemb*” or "thromboemb*")
(“kidney cancer” or “renal cell carcinoma”) and
("myocardial infarction" or “stroke” )
#1 or #2
Articles included in the literature review

Articles
found
279
92
355
58

Theoretical Framework
The theoretical framework for the study of factors related to ATEs and VTEs in
elderly kidney cancer patients was the advanced epidemiologic triangle, which is
applicable to diseases and conditions other than infectious diseases (Merrill, 2009). This
epidemiologic triangle consists of three components –population, causative factors, and
environmental factors, and also incorporates time (Merrill, 2009). The advanced
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epidemiologic triangle does not assume a single cause or etiology, and allows for the
modeling the complex nature of conditions (Merrill, 2009).
The outcome, ATE or VTE, in elderly kidney cancer patients is influenced by
several factors, some directly and others indirectly. The population factors are increasing
age, gender, marital status, region of residence or diagnosis, number of comorbidities,
and history of cardiovascular or thromboembolic events. These characteristics have been
shown to be risk factors for VTEs (Alcalay et al., 2006; Chew et al., 2007; ConnellyFrost et al., 2013; Hall et al., 2009; Walker et al., 2013). The causative factor or exposure
of interest in this study is kidney cancer. The factors which may affect development of a
VTE or ATE are year of diagnosis, cancer stage, and cancer treatment. Cancer treatments
include receipt of chemotherapy or immunotherapy, receipt of targeted therapies, or
undergoing a cancer-directed surgery (e.g., nephrectomy). Whether tumor histology
group is a risk factor for thromboembolic events in kidney cancer patients has not been
assessed. However, in some cancer types, histology has been an independent risk factor
for thromboembolic events (Alcalay et al., 2006; Chew et al., 2007). Major cardiac or
vascular surgery and placement of a central venous catheter are grouped with the
environmental risk factors for thromboembolic events (Alcalay et al., 2006; Khorana &
Connolly, 2009; NCCN, 2015).
Thus the framework for this study was constructed from patient and tumor
characteristics, kidney cancer treatments, and whether the patient had the insertion of a
central venous catheter or underwent a major cardiac or vascular surgery. Studies of risk
factors for ATEs and VTEs in cancer patients using the SEER-Medicare database
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included these factors in their initial or final multivariate models (Connelly-Frost et al.,
2013; Doyle et al., 2005; Hall et al., 2009). The Connelly-Frost et al. (2013) article, the
only one which analyzed any kidney cancer patients, found that atherosclerosis, presence
of a central venous catheter, diabetes, high-risk surgery, history of CVD, and kidney
disease were effect measure modifiers of the risk of VTEs in RCC patients compared to
the matched, noncancer cohort. Male gender; diagnoses of atherosclerosis, diabetes,
hypercholesterolemia, kidney disease, varicose veins, history of cancer diagnosis, history
of VTE; receipt of chemotherapy or immunotherapy treatment; placement of a central
venous catheter; undergoing high-risk surgery; and cancer stage were statistically
significant predictors of new VTEs (DVT, pulmonary embolism or other thromboembolic
events) in the 12 months after RCC diagnosis (Connelly-Frost et al., 2013). Other studies
which examined risk factors of VTEs using other data sources found some of these
factors as independent predictors in multivariate models (Agnelli et al., 2006; Alcalay et
al., 2006; Blom et al., 2004; Chew et al., 2008; Khorana et al., 2008; Moore et al., 2011;
Scappaticci et al., 2007). Where available they also included clinical data, which was not
available in the SEER-Medicare data (Agnelli et al., 2006; Blom et al., 2004; Khorana et
al., 2008; Moore et al., 2011).
Smith et al. (2014) used a subset of these factors to estimate the risk of VTEs in a
kidney cancer population compared to a noncancer population matched on age, sex, and
comorbidity score. After adjusting for the matching and year of cancer diagnosis, they
found that the risk of VTEs after cancer diagnosis was higher than the risk in a noncancer
population after adjusted for matching and year of cancer diagnosis (Smith et al., 2014).
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The increased risk persisted even after stratifying by comorbidity score, time since cancer
diagnosis, whether or not the cancer was metastatic, and presence of surgery within 3
months of VTE (Smith et al., 2014). These factors, measureable in the SEER-Medicare
database, are discussed in further detail below.
The advantage of this framework was that it is comprehensive yet flexible enough
to assess risk factors for VTEs in the population of interest. The weakness of the
framework was that it can only include measurable information available in the study
data and therefore does not include clinical information or other variables which were
identified as risk factors in other studies.
Incidence of Venous Thromboembolic Events
Methods
The studies of incidence rates of VTEs for kidney cancer have analyzed different
populations with some variations of methods (Agnelli et al., 2006; Blom et al., 2006;
Chew et al., 2006; Connelly-Frost et al., 2013; Walker et al., 2013). The Walker et al.
(2013) study analyzed patients registered with a general practitioner in the United
Kingdom, diagnosed with a cancer in the national cancer registry database between 1997
and 2006, were 18 or older at time of cancer diagnosis, were included in the UK Clinical
Practice Research Datalink (CPRD) database linked to the Hospital Episode Statistics
data, had no history of VTE prior to the first cancer diagnosis, and the cancer diagnosis
occurred during a registration period but after the first year of registration at a practice (p.
1405). Cancer diagnoses were based on cancer registry data and only the first cancer was
selected for analyses (Walker et al., 2013). Duration of follow-up for the incidence rates
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was calculated as time from cancer diagnosis until diagnosis of a VTE, death, exit from a
practice which was linked to CPRD, or December 31, 2010. The median follow-up time
was 2 years with an interquartile range of 0.3 to 5.7 years for all cancer patients (Walker
et al., 2013). Statistics on follow-up time were not presented separately by cancer type, so
the corresponding information for the kidney cancer patients was not reported. Chew et
al. (2006) also analyzed cancer registry data; however it was linked to state hospital
discharge data. Connelly-Frost et al. (2013) reported incidence rates of VTEs in a subset
of kidney cancer patients using the SEER-Medicare database which is cancer registry
data linked to the Medicare claims database. The Medicare claims database includes
patient information from inpatient, outpatient, long-term, short-term, hospice and other
stays (Applied Research Program, 2013). Similarly, Blom et al. (2006) analyzed cancer
registry data linked to another data source, anticoagulation clinic data. However, the
study population for the Agnelli et al. (2006) study was selected prospectively from
patients undergoing cancer-directed surgery in Italian surgical departments. The main
strength of using cancer registry data is that it is a population-based data source. Linkages
with data sources where patients with VTEs are likely to be treated (e.g., hospitalization
data, anticoagulation clinics) increase the likelihood of capturing VTEs, however some
incidents may not be captured if the patient died prior to hospitalization or
anticoagulation treatment (Blom et al., 2006).
Unlike Walker et al. (2013), other studies restricted the maximum amount of
follow-up post cancer diagnosis. Chew et al. (2006) presented incidence rates and
cumulative incidence of VTEs in the first two years after cancer diagnosis, whereas
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Chavez-MacGregor et al. (2011), Connelly-Frost et al. (2013) and Shantakumar,
Connelly-Frost, Kobayashi, Allis, and Li (2015) restricted to a maximum of one year.
Studies reporting cumulative incidence of VTEs in kidney cancer patients used follow-up
of six months or less with follow-up starting at time of cancer diagnosis or date of cancerdirected surgery (Agnelli et al., 2006; Blom et al., 2006). Researchers have consistently
shown that VTEs after cancer diagnosis more frequently occur closer to the date of the
cancer diagnosis and are less common as time increases (Chavez-MacGregor et al., 2011;
Chew et al., 2006; Connelly-Frost et al., 2013; Walker et al., 2013). Thus, while
restriction of the duration of follow-up is reasonable, variations in reported incidence
measures may be due to differences in duration of follow-up time used. Another
difference in reported incidence measures may be due to the exclusion of patients with
prior VTEs. Walker et al. (2013) and Chew et al. (2006) excluded patients with prior
VTEs from analyses. Agnelli et al., (2006), Blom et al. (2006), and Connelly-Frost et al.
(2013) did not exclude patients with prior VTEs allowing for estimation of incidence
measures or risk by history of VTE. As history of VTE was shown to increase the risk of
a future VTE, the incidence measures from these studies are expected to be higher than
those from studies where patients with a prior VTE were excluded (Agnelli et al., 2006;
Blom et al., 2006; Connelly-Frost et al., 2013).
Three studies examined the incidence of VTEs in cancer patients in the period
prior to cancer diagnosis (Connelly-Frost et al., 2013; Shantakumar et al., 2015; White et
al., 2005). White et al. (2005) presented the number of VTE events in the 12 months prior
to the cancer diagnosis and the standardized incidence ratio comparing the observed
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counts to the expected counts in the general California population. The study population
consisted of all patients age 18 or older with a cancer diagnosed between 1993 and 1995
or 1997 and 1999 which was recorded in the California Cancer Registry (White et al.,
2005). Connelly-Frost et al. (2013) presented incidence rates in the 12 months prior to
RCC diagnosis for DVT, pulmonary embolism and OTE separately. Shantakumar et al.
(2015) presented incidence rates in the 12 months prior to soft tissue sarcoma diagnosis
for DVT, pulmonary embolism and OTE separately. Both Connelly-Frost et al. (2013)
and Shantakumar et al. (2015) used SEER-Medicare database and included patients 65
years of age or older at cancer diagnosis who had continuous coverage by Medicare Parts
A and B without participation in a managed care plan for at least 24 months prior to the
cancer diagnosis. Only the White et al. (2005) study excluded patients with a VTE
diagnosed more than 1 year prior to cancer diagnosis from the incidence calculations.
For this study, incidence rates were calculated prior to and after cancer diagnosis.
Incidence rates were calculated using 12 months in the period prior to cancer diagnosis
for kidney cancer patients and index date for the matched noncancer patients. For the
period after cancer diagnosis/index date, incidence rates were presented for the entire
follow-up period.
Incidence
Table 3 summarizes the incidence rates by cancer type, patient age, and stage for
several solid tumor types. Few studies contributed information for the same cell (e.g.,
reporting 60 years and older versus reporting 65 years and older) and one study
(Connelly-Frost et al., 2013) reported incidence rates separately for each type of VTE
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(DVT, pulmonary embolism, and OTE) for elderly patients diagnosed with RCC, a subset
of kidney cancer. Connelly-Frost et al. (2013) did not report an overall incidence rate for
any type of VTE, while most other articles reported overall incidence rates without
separating the rates by type of VTE.
Of the four studies which reported the incidence of VTEs in kidney cancer
patients, only one provided incidence rates for older patients (Agnelli et al., 2006; Blom
et al., 2006; Chew et al., 2006; Walker et al., 2013). The incidence rate for patients
diagnosed at age 60 or older at diagnosis was 14 per 1,000 person-years (95% CI 10 – 18)
(Walker et al., 2013). Although other studies of multiple cancer types have reported
differences in the incidence of VTEs for younger and older patients, Walker et al. (2013)
found that the incidence rate for kidney cancer patients diagnosed at ages 18 to 60 (12 per
1,000 person-years, 95% CI 8.1-19) was similar to the rate for the older patients (Chew,
Wun, Harvey, Zhou, & White, 2007; Hall et al., 2009). Walker et al. (2013) reported that
although the overall incidence rate for VTEs in all cancer patients 60 or older was higher
than the rate for younger cancer patients, that pattern did not hold for all individual
cancer types and for some types the pattern was reversed (Walker et al., 2013).
Timing relative to cancer diagnosis, stage at diagnosis, and time since cancer
diagnosis appeared to effect differences in incidence rates. Chew et al. (2006) reported
first and second year incidence rates for VTEs after a kidney cancer diagnosis by
summary staging. The first year incidence rates were higher than the second year, and
incidence rates increased with later stage (Chew et al., 2006). The incidence rates for
VTEs in the first year after cancer diagnosis were 12, 37, and 60 per 1,000 person-years
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for localized, regional, and distant metastatic stage, respectively (Chew et al., 2006). The
rates in the second year were approximately a quarter of the rates for the first year for
each stage (Chew et al., 2006). Other studies also consistently found that the incidence
rates or proportions of VTEs in kidney cancer patients or cancer patients with other tumor
types were highest in the periods directly after the date of cancer diagnosis, then
decreased for later periods from the date of cancer diagnosis (Chew et al., 2008;
Connelly-Frost et al., 2013; Moore et al., 2011; Walker et al., 2013). Studies of other
tumor types also reported higher incidence rates in patients diagnosed with later stages of
cancer (Alcalay et al., 2006; Chew et al., 2007, 2008; Connelly-Frost et al., 2013; Moore
et al., 2011).
Studies of breast, lung, and colorectal cancer patients have been inconsistent as to
whether incidence rates of VTEs differ by histology group (Alcalay et al., 2006; Blom et
al., 2004; Chew et al., 2007, 2008). A study of colorectal cancer patients found
statistically significant differences in the 2-year cumulative incidence of VTEs by
histology group (Alcalay et al., 2006). Incidence rates also appear to vary by histology
group in lung cancer patients as well. The incidence rates in patients with squamous cell
carcinoma was 21.2 per 1,000 person-years (95% CI 10.1-36.2) as compared to 66.7 per
1,000 person-years (95% CI 36.2-106.2) in patients with adenocarcinoma lung cancers
(Blom et al., 2004). The increased risk persisted even after adjusting for age, gender, and
cancer treatment. The incidence rates of VTEs also appeared to differ by histology group
in lung cancer patients in a study by Chew et al. (2008), however no statistical testing
was done to compare the incidence rates by histology type nor were confidence intervals
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for the incidence rates reported. However, a study of breast cancer patients reported little
difference between incidence rates by histology group (Chew et al., 2007). No studies
were identified which calculated incidence rates of VTEs in kidney cancer patients by
histology group.
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Table 3
Incidence Rates of VTEs by Cancer Type and Age
All
Ages

Pancreatic

98
-

Less
than
60
years
of age
127
-

Lung

44
44
-

48
-

42
-

11
-

50
-

60

Walker et al., 2013
Blom et al., 2004
Chew et al., 2006
Hall et al., 2009

Breast

9
12
-

5
-

12
-

8
5
-

68
28
-

50

Walker et al., 2013
Chew et al., 2007
Chew et al., 2006
Hall et al., 2009

Colorectal

17
-

16
-

17
-

9
-

43
-

50

Walker et al., 2013
Chew et al., 2006
Hall et al., 2009

Prostate

9
-

7
-

9
-

8
-

9
-

14

Walker et al., 2013
Chew et al., 2006
Hall et al., 2009

Kidney

13
13
25
-

12
-

14
-

12

60

-

-

-

108

-

-

229

RCC

60 years
or older/
65 years
or older

All ages,
localized
stage

All ages,
advanced
stage

65 years
or older,
advanced
stage

References

89
-

42
-

200
-

174

Walker et al., 2013
Chew et al., 2006
Hall et al., 2009

-

-

-

Walker et al., 2013
Blom et al., 2006
Agnelli et al., 2006
Chew et al., 2006
Connelly-Frost et
al., 2013

Noncancer 3.0
1.0
4.3
Walker et al., 2013
cohort
Note. Rates are per 1,000 person-years and based on the first year after cancer diagnosis, except for rates
from Blom et al. (2006) and Chew et al. (2007) which are based on the first six months after cancer
diagnosis.

Of the studies identified which contained incidence of VTEs in kidney cancer
patients, only one reported rates in older patients, one stratified by cancer stage, and the
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others reported cumulative incidence. Differing patient populations and methods makes
comparison across studies challenging. The increased incidence of VTEs in the period
just after kidney cancer diagnosis is consistent with findings in other cancer types,
however the incidence of VTEs may not follow the pattern of higher incidence in older
patients and whether there are any differences by histology group has not been assessed.
Risk Factors for Venous Thromboembolic Events
Methods
Most studies used the Cox proportional hazards model to analyze the time to the
first VTE after cancer diagnosis and generate hazard ratios for risk factors (Alcalay et al.,
2006; Blom et al., 2004; Chew et al., 2006, 2007, 2008; Connelly-Frost et al., 2013; Hall
et al., 2009; Walker et al., 2013). The hazard ratio estimates the incidence rate ratio as
long as the Cox proportional hazards assumption holds true (Hoffman et al., 2008;
Spruance, Reid, Grace, & Samore, 2004). Less commonly, odds ratios from multivariate
logistic regression analyses were presented based on an outcome of occurrence of a VTE
during follow-up (Agnelli et al., 2006; Blom et al., 2005; Khorana et al., 2008; Moore et
al., 2011). One study used logistic regression and generated odds ratios for identifying
risk factors (Chavez-MacGregor et al., 2011).
The main strength of using the hazard ratio over using the odds ratio as the
epidemiologic measure includes the ability to account for varying patient follow-up time.
This is important as survival time differs greatly by one potential risk factor, stage, and
forcing a minimum amount of follow-up/survival time could bias the study towards
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including only the patients with lower stage or who are healthier (American Cancer
Society, 2014).
Cox proportional hazards model were used to compare the incidence rates of
VTEs during the 12 months prior to the index date between exposed patients and matched
unexposed patients (Research Question 1) and for the period after index date (Research
Question 2).
Tumor Type
Several studies have reported differences in the risk of VTEs in cancer patients by
tumor type (Blom et al., 2005; Hall et al., 2009; Walker et al., 2013; White et al., 2005).
A study comparing the incidence of VTEs in California cancer patients diagnosed
between 1993 and 1995 or 1997 and 1999 to the incidence rates in the total California
population reported standardized incidence ratios (SIRs) ranging from 0.6 to 4.2
depending on tumor type (White et al., 2005). The standardized incidence ratio for VTE
in kidney cancer patients was 2.5 (95% CI 1.5-3.9), the standardized incidence ratio for
acute myelogenous leukemia patients was 4.2 (95% CI 2.4-6.8), and for melanoma the
standardized incidence ratio was 0.6 (95% CI 0.2-1.1) (White et al., 2005). Similarly, a
study of cancer patients in the Netherlands reported adjusted odds ratios of 1.6 to 28.0 for
VTEs depending on the type of cancer (Blom et al., 2005). The adjusted odds ratio for
VTE in kidney cancer patients was 6.2 (95% CI 0.8-46.5), but patients with a
hematologic cancer had an adjusted odds ratio of 28.0 (95% CI 4.0-199.7) (Blom et al.,
2005). Venous thromboembolic events occurred at a higher rate in breast cancer patients
(HR = 4.86, 95% CI 2.93-8.08), female pancreatic cancer patients (HR = 21.57, 95% CI
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12.21-38.09), and male pancreatic cancer patients (HR = 17.68, 95% CI 9.48-32.95)
compared to prostate cancer patients (Hall et al., 2009). Cancer is comprised of several
heterogeneous diseases which vary in presentation, characteristics, risk factors, and
treatments (National Cancer Institute, 2013). Differences in the risks of VTE by tumor
type indicate that findings based on one tumor type may not necessarily hold true in other
tumor types. Thus, there is a need for assessment of the risk factors for VTEs by specific
tumor type. My goal in conducting this study is to add to the evidence for or against the
association between previously identified risk factors and the occurrence of VTEs in
kidney cancer patients.
Age at Diagnosis
Similar to the inconsistent findings regarding differences in incidence rates by age
group, study results have not been consistent as to whether age is an independent risk
factor for VTEs in cancer patients after adjusting for other factors. Additionally, the
majority of evidence was based on studies of multiple tumor types combined or
individual tumor types other than kidney cancer.
One study which assessed the association between age and incidence of VTE in
the year after kidney cancer diagnosis found no significant risk with increasing age after
adjusting for race, gender, and stage (HR = 1.0, 95% CI 0.8-1.1) (Chew et al., 2006).
Chew et al. (2006) analyzed patients diagnosed between 1993 and 1995 in California and
excluded any patient with a hospitalization for VTE between 1991 and the cancer
diagnosis. In a study of elderly RCC patients Connelly-Frost et al. (2013) similarly found
no association between age at diagnosis and development of VTE after cancer diagnosis.
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Some studies of combined tumor types reported that the risk of VTEs in cancer
patients increases with age. In one study, the risk increased 19% (OR = 1.19, 95% CI
1.02-1.39) for each 10-year increase in age at diagnosis after adjusting for gender, race,
presence of a CVC, stage and performance status (Moore et al., 2011). A study of cancer
patients of all ages and multiple types undergoing cancer-directed surgery found a 2.6fold risk of VTEs in patients age 60 or older compared to patients under 60 (OR = 2.6,
95% CI 1.2-5.7) (Agnelli et al., 2006).
Studies of the association between age and risk of VTE within specific tumor
types have shown inconsistent results. Researchers focusing on breast cancer and
colorectal cancer patients reported increasing risk of VTE in older age groups compared
to patients less than 45 years old or 50 years old or younger at diagnosis (Alcalay et al.,
2006; Chew et al., 2007). In a study of breast cancer patients 66 years or older at
diagnosis, researchers also reported increasing risk of VTEs with increasing age at
diagnosis (Chavez-MacGregor et al., 2011). Another study of patients with ovarian
serous or clear cell carcinoma reported that age of 60 years or older increased the risk
compared to patients less than 60 years of age (Matsuo et al., 2015). In contrast, a study
of lung cancer patients found that age at diagnosis after age 44 was protective against the
development of VTE after cancer diagnosis in non-small cell lung cancer (Chew et al.,
2008). The adjusted hazard ratios for increasing age groups in patients diagnosed with
small cell lung cancer were also less than 1.0; however they did not reach statistical
significance (Chew et al., 2008). Age was also not associated with development of VTE
after adjusting for tumor type, gender, and receipt of chemotherapy in a study of elderly
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late stage breast, lung, colon, prostate and pancreatic cancer patients (Hall et al., 2009). A
study of chemotherapy-associated VTE in cancer patients of multiple tumor types also
did not find an association with age after adjusting for other risk factors (Khorana,
Kuderer, Culakova, Lyman, & Francis, 2008). Other studies in multiple tumor types
adjusted for age in the multivariate models assessing risk factors for VTEs without
indicating whether age was evaluated as an independent risk factor (Blom et al., 2004,
2005, 2006).
Given the inconsistent results in the literature, there is a need to assess whether
there are differences in the risk of VTE by age group within the elderly kidney cancer
population independent of other risk factors. The prevalence of comorbidities varies by
age group and patterns of other risk factors, such as receipt of cancer treatment, are
different in elderly patients as compared to younger cancer patients (NCCN, 2015;
Piccirillo et al., 2008). Thus the identification of risk factors in elderly kidney cancer
patients as the risk factors may be different than those in younger kidney cancer patients
was a focus of this study.
Tumor Stage of Disease
Most studies reported that tumors with distant metastases have higher risks of
VTEs than patients with tumors without distant metastases. The risk in one study of
patients in the Netherlands reported an adjusted odds ratio of 58.0 (95% CI 9.7-346.7) for
patients with metastatic tumors compared to noncancer patients, and adjusted odds ratio
of 19.8 (95% CI 2.6-149.1) compared to patients with nonmetastatic tumors (Blom et al.,
2005). A study of cancer patients treated with surgery also reported increased risk with
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advanced and metastatic tumors compared to early stage tumors (OR = 2.7, 95% CI 1.45.2) (Agnelli et al., 2006). In elderly Medicare enrollees with breast cancer, patients
diagnosed with Stage IV cancer were at 1.5 to two-fold risk of venous thromboembolic
events compared to patients with Stage I tumors at diagnosis (Chavez-MacGregor et al.,
2011). A study of advanced and metastatic breast, colon, lung, and pancreatic cancers
reported that the risk of VTEs was higher in metastatic (Stage IV) tumors compared to
advanced (Stage III) tumors (HR = 1.75, 95% CI 1.44-2.12) (Hall et al., 2009). These
studies included none or few (less than 4%) of kidney cancer patients (Agnelli et al.,
2006; Blom et al., 2005; Hall et al., 2009). However, a study of elderly RCC patients also
reported higher rates of VTEs in patients with regional or distant summary stage
compared to localized stage (Connelly-Frost et al., 2013).
Tumor stage at diagnosis was assessed as a potential risk factor for development
of VTEs in elderly kidney cancer patients. Tumor stage in this study was defined by
AJCC staging which is more clinically relevant for treatment and prognosis than stage
defined by summary staging.
Histology
Two studies of lung cancer patients reported statistically significant increases in
the risk for VTEs in patients with adenocarcinoma compared to patients with squamous
cell carcinoma (Blom et al., 2004; Chew et al., 2008). Chew et al. (2008) also reported
increased risk for patients with carcinoma not otherwise specified compared to squamous
cell carcinoma lung cancer. Conversely studies of breast cancer patients and colorectal
cancer patients found no statistically significant difference in the risk of VTEs by
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histologic subtype (Alcalay et al., 2006; Chew et al., 2007). A study of ovarian cancer
patients, reported that risk for VTEs was increased in patients with advanced stage
ovarian clear cell carcinoma compared to advanced serous ovarian carcinoma (Matsuo et
al., 2015). Neither early stage serous ovarian carcinoma nor early stage ovarian clear cell
carcinoma increased the risk compared to advanced serious ovarian carcinoma (Matsuo et
al., 2015). No study was found comparing the risk of VTEs in kidney cancer patients by
histology group. Kidney cancer histology groups differ from the groups in other tumor
types, thus it cannot be inferred from the findings of other tumor types as to whether
there is any difference in risk by kidney cancer histology group. This study was the first
study (known to date) in which incidence rates of VTEs by histology group in elderly
kidney cancer patients were calculated. The risk of developing incident VTEs by
histology groups was also assessed. The histology analyses were unique contributions of
this study to the literature and further informed healthcare providers regarding the risks of
VTEs in kidney cancer patients.
History of VTE
Previous VTE (OR = 6.0, 95% CI 2.1-16.8), was a significant risk factor for VTEs
in cancer patients undergoing cancer-directed surgical treatment (Agnelli et al., 2006).
Similarly, in a study of elderly RCC patients, previous VTE prior to cancer diagnosis
increased the risk for DVT (HR = 5.4, 95% CI 4.4-6.4), pulmonary embolism (HR = 20.1,
95% CI 13.8-29.2), and OTE (HR = 7.6, 95% CI 5.9-9.9) (Connelly-Frost et al., 2013).
Some researchers have chosen to exclude patients with a prior VTE from the analysis
(Chew et al., 2006; Walker et al., 2013). However, such a restriction may exclude some
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of the patients at highest risk of developing VTEs after cancer diagnosis (Connelly-Frost
et al., 2013). Therefore, information about the history of VTE as a potential risk factor for
development of a subsequent VTE after cancer diagnosis was needed.
Cancer Treatments
The main treatments for RCC are nephrectomy, chemotherapy, and
immunotherapy (Kirkali, 2009; NCCN, 2015). All three of these treatments may be risk
factors for VTEs to varying levels. The evidence for increased risk after cancer-directed
surgery is mostly based on studies which included few to no kidney cancers and did not
analyze specific surgical types (Agnelli et al., 2006; Blom et al., 2006; Hall et al., 2009).
Nephrectomy. Connelly-Frost et al. (2013) reported incidence rates of VTEs
among RCC patients for DVT, pulmonary embolism and OTE by nephrectomy. Radical
and partial nephrectomies were not distinguished, and the incidence rates for each VTE
were higher in the patients who did not undergo nephrectomy (Connelly-Frost et al.,
2013). The unadjusted incidence rates per 1,000 person years for DVT, pulmonary
embolism and OTE were 95.5, 28.1, and 47.6 for patients who had a nephrectomy,
respectively (Connelly-Frost et al., 2013). For the patients who did not have a
nephrectomy, the incidence rates for the three VTEs were 148.6, 35.9, and 53.3,
respectively (Connelly-Frost et al., 2013). Nephrectomy was not an independent predictor
of individual VTEs in the study; however high risk cardiac or vascular surgeries in the
year after RCC diagnosis appeared to reduce the risk of VTE after adjusting for age and
race (Connelly-Frost et al., 2013). The authors hypothesize that the decreased risk may
have been due to prophylaxis and monitoring for VTE after surgery, as the clinical
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guidelines recommend risk assessment for VTE among cancer patients (Connelly-Frost et
al., 2013; NCCN, 2015). Similarly, if patients who underwent a nephrectomy received
thromboembolism prophylaxis, this may have accounted for the lowered incidence rates
and finding that nephrectomy did not have a statistically significant impact on risk of
VTE. Additionally, the patients who were at higher risk of VTE may have been poor
candidates for surgical treatment.
Hall et al. (2009) reported higher risk of VTE associated with cancer-directed
surgery in the year after a diagnosis of advanced lung, breast, colon, prostate or pancreas
cancer in elderly patients (RR = 4.0, 95% CI 3.49-4.57). However, receipt of surgery was
not a significant risk factor in the multivariate cox proportional hazards model (Hall et
al., 2009). A study of Dutch cancer patients also reported no significant increase in risk of
VTE in patients with cancer-directed surgery as the first course of treatment (adjusted RR
= 1.0; 95% CI 0.8–1.2) (Blom et al., 2006). This study included patients of multiple
tumor types and ages, and the risk of VTE by specific tumor type or surgery type was not
reported (Blom et al., 2006).
Agnelli et al. (2006) studied 2,373 cancer patients undergoing cancer-directed
surgeries in Italy, of which 79 (3.3%) had kidney cancer. It was reported that 71% to 87%
of the patients received in-patient antithrombotic prophylaxis and approximately 30% of
patients received prophylaxis treatments at discharge (Agnelli et al., 2006). The incidence
of VTE (DVT or pulmonary embolism) was higher in general surgery and gynecologic
surgery patients (2% to 2.8%) than in patients who underwent urologic surgery (0.87%)
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(Agnelli et al., 2006). Because all of the patients had surgery, incidence of VTEs could
not be compared to the incidence in patients without surgery.
Nephrectomy was defined dichotomously (i.e., receipt of nephrectomy or lack
thereof) instead of being defined by type of nephrectomy (e.g., no nephrectomy, partial
nephrectomy, or radical nephrectomy). Prophylaxis therapy for VTEs was not well
captured in the SEER-Medicare data and so was not assessed.
Chemotherapy. The approved chemotherapy treatments for kidney cancer are
targeted therapies, specifically the following tyrosine kinase inhibitors (TKIs):
bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, temsirolimus, axitinib, and
erlotinib (Monsuez et al., 2010; NCCN, 2015). Bevacizumab is also a monoclonal
antibody, while the other medications listed above are small molecule TKIs (Monsuez et
al., 2010). A meta-analyses and pooled studies of the association of treatment with
bevacizumab and the risk of VTEs in cancer patients reported conflicting results. One,
which included a study of RCC patients, reported an increased risk of VTE in patients
treated with bevacizumab plus chemotherapy (RR = 1.29, 95% CI 1.03-1.63) compared to
patients treated with chemotherapy without bevacizumab (Nalluri, Chu, Keresztes, Zhu,
& Wu, 2008). Two pooled studies found no statistically significant increase in the risk of
VTE in patients who were treated with chemotherapy plus bevacizumab, however neither
of those studies included RCC patients (Hurwitz et al., 2011; Scappaticci et al., 2007). Of
note, of the 15 studies included in the meta-analyses, the largest relative risk in a single
study was the analysis of RCC patients and that study was only one of two studies which
had statistically significant elevated risks (Nalluri et al., 2008). This study provided the
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estimation of risk for VTEs from chemotherapy for RCC patients as well as transitional
cell kidney cancer patients and risk for each histology group in all kidney cancer patients.
Evidence for an association between one of these newer treatments, bevacizumab,
and risk of VTE from meta-analyses or pooled studies is inconsistent (Hurwitz et al.,
2011; Nalluri, Chu, Keresztes, Zhu, & Wu, 2008; Scappaticci et al., 2007). The
cardiovascular risks of small molecule TKIs are primarily associated with ATEs, and no
associations were found with VTEs (Qi et al., 2013; Sonpavde et al., 2013; Svoboda,
Poprach, Dobes, Kiss, & Vyzula, 2012; Yeh & Bickford, 2009). However, similar to
bevacizumab, the meta-analyses evidence for VTEs was based on trial data, included
many tumor types, and patients of all ages.
Receipt of chemotherapy increased the risk of VTEs in one study of elderly breast
cancer patients (Chavez-MacGregor et al., 2011). A different study of specific
chemotherapies (cyclophosphamide, methotrexate, fluorouracil, doxorubicin, and any
chemotherapy not otherwise specified) in elderly breast cancer patients reported that none
of the chemotherapy types nor receipt of any chemotherapy were statistically significant
with an increase in myocardial infarction and had wide confidence intervals, after
adjusting for age, race, stage, year of breast cancer diagnosis, preexisting heart disease,
and comorbidity score (Doyle et al., 2005). The study had 31,748 women in the study,
5,575 of which received any chemotherapy, however the authors did not report the
number of patients with myocardial infarction (Doyle et al., 2005). Thus, it is difficult to
know whether the lack of association between myocardial infarction and chemotherapy
was due to no true association or small numbers in the model.
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A study of Dutch patients diagnosed with any cancer type reported a two-fold
relative risk of VTE in patients treated with chemotherapy for patients without metastases
(RR = 2.0, 95% CI 1.6-2.7) and for patients with metastatic tumors (RR = 2.3, 95% CI
1.7-3.1) (Blom et al., 2006). A study of VTEs in lung cancer patients also reported twofold elevated risks in patients with chemotherapy (OR = 2.9, 95% CI 1.8-4.0) (Blom et
al., 2004). Similarly, a study of advanced or metastatic breast, colon, lung and pancreatic
cancer reported higher risk of VTEs in patients treated with chemotherapy (HR = 1.31,
95% CI 1.10-1.57) (Hall et al., 2009).
Although there are several types of immunotherapy used to treat cancers, the main
immunotherapies used to treat RCC are two cytokines, interleukin-2 (IL-2) and interferon
alfa (NCCN, 2015). Neither IL-2 nor interferon alfa are listed as risk factors in the
clinical guidelines for VTE in cancer patients (NCCN, 2015). However, there is some
evidence for cardiovascular toxicity for both drugs. Cardiovascular disorders due to
treatment with interferon alfa are rare, however the evidence is based on studies limited
by small sample sizes, were not in RCC or kidney cancer patients, or were conducted
more than a decade ago (Sleijfer, Bannink, Van Gool, Kruit, & Stoter, 2005).
Cardiovascular toxicity is more common with IL-2, possibly due in part to its adverse
effect of vascular leak syndrome (Clark et al., 2013; Siegel & Puri, 1991). Based on the
toxicity profile of IL-2, it has not been widely used in elderly cancer patients (Clark et al.,
2013). However, a recent study of 22 elderly metastatic cancer patients reported less
toxicity for most adverse events compared to patients under age 65 years (Clark et al.,
2013). The main limitation of the study was the small sample size (Clark et al., 2013). In
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addition, it was not possible to assess the impact of bias introduced if the older patients
treated with IL-2 were healthier than the treated younger patients.
This study assessed receipt of chemotherapy and receipt of immunotherapy
dichotomously, without attempting to identify individual chemotherapy and
immunotherapy drugs or drug classes, as that level of detail was outside the scope of this
study.
Other Factors
The study of elderly RCC patients by Connelly-Frost et al. (2013) reported that
CVC and cardiac or vascular surgeries which occurred more than 30 days before the
event were independent risk factors protective for DVT, pulmonary embolism, and OTE
in RCC patients after the cancer diagnosis. The authors hypothesize that the decreased
risk observed may have been due to prophylactic treatment given to these patients
because of the association between surgery and CVC and VTE risk (Connelly-Frost et al.,
2013; NCCN, 2015). Additionally, the reduced risk from cardiovascular surgeries and
CVD may have also been due to selection bias as elderly patients undergo geriatric
assessments as an additional screening when determining how to treat the patient’s cancer
(NCCN, 2015). The study by Alcalay et al. (2006) of colorectal cancer patients also
reported lower incidence of VTEs in patients who undergone a major abdominal surgery
compared to those who never had (HR = 0.4, 95% CI 0.3-0.4). This study also was unable
to assess use of prophylactic therapy (Alcalay et al., 2006). Similarly, a study of breast
cancer patients age 18 or older reported lower incidence risk of VTE in patients who
underwent breast-related surgery (HR = 0.6, 95% CI 0.5-0.7) (Chew et al., 2007).
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Conversely, the study by Chavez-MacGregor et al. (2011) in breast cancer patients
reported placement of a CVC within the first year after the cancer diagnosis increased the
risk of VTEs. CVC was not assessed as a potential risk factor in the Alcalay et al. (2006)
or Chew et al. (2007) studies.
A study of cancer patients aged 19 or older at diagnosis and treated with cisplatin
at the Memorial Sloan-Kettering Cancer Center in 2008 reported that a central venous
catheter increased the risk of a thromboembolic event, even after adjusting for age,
gender, race, Karnofsky performance status, cancer stage, and risk group (OR = 1.61,
95% CI 1.10-2.36) (Moore et al., 2011). Surgery was also assessed as a risk factor, but
was not statistically significant in univariate analyses. However, the timing of the surgery
variable was within two months of starting cisplatin treatment and the types of surgery
included in the variable were not described (Moore et al., 2011). This study included 932
cancer patients of multiple cancer types. Ten percent of the study population was
classified as “other” cancer types, which may have included kidney cancer (Moore et al.,
2011). The number and proportion of kidney cancer patients could not be determined
from the publication.
A study of elderly breast, colon, lung, prostate, and pancreas cancer patients with
Stage III or IV cancers found an increased incidence of VTEs in patients who had cancerdirected surgeries (p < 0.01), however the risk was not statistically significant in the
multivariate analysis (Hall et al., 2009). The risk of VTE varied widely by cancer type,
was increased in Stage IV cancers (HR = 1.75, 95% CI 1.44-2.12) compared to Stage III
patients, and receipt of chemotherapy (HR = 1.31, 95% CI 1.10-1.57) (Hall et al., 2009).
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A study of the risk of heart diseases, including myocardial infarction, in elderly breast
cancer patients reported that neither breast cancer surgery nor histologic subtype were
associated with the broad category of heart disease in this population after adjusting for
other factors (Doyle et al., 2005). CVC and other surgical procedures were not assessed
in the Doyle et al. (2005) study. This study included binary variables indicating insertion
of a CVC and receipt of a high risk surgery as potential risk factors for development of
VTEs.
Incidence of Arterial Thromboembolic Events
Incidence rates of ATEs in kidney cancer patients were not found in the published
literature, but cumulative incidence was found in RCC patients treated with
chemotherapy. According to prescribing information, the incidence of myocardial
infarction in clinical trials of Nexavar-treated patients with late-stage RCC was 2.9%
(Bayer HealthCare Pharmaceuticals, 2013). Similarly, clinical trials of Votrient-treated
patients with late-stage RCC reported 2% incidence of myocardial infarction or ischemia
(GlaxoSmithKline, 2014). However this information is from clinical trial data, may not
have been published, is not population-based, and is often limited by small sample size.
A meta-analysis of clinical trials which reported on the incidence of ATEs
(defined as myocardial infarction, arterial thrombosis, cerebral infarct, cerebral ischemia,
cerebrovascular accident, or myocardial ischemia) in RCC patients was restricted to
advanced or metastatic patients who received specific targeted therapies as treatment
(Choueiri et al., 2010). The incidence of ATEs in these RCC patients was 1.8% (Choueiri
et al., 2010). Another meta-analysis of clinical trial data reported an incidence of ATEs in
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RCC patients of 2.0% (95% CI = 1.5–2.7%) (Qi et al., 2014). There was some overlap in
the studies used by Choueiri et al. (2010) and Qi et al. (2014).
A pooled analysis of clinical trial data, but which included no kidney cancer
patients, reported an incidence of ATEs as 2.5% in control patients and 7.1% in
bevacizumab-treated patients 65 years of age or older (Scappaticci et al., 2007). In the
patients 65 years of age or older, the incidence of ATE was 2.6% and 4.4% in patients
without a history of ATE and 2.2% and 17.9% with a history of ATE, in the controls and
bevacizumab-treated patients respectively (Scappaticci et al., 2007). The definition of
ATEs used by Scappaticci et al. (2007) included the same events as Choueiri et al. (2010)
but also included angina pectoris. Neither Scappaticci et al. (2007), Choueiri et al. (2010),
nor Qi et al. (2014) reported incidence for individual ATE events.
A meta-analysis of patients with various cancers who participated in randomized
clinical trials of anti-EGFR agents reported an incidence of arterial thromboembolic
events of 4.5% in the patients the cituximab or erlotinib versus 3.4% in the comparison
group (Petrelli, Cabiddu, Borgonovo, & Barni, 2012). One of the studies was of RCC
patients, however the sample size was only 104 patients total with only 1 ATE event.
Myocardial infarction was included in the definition of ATEs, but ischemic stroke was
not.
One study of cancer patients treated with cisplatin-based chemotherapy reported
incidence of 0.2% for myocardial infarction and 2% for any arterial events (Moore et al.,
2011). This study analyzed 932 cancer patients aged 19 to 87 years of age treated in
2008, and it was unclear if any kidney cancer patients were included (Moore et al., 2011).

61
A study reported an incidence rate for ischemic stroke of 21.80 per 1,000 p-y in
the lung cancer group and 15.10 per 1,000 p-y in the noncancer comparison group (Chen,
Muo, Lee, Yu, & Sung, 2011). The patients were 20 or older at lung cancer diagnosis,
diagnosed between 1999 and 2007, and matched by age, sex, and month of lung cancer
diagnosis to a noncancer comparison group (Chen et al., 2011). All patients were
beneficiaries of the Taiwan National Health Insurance.
A study of Dutch lung cancer patients of all ages reported incidence rates of 4.5
and 3.8 per 1,000 p-y for myocardial infarction and ischemic stroke in the first six
months after cancer diagnosis (van Herk-Sukel et al., 2013). For 6 months after lung
cancer diagnosis until the end of follow-up, the incidence rate for myocardial infarction
and ischemic stroke were 1.9 and 1.8, respectively (van Herk-Sukel et al., 2013). There
were no statistically significant differences in incidence rates for the lung cancer patients
compared to a noncancer comparison group for myocardial infarction or ischemic stroke.
However because there were less than 15 of either myocardial infarction or ischemic
stroke events in those periods, there may not have been sufficient power to distinguish
any differences.
The 1-year cumulative incidence of ischemic stroke in cohorts of elderly cancer
patients and matched cohorts of noncancer patients vary by cancer type. The cumulative
incidence for breast cancer patients and the noncancer cohort were 3.6% and 3.6%
respectively (Navi et al., 2015). The incidences for prostate cancer and its comparison
cohort were similar to those for the breast cancer cohorts, 3.3% and 3.3%. However, the
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incidence rates were higher for colorectal cancer, 5.8% and 4.3%, and for lung cancer,
7.3% and 4.1% (Navi et al., 2015).
A study of Dutch patients of all ages who had been hospitalized for breast cancer
reported incidence rates of 1.6, 1.6, and 1.8 per 1,000 p-y for myocardial infarction in the
first six months after breast cancer hospitalization, 6 to 12 months after, and 12 months to
end of follow-up (van Herk-Sukel et al., 2011). For ischemic stroke, the incidence rates
for the same periods were 1.5, 1.8, and 1.6 (van Herk-Sukel et al., 2011). The number of
events was small (less than 10) in each period in the first 12 months after the breast
cancer hospitalization, but increased in the rest of the follow-up period. Similar to the
lung cancer study, after adjusting the incidence rates were not statistically significantly
different from a noncancer comparison group (van Herk-Sukel et al., 2011).
No report of incidence (rates or cumulative) of ATEs myocardial infarction, or
ischemic stroke in the broader kidney cancer population was identified. This study was
the first (known to date) to calculate incidence rates for ATEs in elderly kidney cancer
patients utilizing a large, population-based data source, and which presented the
incidence rates stratified by patient and tumor characteristics. Incidence rates for ATEs
were presented overall as well as for individual ATEs (myocardial infarction and
ischemic stroke). Although ATEs were rarer than VTEs, the incidence and risk of ATEs
were of interest particularly for understanding the background rate of these conditions
and interpreting clinical trial or post-marketing drug safety profiles (FDA, 2011).
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Risk Factors for Myocardial Infarction and Ischemic Stroke
Myocardial infarction and ischemic stroke may be higher in cancer patients than
noncancer patients, although the risk may vary by cancer type. The standardized
incidence ratio for ischemic stroke in Swedish kidney cancer patients was 1.1 (95% CI
1.1 – 1.2) (Zoller, Ji, Sundquist, & Sundquist, 2012). The standardized incidence ratios
for other cancers in this population ranged from 0.7 to 1.6, with an overall standardized
incidence ratio of 1.2 (95% CI 1.2 – 1.2) (Zoller et al., 2012). Another study of Swedish
breast cancer patients reported an increased risk of ischemic stroke in breast cancer
patients aged 55 to 69 (RR = 1.1, 95% CI 1.0–1.3) and breast cancer patients 70 years or
older (RR = 1.1, 95% CI 1.0–1.2) compared to the expected numbers of events in the
general population of those age groups (Nilsson et al., 2005).
A study of Taiwanese cervical cancer patients who underwent radiotherapy had
higher risks of myocardial infarction and ischemic stroke than a comparison group of
appendectomy patients. The adjusted hazard ratios for myocardial infarction and
ischemic stroke in cancer patients compared to the comparison group were 1.58 and 1.52,
both with p-values of 0.01 or less (Tsai et al., 2013). A study of Taiwanese head and neck
cancer patients reported higher risk of stroke compared to noncancer patients (adjusted
HR = 1.5, 95% CI 1.4 – 1.7) (Chu et al., 2011).
Two articles were identified which assessed risk factors for myocardial infarction
or ischemic stroke in lung and breast cancer patients (van Herk-Sukel et al., 2011, 2013).
Both studies were conducted in Dutch cancer patients of all ages. The risk factors for
myocardial infarction after breast cancer hospitalization increased with age 50 and older
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compared to 49 and younger, prior use of antihypertensive drugs, and a hospitalization of
11 or more days within the first six months after breast cancer hospitalization (van HerkSukel et al., 2011). The risk factors for ischemic stroke was age of 70 or older compared
with patients 49 or younger at diagnosis, prior use of platelet aggregation inhibitor drugs,
prior use of antihypertensive drugs, and prior use of antidiabetic drugs (van Herk-Sukel et
al., 2011).
The risk factors for myocardial infarction or ischemic stroke in lung cancer
patients in the period starting sex months after the cancer diagnosis to the end of the
follow-up period were age of 65 years or older, prior hospitalization for the condition,
prior drug use of antithrombotic drugs, cardiovascular drugs, or antidiabetic drugs (van
Herk-Sukel et al., 2013). Female gender was protective for both conditions (van HerkSukel et al., 2013).
In a study of lung cancer patients in Taiwan, the risk factors for any type of stroke
(other than traumatic stroke) were age, male gender, blue collar or other work compared
to white collar work, history of hypertension, history of diabetes, history of coronary
heart disease, history of atrial fibrillation, and history of coronary obstructive pulmonary
disorder (Chen et al., 2011). Decreasing urbanization was identified as protective against
stroke (Chen et al., 2011). These findings were based on the unadjusted hazard ratios as
adjusted model results were not presented.
Studies of risk factors for ischemic stroke comparing cancer patients and
noncancer patients have reported similar prevalence of several risk factors in the two
groups. Two studies reported lower prevalence of atrial fibrillation in cancer patients who
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had a stroke than in noncancer stroke patients (Karlinska, Gromadzka, Karlinski, &
Czlonkowska, 2015; Kim & Lee, 2014). No differences in the prevalence of diabetes or
smoking status were found (Karlinska et al., 2015; Kim & Lee, 2014). The Karlinska et
al. (2015) article found a lower prevalence of previous stroke in cancer patients, but no
difference in the prevalence of hypertension, or congestive heart failure. Kim and Lee
(2015) reported lower prevalence of hypertension, ischemic heart disease,
hyperlipidemia, and family history of stroke in cancer patients compared to the noncancer
patients. There was no difference in the prevalence of previous stroke in the cancer and
noncancer patients (Kim & Lee, 2014). Although both studies included patients with
various kinds of cancers, neither Karlinska et al. (2015) nor Kim and Lee (2014) had
more than five kidney cancer patients in their studies.
The published literature regarding risk factors for myocardial infarction or
ischemic stroke in cancer patients was limited to a couple of tumor types. Age, comedications, and comorbidities increased the risk of the outcomes. In comparison with
noncancer patients, the prevalence of risk factors for ATEs was similar for smoking and
diabetes, but lower for atrial fibrillation. Whether the prevalence of other risk factors
differed between cancer and noncancer patients depended on the study population and
methodology. Research on the risk factors for ATEs in kidney cancer patients was not
found, and so this study will make a contribution to the literature by providing
information in this area.
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Summary and Conclusions
This literature review summarized what was known about the incidence of VTEs
and ATEs in kidney cancer patients and the assessed risk factors for VTEs. Incidence
rates for VTEs in kidney cancer patients are approximately 13 – 14 per 1,000 personyears overall, but are higher for more distant stage (Chew et al., 2006; Walker et al.,
2013). No significant differences in the rates of VTEs in kidney cancer were observed for
older patients compared to younger patients (Chew et al., 2006; Walker et al., 2013).
Studies of other tumor types have been inconsistent as to whether there are differences in
rates or risk of VTEs by age at cancer diagnosis (Alcalay et al., 2006; Chew et al., 2007,
2008; Hall et al., 2009; Khorana et al., 2008). While studies have consistently shown that
the risk of VTE varies significantly by tumor type, there are very few studies conducted
specifically in kidney cancer patients (Blom et al., 2005; Hall et al., 2009; Walker et al.,
2013; White et al., 2005). Thus, it is unclear whether VTE risk factors identified in other
tumor types are risk factors for VTEs in kidney cancer patients as well. In addition,
incidence and risk of VTEs and ATEs is noticeably absent for kidney cancer histology
groups. Venous thromboembolic events in cancer patients have been more studied than
ATEs for all tumor types including kidney cancer. This study provided incidence rates for
VTEs and ATEs in elderly kidney cancer patients, described incidence rates by histology
group, and assessed independent risk factors for VTEs in this population including
histology group.
Chapter 3 provides more detail on the study population criteria, calculation of
incidence rates, and the Cox proportional hazards models which were conducted for the
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descriptive analyses and to answer the research questions. Each variable and how it was
constructed are provided. Threats to validity and ethical concerns are discussed as related
to this study.
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Chapter 3: Research Method
Introduction
The previous chapters described the importance of VTEs and ATEs in elderly
cancer patients, summarized the literature, and highlighted the gaps in knowledge. The
problem was that incidence rates of VTEs and ATES for elderly kidney cancer patients
(ages 65 years or older at diagnosis) are not readily available in the literature, much less
incidence rates by histology group, and other patient and tumor characteristics. Analysis
of risk factors for VTEs in elderly kidney cancer patients was also needed.
This chapter described the rationale and methodology for using a quantitative,
retrospective cohort study design. The study population, inclusion and exclusion criteria,
the data set characteristics and procedures for accessing the data set, operational
constructs, the data analysis plan, threats to validity, and ethical procedures were
thoroughly discussed.
Research Design and Rationale
The dependent variables were diagnoses of VTE or ATE, depending on the
analysis or research question. For Research Question 1, the outcome was the calculation
of incidence rates for diagnosis of the first incident VTE/ATE in the year prior to kidney
cancer diagnosis or index date. Hazard ratios were calculated to estimate the incidence
rate ratios of VTE/ATEs comparing the exposed to unexposed groups. For Research
Question 2, the dependent variable was the calculated hazard ratio approximating the
incidence rate ratios of the incidence rate of VTE/ATE in the exposed and the incidence
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rate of VTE/ATE in the unexposed. Only the first incident event was counted for all
analyses.
The exposed and unexposed patients were matched on age (in years) at kidney
cancer diagnosis (exposed) or index date (unexposed), gender, race, SEER registry area,
and duration of follow-up. For matching, duration of follow-up for the unexposed was
required to be equal to or greater than the duration of follow-up for the exposed.
However, for the analyses, the duration of follow-up for the unexposed was truncated to
the same value as the corresponding kidney cancer patient. Patients from the exposed and
unexposed cohorts were matched in order to reduce the likelihood that the differences in
the incidence rate ratios are due to age, gender, or any of the other matching factors, as
estimating any difference in rate ratios due to exposure status is the objective.
The analysis for Research Question 3 included kidney cancer patients only. The
dependent variable was the time in years from kidney cancer diagnosis to occurrence of
the first VTE or duration of follow-up. Individual dependent variables were created for
each VTE and for any VTE. The potential predictors included in the initial (full) model
were age at diagnosis, race, gender, diabetes, atherosclerosis, varicose veins,
cardiovascular surgery, central venous catheter, kidney disease, history of VTE, history
of cardiovascular disease, AJCC stage, treatment type (immunotherapy, nephrectomy,
chemotherapy), histology group, SEER registry region, Charlson comorbidity score, and
year of diagnosis.
This study was a quantitative, retrospective cohort study. A cohort study was the
appropriate study design for assessing incidence rates and incidence proportions for the
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descriptive analyses and research questions (Aschengrau & Seage, 2008; Rothman,
1986). The resource constraint from the use of a retrospective cohort design using
secondary data for this research study was that only the data on outcomes and
independent variables included in the dataset were available. Thus measurement of some
risk factors for incident VTEs and ATEs were not in the dataset, and were not included in
this study. The use of the study design was consistent with other studies which add to the
understanding of incident VTEs and ATEs in cancer patients (Connelly-Frost et al., 2013;
Walker et al., 2013).
Data Source
The SEER-Medicare database is a linkage of the SEER cancer registry data with
Medicare claims data, creating a population-based resource for cancer-related analyses
(Warren et al., 2002a). Also available with the SEER-Medicare database is Medicare
enrollment and claims data for a sample of noncancer patients. The noncancer patients
are selected from a 5% random sample of Medicare beneficiaries who reside in the same
SEER registry areas and who are not in the SEER cancer registry database (Applied
Research Program, 2013; Warren et al., 2002a). The noncancer patient cohort was used in
this research study as the unexposed comparison group.
The SEER data contains newly diagnosed cancers in the SEER registry areas,
some of which began collecting data in 1973. As of 2013, there were 18 registry areas
which covered approximately 27% of the entire U.S. population (SEER, 2013). The
SEER data are of high quality and annually meet quality criteria of the North American
Association of Central Cancer Registries (Warren et al., 2002a).
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Medicare is a government program to insure the elderly in the United States,
although persons with disabilities or end-stage renal disease may qualify for Medicare
coverage before 65 years of age. The Medicare data include claims plus demographic and
entitlement information from the Medicare master enrollment file (Applied Research
Program, 2013; Warren et al., 2002a).
The two databases were first linked in 1991 and updated in subsequent years, with
current plans to update the linkage every two years (Applied Research Program, 2013;
Warren et al., 2002a). Social security number, sex, name, and date of birth are used to
link the databases (Warren et al., 2002a), however personal identifiers such as social
security number and name are not included in the final database for release to
researchers. Generalizability of the database has been assessed as well. On characteristics
such as age and sex, the database population is similar to the U.S. elderly population
(Warren et al., 2002a). However, the database differs from the U.S. elderly population in
race, residence in an urban (versus rural) location, participation in a Medicare managed
care plan, and cancer mortality rate (Warren et al., 2002a).
Although the linked SEER-Medicare database is a high-quality, population based
resource for researchers, it has several limitations. Limitations identified include no
information about services which are not covered by Medicare or which are paid for out
of pocket, incomplete claims for persons enrolled in Medicare managed care plans, and
the general limitations which affect any administrative claims databases (Warren et al.,
2002a). However, the database can be used for various types of studies along the entire
continuum of care for cancer patients (Applied Research Program, 2013). Study topics
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published include cancer screening, treatment patterns and outcomes, hospice and other
resource utilization, health economic studies, healthcare disparities, and survival analyses
(Applied Research Program, 2013; Warren et al., 2002a).
Study Population
The exposed cohort consisted of patients in the SEER-Medicare database
diagnosed with kidney cancer at age 65 years or older, diagnosed between the years of
2004 and 2009, and whose kidney cancer was their first primary cancer. Patient followup was from the month of kidney cancer diagnosis until death, participation in a managed
care plan, coverage by only Part A or B of Medicare, or December 31, 2010. For this
study, the estimated number of kidney cancer patients was 12,240. This estimate was
calculated by summing the number of kidney cancer patients in the SEER-Medicare
database between 2004 and 2009 (Applied Research Program, 2013) and multiplying by
69% to estimate the number of patients remaining after applying the study inclusion and
exclusion criteria. The percentage remaining after applying inclusion and exclusion
criteria was based on the proportion remaining after applying the same criteria for the
Connelly-Frost et al. (2013) study.
The patient criteria applied for the counts from the Applied Research Program
(2013) were: (a) patients 65 years of age or older at diagnosis, (b) kidney cancer was the
first diagnosed cancer (sequence number 00 or 01), and (c) patients had Medicare Part A
and B coverage and were not participating in a Medicare managed care program during
the month of diagnosis.
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A comparison cohort of noncancer patients were individually matched, without
replacement, to the kidney cancer patients by age at index date, sex, SEER registry
region, and duration of follow-up. The index date of the matched noncancer patient was
assigned as the month and year of diagnosis of its corresponding kidney cancer patient.
The unexposed patients were also required to have two years of continuous enrollment in
Medicare parts A and B prior to the index date with no participation in a managed care
program during that time. Each unexposed patient were required to have at least as much
follow-up as their corresponding exposed patient, however the follow-up for the
unexposed was truncated to the same month as the corresponding cancer patient. With
659,639 noncancer patients in the potential comparison group, the majority of exposed
patients were matched to an unexposed patient.
Sampling Strategy
The sampling strategy for the exposed cohort was to include all kidney cancer
patients who met the inclusion and exclusion criteria and were matched to a
corresponding unexposed patient. Cancer patients who developed multiple primary
cancers before or at the time of the initial kidney cancer diagnosis were excluded.
Inclusion criteria required all patients to have at least two years of continuous enrollment
in Medicare parts A and B prior to the index date and at least one month of survival after
the index date. Patients who participated in a managed Medicare plan in the two years
prior to the index date were excluded. The same inclusion and exclusion criteria were
applied to matched patients using the index date.
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Power calculations were not generated for the descriptive analyses. For Research
Question 1, the required sample size to achieve power of 0.8 ranged from 848 to 3594,
depending on the unknown true values of the overall response probability, covariate
standard deviation, and odds ratios for specific VTE or ATE. The assumptions used were
alpha level 0.05, covariate odds ratio of 1.2, and odds ratio for test predictor of 1.5 to
1.75. The ranges for the covariate odds ratio and test predictors were based on the values
reported by Connelly-Frost (2013).
For the second and third research questions, power calculations were generated to
compare two survival curves using the log-rank test. Using the assumptions that both
survival curves are exponential, a year (12 months) of follow-up time, and a two-sided
test at alpha level 0.05, a sample size of 1,044 per group is needed to achieve power of
0.8 and a sample size of 1,194 per group is needed to achieve power of 0.85. All power
calculations were generated using SAS 9.3 software.
Variable Definitions and Operationalization
Variables to identify the kidney cancer patients, variables related to the kidney
cancer diagnosis, patient characteristics and Medicare coverage or managed Medicare
plans were contained in or constructed from information in the SEER-Medicare Patient
Entitlement and Diagnosis Summary File. The Patient Entitlement and Diagnosis
Summary File contains cancer information at diagnosis and during first course of
treatment from the SEER program. The Medicare claims files were used to identify
cancer treatments, diagnoses of venous and arterial thromboembolic events, and the
medical conditions which are potential confounders or effect measure modifiers.
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The Medicare Entitlement files contain monthly indicators of participation in Part
A, Part B, or managed care plans. To determine eligibility, a patient must have had
coverage by Parts A and B of Medicare for 24 months prior to index date and no
participation in HMO during that time. Thus, each of the 24 variables for the period prior
to index date indicating Medicare coverage must have a value of 3, Parts A and B
coverage. Each of the 24 variables for the period prior to index date indicating managed
care participation must have a value of 0 indicating no participation to be eligible.
Duration of follow-up was calculated as the number of months after the index date until
the variable indicating coverage does not have a value of 3, the variable indicating
managed care participation has a value other than 0, the patient dies (using month and
year of death), or December 2010.
The index date for patients was defined as follows. For kidney cancer patients, the
index date was first day of the month and year of the first kidney cancer diagnosis. For
the matched, noncancer comparison group, the index date was the same as the index date
of the corresponding kidney cancer patient it is matched to. One of the matching criteria
was the comparator patient must meet the same Medicare coverage and managed care
criteria in the month of the index date.
Age at index date was calculated as the number of years between year of birth and
year of index date. Age was grouped into the following categories: 65-69, 70-74, 75-79,
80-84, and 85 or older.
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Race was provided by the Medicare Entitlement information and was categorized
as White, Black and other race. Because there were less than 10 patients in each cohort
with unknown race, those patients were included with the other race group.
Gender was categorized as male or female, and was provided in the Medicare
Entitlement file.
SEER registry area of diagnosis or residence was categorized using the United
States Census Region groupings for analysis of geographic region. The regions were
Northeast, Midwest, South and West. The states which make up each region are listed in
Appendix B.
For analyses of Research Questions 1 and 2, the unexposed patients (the
noncancer patients) were matched to the exposed patients on age at index date, gender,
race, SEER registry area, and duration of follow-up. The matched, unexposed patients
were assigned the same index date as the corresponding exposed patient, and thus were
required to meet the same criteria of Part A and B Medicare coverage with no managed
care participation prior to the same index date.
Kidney cancer was defined using International Classification of Diseases for
Oncology, 3rd edition (ICD-O-3) coding site for the kidney (C64.9), excluding histology
codes 9590-9989. Only malignant tumors were included.
The types of kidney cancer, transitional cell and RCC, were defined by ICD-O-3
codes as well. Transitional cell kidney cancer was defined as kidney cancers with
histology codes 8050-8130 (inclusive). RCC was defined as kidney cancers excluding
histology codes 8050-8130 (inclusive). The types of RCC were defined as Clear Cell
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(ICD-O-3 histology codes 8310 or 8312); Papillary (ICD-O-3 histology code 8260);
Chromophobe (ICD-O-3 histology codes 8317, 8270) and Other RCC (ICD-O-3
histology codes excluding 8050-8130 inclusive, 8310, 8312, 8317, 8260, and 8270).
For VTEs, each condition (deep vein thrombosis, pulmonary embolism, or other
thromboembolic events) were coded dichotomously, indicating whether or not a
diagnosis of the condition was recorded. The codes used to define these conditions are
located in Appendix B. A derived variable for any VTE was coded dichotomously.
Similarly, for ATEs, each condition (myocardial infarction or ischemic stroke)
were coded dichotomously, indicating whether or not a diagnosis of the condition was
recorded. For ischemic stroke, diagnoses were only included if they occurred during a
hospitalization. This is because outpatient claims with a diagnosis of ischemic stroke may
be for rehabilitation or other follow-up care and not actually indicate the incident stroke
event. The codes used to define these conditions are located in Appendix B. A derived
variable for any ATE was coded dichotomously.
Cancer treatments were coded as follows. Any chemotherapy was coded
dichotomously, indicating whether or not a cancer patient received chemotherapy. The
procedure and NDC codes used to identify chemotherapy are located in Appendix B. Any
immunotherapy was coded dichotomously, indicating whether or not a cancer patient
received immunotherapy. The procedure and NDC codes used to identify immunotherapy
are located in Appendix B. Nephrectomy was coded dichotomously, indicating whether
or not a procedure code for nephrectomy was coded. The procedure codes to identify
nephrectomy are in Appendix B.

78
The following conditions were defined dichotomously, with a value of 1
indicating whether or not the condition was reported in the claims data: diabetes,
atherosclerosis, varicose veins, high risk cardiovascular surgeries, placement of a CVC,
and kidney disease. The diagnosis and procedure codes to define each of these conditions
are located in Appendix B. High risk surgeries and placement of a CVC events were
restricted to those events which occurred more than 30 days prior to the outcome.
A weighted score was calculated from the conditions in the adapted Charlson
comorbidity index. The score was analyzed as 0, 1, 2, and 3 or greater. See Appendix C
for the index conditions and the ICD-9-CM diagnosis and procedure codes used to define
the score. See Appendix D for the program to calculate the score.
Data Analysis Plan
SAS 9.3 was used to perform all analyses. Analyses for each research question
and hypotheses are described below. Univariate and bivariate frequencies and descriptive
statistics were generated for variables to identify outliers and unusual values.
Descriptive Analysis 1
The first analysis involved the calculation of the incidence rates of individual
VTEs and of ATEs in elderly kidney cancer patients over the 12 months before and in the
follow-up period after cancer diagnosis. Incidence rates were calculated as the number of
incident events in the study period divided by the sum total of person-time at risk during
the period. No statistical tests were performed. For each of the prespecified patient and
tumor characteristics, the incidence rates of VTEs and ATEs were presented by age
group, race, gender, history of VTE/ATE, history of cardiovascular disease, AJCC stage,
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treatment by immunotherapy, treatment by nephrectomy, treatment by chemotherapy or
targeted therapy, histology group, Charlson Comorbidity Index, SEER registry region,
and year of diagnosis.
Descriptive Analysis 2
For this analysis, the proportion of elderly kidney cancer patients who
experienced incident VTEs and incident ATEs in discrete, mutually exclusive time
periods during follow-up (0 to 90 days, 91 to 180 days, 181 to 270 days, and 271 to 365
days) after cancer diagnosis were calculated. Incidence proportions were calculated as the
number of incident events in the time period divided by the number of patients still at risk
for an incident VTE or ATE during the period. No statistical tests were performed.
Research Question 1
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly
exposed (kidney cancer) patients 12 months before index date compare to a matched
unexposed (noncancer) Medicare population during the same 12-month timeframe?
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are
statistically significantly greater in the exposed patients than in the unexposed patients.
H01: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the year prior to the index date in the exposed patients and in the matched
unexposed patients.
Hazard ratios were calculated to compare the incidence rates of VTEs and ATEs
in cancer patients to the matched noncancer cohort in the period after diagnosis (index
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date). Adjustment was made for the matching of the cohorts using the STRATA
statement in the PHREG procedure of SAS.
Research Question 2
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in
elderly exposed (kidney cancer) patients after index date compare to a matched
unexposed (noncancer) Medicare population during the same timeframe?
HA2: In the follow-up period after the index date, the incidence rates of VTEs or
of ATEs are statistically significantly greater in the exposed patients than in the
unexposed patients.
H02: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the period after index date in the exposed patients and in the matched
unexposed patients.
Hazard ratios were calculated to compare the incidence rates of VTEs and ATEs
in cancer patients to the matched noncancer cohort in the period after diagnosis (index
date). Adjustment was made for the matching of the cohorts using the STRATA
statement in the PHREG procedure of SAS.
Research Question 3
Research Question 3: In the follow-up period after kidney cancer diagnosis, what
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE,
or OTE)?
HA3: No factors are statistically significantly associated with the time to newly
diagnosed VTEs in the period after kidney cancer diagnosis.
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H03: Tumor histology and other factors are statistically significantly associated
with the time to newly diagnosed VTEs after kidney cancer diagnosis.
For each question, a Cox proportional hazard model was used to identify
independent predictors for each outcome. The outcome was time to the occurrence of the
first VTE or ATE after kidney cancer diagnosis or duration of follow-up. The potential
predictors to be included in the initial (full) model were age at diagnosis, race, gender,
diabetes, atherosclerosis, varicose veins, cardiovascular surgery, central venous catheter,
kidney disease, history of VTE, history of cardiovascular disease, AJCC stage, treatment
type (immunotherapy, nephrectomy, chemotherapy), histology group, SEER registry
region, and year of diagnosis. Exploration of the data and these variables prior to
modeling included production of a correlation matrix to identify any highly correlated
variables. Highly correlated variables were those with an absolute value of the correlation
coefficient greater than or equal to 0.7 (Taylor, 1990). If two variables were highly
correlated, then only one variable of the pair were included in the model to avoid
redundancy.
Potential effect measure modifiers were identified by testing the equality of
survivorship over strata for each variable. If a variable had a p-value for the log rank test
less than 0.05, then this variable were characterized as a potential effect measure modifier
(Szklo & Nieto, 2006). Potential confounders were identified as those variables which
were a) associated with exposure and b) associated with outcome among the unexposed.
Mediating variables are variables which are on the causal pathway between the
independent and dependent variables (Creswell, 2009). None of the variables for the

82
model were considered mediating variables. The initial full model contained all potential
effect measure modifiers and confounders. The proportional hazards assumption was
tested for each variable. If the proportional hazards assumption did not hold true for any
variable, stratification of the model by this variable was used to account for the violation.
For those variables for which the proportional hazards assumption held, the final test for
effect measure modifiers were conducted by determining whether the p-value for
interaction term was less than 0.05 in the full model. Next the final confounders for the
model were identified as those variables for which there is a 15% change in the hazard
ratio estimate for the adjusted versus unadjusted model.
Alternative models were run using a Deyo-Romano adaptation of the Charlson
Comorbidity Index (CCI) instead of the individual variables (diabetes, cardiovascular
surgery, kidney disease, and history of cardiovascular disease), as the CCI includes these
procedures and diagnoses in addition to others (see Appendix C).
Survival curves were generated for incidence of VTEs and ATEs stratified by
patient and tumor characteristics, using the log-rank test to distinguish statistically
significant differences in curves at the 0.05 level.
Threats to Validity
The main threat to validity was unmeasured factors, such as smoking and patient
platelet counts, which may impact the incidence or risk of VTEs or ATEs. Other threats
to validity were minimized by the use of previously defined constructs for comorbidity
classification, exposure and independent variable definitions. Bias may also have been
introduced if any of the covariates in the model were mediator variables. Inclusion of
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mediator variables in the model will introduce bias if (a) confounders of the mediatoroutcome relationship are not adjusted for in the model, (b) the mediator-outcome
confounders are affected by exposure, or (c) there is an interaction effect between the
exposure and the mediator variables (Richiardi, Bellocco, & Zugna, 2013). None of the
variables in this study were considered mediator variables but were adjusted for as
confounders or effect measure modifiers.
Ethical Procedures
Accessing the Data
In order to access the SEER-Medicare database, several steps were completed.
The first step was to submit an application for review. The application contained the
completed application form which included a description of the study project and a
signed data use agreement (Applied Research Program, 2013). The data was only
available for purchase after the application has been approved. The proposal for the
original study using SEER-Medicare data was submitted and approved in 2006. The
request to update the study with additional cancer sites, years of data, and outcomes was
approved January 2013. As this project does not require restricted variables which may
compromise patient or provider confidentiality, the request form for these variables was
not necessary.
The data was accessed through a pharmaceutical company. The SEER-Medicare
account manager at the company was listed as the Principal Investigator and signatory on
the data use agreement, although the use of the data was restricted to my analysis as the
data may only be used for the project approved in the application (Applied Research
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Program, 2013). The study proposal for the research questions and hypotheses were
approved prior to purchase of the data. Note that IRB approval was not required as the
original proposal was approved prior to the inclusion of IRB approval as an application
component. However, IRB approval of this study was requested through Walden
University prior to start of any data analysis. The Walden University IRB approval
number for this study is 07-23-15-0083161.
The National Cancer Institute has taken multiple steps to protect patient and
provider confidentiality in the SEER-Medicare database and it is considered a limiteddata set per the Health Insurance Portability and Accountability Act (HIPAA) regulations
(Applied Research Program, 2013). The database uses encrypted identifiers for patients,
providers and hospitals; and does not provide variables such as patient zip code unless
justification is provided that the data are absolutely necessary for the research project.
Additional conditions to protect the data confidentiality and usage are required as part of
the data use agreement, including suppression of cell sizes less than 11 in tables.
The data was uploaded to a departmental LINUX server and stored securely and
centrally. No duplications were made. Access to this server was restricted solely to
qualified data analysts via a secure connection on a validated environment. Access to
source data directories and files were further protected by means of an electronic gateway
system which ensured that the data were accessible only to authorized users who
understood and agreed to comply with contractual obligations specific to the data source.
All work with the dataset was carried out by authorized personnel of the Worldwide
Epidemiology Department via the secured company network, and no data was stored on
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computer hard drives at any time. I was required to comply with existing policies and
procedures to ensure proper computer security and appropriate data access, storage, use,
and confidentiality. The data will be destroyed after five years, unless other arrangements
are made, as stipulated in the data use agreement.
Summary
This study aimed to address deficiencies in the published literature regarding the
incidence of VTEs and ATEs and the risk factors for VTEs in elderly kidney cancer
patients with Medicare coverage. Overall and stratified incidence rates and incidence
proportions were calculated for descriptive analyses 1 and 2. Rate ratios and 95%
confidence intervals were calculated for each VTE and ATE for the three research
questions, accounting for matching (for Research Questions 1 and 2) and differing
duration of follow-up for study population in the year after index date (Research
Questions 2 and 3). Cox proportional hazard models were used to identify statistically
significant predictors for each VTE to answer Research Question 3. The study used the
SEER-Medicare database which is a large, population-based data source consisting of
cancer registry data linked with Medicare claims data. Strengths of this study included
use of a large study population size (11,463 cancer patients and 11,463 matched
noncancer patients). Limitations included lack of lab data and limitations inherent in the
use of administrative claims databases. The contribution of this study was to improve the
knowledge surrounding the risks associated with these potentially serious events in
elderly kidney cancer patients.
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The following chapter presents the data analyses conducted to address the
descriptive analyses and research questions. Baseline descriptive and demographic
characteristics of the study population are presented in tabular form. The results for the
descriptive analyses and Research Questions 1 and 2 were reported and interpreted. For
Research Question 3, each step of testing and decision making for the potential
confounders and effect measure modifiers were presented along with the rationale for
including or excluding each variable from the final model. The chapter concludes with a
summary of the study results.

87
Chapter 4: Results
Introduction and Purpose of the Study
The purpose of this retrospective cohort study was to describe the incidence rates
of venous and arterial thromboembolic events in elderly kidney cancer patients and
compare the incidence rates in cancer patients with matched noncancer elderly patients.
In addition, the risk factors for venous thromboembolic events in elderly kidney cancer
patients were assessed. The three research questions and associated hypotheses are listed
below.
Research Question 1
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly
exposed (kidney cancer) patients 12 months before index date compare to a matched
unexposed (noncancer) Medicare population during the same 12-month timeframe?
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are
statistically significantly greater in the exposed patients than in the unexposed patients.
H01: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the year prior to the index date in the exposed patients and in the matched
unexposed patients.
Research Question 2
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in
elderly exposed (kidney cancer) patients after index date compare to a matched
unexposed (noncancer) Medicare population during the same timeframe?
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HA2: In the follow-up period after the index date, the incidence rates of VTEs or
of ATEs are statistically significantly greater in the exposed patients than in the
unexposed patients.
H02: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the period after index date in the exposed patients and in the matched
unexposed patients.
Research Question 3
Research Question 3: In the follow-up period after kidney cancer diagnosis, what
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE,
or OTE)?
HA3: No factors are statistically significantly associated with the time to newly
diagnosed VTEs in the period after kidney cancer diagnosis.
H03: Tumor histology and other factors are statistically significantly associated
with the time to newly diagnosed VTEs after kidney cancer diagnosis.
This chapter describes the process of identifying the data eligible for the study,
the data analyses processes including variable selection and modeling, and the analyses
results. The study results for each of the descriptive analyses and research questions are
thoroughly discussed.
Data Collection
All kidney cancer tumors diagnosed 1973 to 2009 were identified in the SEERMedicare database. Kidney cancer was defined by ICD-O-3 coding with malignant
behavior. During this period, 64,659 kidney cancer tumors were identified in 53,804
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patients. After restricting to the first kidney cancer for each patient, 43,784 patients had a
kidney cancer diagnosed between 2004 and 2009. The number of kidney cancer patients
excluded for each criteria are listed in Table 4. The distinct number of cancer patients
excluded for having any of the exclusion criteria was 32,319. The number in the exposed
cohort eligible for this study was 11,465. After matching the exposed cohort to the
unexposed, noncancer patients on age, sex, race, SEER registry region and duration of
follow-up; the final numbers of eligible patients for this study were 11,463 in the exposed
cohort and 11,463 in the unexposed cohort. The two exposed cohort members who were
not matched were male; one was 66 to 69 years of age and one was 85 or older at
diagnosis; and both were of unknown or other (neither White nor Black) race.
The excluded patients were much more likely to be younger (median age of 67
years with a range of 18 to 107 years) compared to the patients eligible for the study
(median age of 76 years with a range of 66 to 108 years). This was not unexpected as the
age, minimum duration of Medicare coverage, and reason for initial Medicare entitlement
criteria in effect excludes patients less than 66 years and 11 months old. The excluded
patients were more likely to be diagnosed in the later years of the study period, be male,
nonwhite, and reside in the West.
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Table 4
Exposed Cohort Exclusion Criteria and Patient Counts
Exclusion Criteria
Prior cancer in the SEER research data
Invalid date of death
Age less than 65 at date of kidney cancer diagnosis
Original reason for Medicare entitlement was disability or ESRD
Less than 24 months of Medicare coverage (A & B) before index date
Medicare managed care plan participation within 24 months before
index date
Less than 1 month follow-up after index date
Note. Exclusion criteria were not mutually exclusive.

Number of
Patients
Excluded
10,254
21
12,569
10,313
14,820
8,093
19,623

After matching by gender, age, region, race, and minimum duration of follow-up,
there were 11,463 patients in each cohort. Because the age-matching was done by
matching the year of birth and year of index date, not including month of birth, the
proportions in each age group differ slightly in spite of the matching. For example, a
patient in the unexposed cohort had the same year of birth and year of index date as
his/her corresponding exposed cohort member, but was born in a different month. Thus,
when I calculated age at index date using month of birth, year of birth, month of index
date and year of index date, the matched patient had an age which was 1 year greater or
younger than the corresponding exposed patient.
The kidney cancers in the exposed cohort were mostly renal cell carcinoma
(97.6%). The histology types were clear cell carcinoma (75.7%), with 8.5% papillary
tumors, 3.6% chromophobe, 9.7% other RCC types, and 2.4% Transitional cell tumors.
Approximately half of the kidney cancers were Stage I, with 7.4% Stage II, 14.5% Stage
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III, 18.1% Stage IV, and 10.3% unstaged or stage unknown. The majority of the cancer
patients were treated with a nephrectomy (66.8%), however less than 11 of the unexposed
cohort had nephrectomies as well. This was not surprising in the cancer patients as
nephrectomy is a primary treatment especially for patients with Stage I, II, and III kidney
cancer (NCCN, 2015). Nephrectomies in these noncancer patients were most likely due
to other conditions. Chemotherapy was used to treat 20.6% of the cancer patients and
immunotherapy was recorded for 4.2% of the cancer patients (Table 5).
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Table 5
Descriptive Characteristics of Study Population
Noncancer
patients
n (%)
Total study participants
11,463 (100)
Age at index date
66-69
1,932 (16.85)
70-74
3,131 (27.31)
75-79
2,885 (25.17)
80-84
2,042 (17.81)
85+
1,473 (12.85)
Gender
Male
6,331 (55.23)
Female
5,132 (44.77)
Race
White
9,788 (85.39)
Black
892 (7.78)
Other or unknown
783 (6.83)
Year of Index
2004
1,845 (16.10)
2005
1,956 (17.06)
2006
1,940 (16.92)
2007
2,002 (17.46)
2008
1,896 (16.54)
2009
1,824 (15.91)
Geographic Region
Midwest
1,451 (12.66)
Northeast
2,388 (20.83)
South
3,102 (27.06)
West
4,522 (39.45)
Cancer Stage
Stage I
Stage II
Stage III
Stage IV
Stage Unknown
-

Kidney cancer
patients
n (%)
11,463 (100)
1,939 (16.92)
3,139 (27.38)
2,867 (25.01)
2,073 (18.08)
1,445 (12.61)
6,331 (55.23)
5,132 (44.77)
9,788 (85.39)
892 (7.78
783 (6.83)
1,845 (16.10)
1,956 (17.06)
1,940 (16.92)
2,002 (17.46)
1,896 (16.54)
1,824 (15.91)
1,451 (12.66)
2,388 (20.83)
3,102 (27.06)
4,522 (39.45)
5,700 (49.73)
848 (7.40)
1,658 (14.46)
2,078 (18.13)
1,179 (10.29)
(continued)
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Noncancer
patients
n (%)
Cancer Histology Group
Chromophobe
Clear Cell
Other RCC
Papillary
Transitional cell tumor
Cancer treated with chemotherapy
No
Yes
Cancer treated with immunotherapy
No
Yes
Nephrectomy after index date
No
Yes

Kidney cancer
patients
n (%)

-

413 (3.60)
8,678 (75.70)
1,117 (9.74)
977 (8.52)
278 (2.43)

-

9,102 (79.40)
2,361 (20.60)

-

10,986 (95.84)
477 (4.16)

- (> 99.9) 3,810 (33.24)
< 11 (< 0.1)
7,653 (66.76)

Note. Numbers less than 11 have been suppressed.
Note. RCC = renal cell carcinoma.

For each outcome, the number of patients with the outcome was higher in the
exposed cohort than in the unexposed cohort (Table 6). For each outcome and cohort, the
number of patients with the outcome was higher in the period after index date as
compared to the year prior to the index date (Table 6).
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Table 6
Frequency of Outcomes Within Study Population
Year prior to index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)

Follow-up period after index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)

Any VTE
No
11,192 (97.64)
11,069 (96.56)
11,022 (96.15)
10,061 (87.77)
Yes
271 (2.36)
394 (3.44)
441 (3.85)
1,402 (12.23)
DVT
No
11,316 (98.72)
11,217 (97.85)
11,174 (97.48)
10,491 (91.52)
Yes
147 (1.28)
246 (2.15)
289 (2.52)
972 (8.48)
PE
No
11,408 (99.52)
11,373 (99.21)
11,363 (99.13)
11,077 (96.63)
Yes
55 (0.48)
90 (0.79)
100 (0.87)
386 (3.37)
Other VTE
No
11,365 (99.15)
11,334 (98.87)
11,336 (98.89)
11,085 (96.70)
Yes
98 (0.85)
129 (1.13)
127 (1.11)
378 (3.30)
Any ATE
No
11,172 (97.46)
11,109 (96.91)
10,838 (94.55)
10,380 (90.55)
Yes
291 (2.54)
354 (3.09)
625 (5.45)
1,083 (9.45)
MI
No
11,310 (98.67)
11,271 (98.33)
11,172 (97.46)
10,848 (94.63)
Yes
153 (1.33)
192 (1.67)
291 (2.54)
615 (5.37)
IS
No
11,318 (98.74)
11,290 (98.49)
11,093 (96.77)
10,915 (95.22)
Yes
145 (1.26)
173 (1.51)
370 (3.23)
548 (4.78)
Note. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.

The following table presents the frequency of each covariate in both cohorts for
the year prior to index date and for the follow-up period after index date.
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Table 7
Frequency of Covariates Within Study Population
Year prior to index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)
Charlson Score
0
1
2 to 3
4+
Type 1 Diabetes
No
Yes
Type 2 Diabetes
No
Yes
Atherosclerosis
No
Yes
Varicose Veins
No
Yes
Kidney Disease
No
Yes
History of CVD a
No
Yes
History of VTE a
No
Yes
History of DVT a
No
Yes
History of PE a
No
Yes
History of Other
VTE a
No
Yes
History of Any
ATE a
No
Yes

Follow-up period after index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)

5,688 (49.62)
2,843 (24.80)
2,182 (19.04)
750 (6.54)

4,446 (38.79)
3,037 (26.49)
2,794 (24.37)
1,186 (10.35)

4,754 (41.47)
2,732 (23.83)
2,700 (23.55)
1,277 (11.14)

2,373 (20.70)
2,098 (18.30)
3,849 (33.58)
3,143 (27.42)

10,964 (95.65)
499 (4.35)

10,711 (93.44)
752 (6.56)

10,776 (94.01)
687 (5.99)

10,307 (89.92)
1,156 (10.08)

8,702 (75.91)
2,761 (24.09)

7,839 (68.39)
3,624 (31.61)

8,230 (71.80)
3,233 (28.20)

7,008 (61.14)
4,455 (38.86)

10,539 (91.94)
924 (8.06)

10,147 (88.52)
1,316 (11.48)

10,094 (88.06)
1,369 (11.94)

9,225 (80.48)
2,238 (19.52)

11,349 (99.01)
114 (0.99)

11,353 (99.04)
110 (0.96)

11,264 (98.26)
199 (1.74)

11,256 (98.19)
207 (1.81)

10,736 (93.66)
727 (6.34)

9,813 (85.61)
1,650 (14.39)

10,063 (87.79)
1,400 (12.21)

6,200 (54.09)
5,263 (45.91)

9,799 (85.48)
1,664 (14.52)

9,526 (83.10)
1,937 (16.90)

9,521 (83.06)
1,942 (16.94)

8,914 (77.76)
2,549 (22.24)

11,247 (98.12)
216 (1.88)

11,225 (97.92)
238 (2.08)

11,192 (97.64)
271 (2.36)

11,069 (96.56)
394 (3.44)

11,358 (99.08)
105 (0.92)

11,324 (98.79)
139 (1.21)

11,316 (98.72)
147 (1.28)

11,217 (97.85)
246 (2.15)

11,419 (99.62)
44 (0.38)

11,429 (99.70)
34 (0.30)

11,408 (99.52)
55 (0.48)

11,373 (99.21)
90 (0.79)

11,374 (99.22)
89 (0.78)

11,368 (99.17)
95 (0.83)

11,365 (99.15)
98 (0.85)

11,334 (98.87)
129 (1.13)

11,213 (97.82)
250 (2.18)

11,228 (97.95)
235 (2.05)

11,172 (98.74)
291 (2.54)

11,109 (96.91)
354 (3.09)

(continued)
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Year prior to index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)
History of MI a
No
Yes
History of IS a
No
Yes
High-risk Surgery
prior to VTEa
No
Yes
CVC prior to
VTEb
No
Yes
High-risk Surgery
prior to DVTb
No
Yes
CVC prior to
DVTb
No
Yes
High-risk Surgery
prior to PEb
No
Yes
CVC prior to PEb
No
Yes
High-risk Surgery
prior to Other
VTEb
No
Yes
CVC prior to
Other VTEb
No
Yes
High-risk Surgery
prior to Any ATEb
No
Yes
CVC prior to Any
ATEb
No
Yes

Follow-up period after index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)

11,340 (98.93)
123 (1.07)

11,335 (98.88)
128 (1.12)

11,310 (98.67)
153 (1.33)

11,271 (98.33)
192 (1.67)

11,326 (98.80)
137 (1.20)

11,349 (99.01)
114 (0.99)

11,318 (98.74)
145 (1.26)

11,290 (98.49)
173 (1.51)

- (> 97.0)
< 11 (< 3.0)

378 (95.94)
16 (4.06)

416 (94.33)
25 (5.67)

1,264 (90.16)
138 (9.84)

- (> 97.0)
< 11 (< 3.0)

383 (97.21)
11 (2.79)

425 (96.37)
16 (3.63)

1,229 (87.66)
173 (12.34)

- (> 96.0)
< 11 (< 4.0)

230 (93.50)
16 (6.50)

271 (93.77)
18 (6.23)

856 (88.07)
116 (11.93)

- (> 96.0)
< 11 (< 4.0)

235 (95.53)
11 (4.47)

277 (95.85)
12 (4.15)

826 (84.98)
146 (15.02)

- (> 80.0)
< 11 (< 20.0)

- (> 88.0)
< 11 (< 12.0)

- (> 89.0)
< 11 (< 11.0)

339 (87.82)
47 (12.18)

- (> 80.0)
< 11 (< 20.0)

- (> 88.0)
< 11 (< 12.0)

- (> 89.0)
< 11 (< 11.0)

329 (85.23)
57 (14.77)

- (> 88.0)
< 11 (< 12.0)

- (> 91.0)
< 11 (< 9.0)

- (> 91.0)
< 11 (< 9.0)

333 (88.10)
45 (11.90)

- (> 88.0)
< 11 (< 12.0)

- (> 91.0)
< 11 (< 9.0)

- (> 91.0)
< 11 (< 9.0)

331 (87.57)
47 (12.43)

279 (95.88)
12 (4.12)

339 (95.76)
15 (4.24)

565 (90.40)
60 (9.60)

936 (86.43)
147 (13.57)

- (> 96.0)
< 11 (< 4.0)

- (> 96.0)
< 11 (< 4.0)

607 (97.12)
18 (2.88)

936 (86.43)
147 (13.57)

(continued)
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Year prior to index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)

Follow-up period after index date
Noncancer patients Kidney cancer
n (%)
patients
n (%)

High-risk Surgery
prior to MIb
No
- (> 92.0)
- (> 94.0)
264 (90.72)
514 (83.58)
Yes
< 11 (< 8.0)
< 11 (< 6.0)
27 (9.28)
101 (16.42)
CVC prior to MIb
No
- (> 92.0)
- (> 94.0)
- (> 96.0)
513 (83.41)
Yes
< 11 (< 8.0)
< 11 (< 6.0)
< 11 (< 4.0)
102 (16.59)
High-risk Surgery
prior to ISb
No
- (> 92.0)
- (> 92.0)
325 (87.84)
459 (83.76)
Yes
< 11 (< 8.0)
< 11 (< 8.0)
45 (12.16)
89 (16.24)
CVC prior to ISb
No
- (> 92.0)
- (> 92.0)
358 (96.76)
473 (86.31)
Yes
< 11 (< 8.0)
< 11 (< 8.0)
12 (3.24)
75 (13.69)
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC = central venous catheter; CVD =
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina
or transient ischemic attack); DVT = deep vein thrombosis; IS = ischemic stroke; MI = myocardial
infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE = venous
thromboembolic event.
a
History is within the 12 months prior to the start of the period of interest.
b
High-risk surgery and central venous catheter were more than 30 days before outcome. Proportion is out
of patients with the outcome.

Results
Descriptive Analysis 1
The purpose of descriptive analysis 1 was to describe the incidence rates of
thromboembolic events in the kidney cancer cohort in the year prior to kidney cancer
diagnosis (Tables 8 to 14) and in the follow-up period after cancer diagnosis (Tables 15
to 21). The incidence rates were described overall and stratified by demographic, cancer,
and other patient characteristics.
The year prior to kidney cancer diagnosis. The incidence rate for any VTE in
the year prior to kidney cancer diagnosis was 35.05 per 1,000 person-years for all patients
(Table 8). Although not a consistent trend, the incidence rates increased with increasing
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age at kidney cancer diagnosis, with the highest rate in the patients 85 or older. Incidence
rates also varied by race with Black patients having incidence rates almost twice that of
the White patients. Females had a higher incidence rate than males, 39.88 as compared to
31.16 per 1,000 p-y, respectively. The incidence rates for any VTE were similar across
geographic regions and year of diagnosis. Within RCC, the incidence rates were similar
and lower than the incidence rate for transitional cell tumors. However, the incidence rate
or 52.30 for transitional cell tumors was based on a small number of events (n = 14) and
had a wide confidence interval (95% CI 28.60-87.76). The incidence rate ranged from
30.04 to 36.54 for patients with Stage I to IV tumors, but was 56.11 for patients with
unstaged or unknown stage tumors (Table 8). A history of any VTE was a major
characteristic driving up the incidence rates overall, with a rate of 1,481 per 1,000 p-y
compared to a rate of 20.67 per 1,000 p-y in patients without a history of any VTE in the
prior year. The incidence rates increased with increasing Charlson score.
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Table 8
Incidence Rates per 1,000 p-y for Any VTE in the Year Prior to Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

394

11,239.8

35.05

31.68-38.69

66-69

54

1,911.92

28.24

21.22-36.85

70-74

98

3,087.67

31.74

25.77-38.68

75-79

101

2,806.75

35.98

29.31-43.72

80-84

69

2,031.17

33.97

26.43-42.99

85+

72

1,402.25

51.35

40.18-64.66

Black

53

862.25

61.47

46.04-80.40

Other/Unknown

22

769.50

28.59

17.92-43.29

White

319

9,608.00

33.20

29.66-37.05

Female

200

5,014.75

39.88

34.55-45.81

Male

194

6,225.00

31.16

26.93-35.87

Midwest

51

1,424.25

35.81

26.66-47.08

Northeast

92

2,335.83

39.39

31.75-48.30

South

104

3,041.67

34.19

27.94-41.43

West

147

4,438.00

33.12

27.99-38.93

2004

67

1,812.17

36.97

28.65-46.95

2005

64

1,918.92

33.35

25.69-42.59

2006

59

1,910.00

30.89

23.51-39.85

2007

76

1,956.42

38.85

30.61-48.62

2008

60

1,859.17

32.27

24.63-41.54

2009

68

1,783.08

38.14

29.61-48.35

Chromophobe

12

406.92

29.49

15.24-51.51

Clear Cell

296

8,512.58

34.77

30.92-38.97

Other RCC

41

1,092.58

37.53

26.93-50.91

Papillary

31

960.00

32.29

21.94-45.84

Transitional cell
tumor

14

267.67

52.30

28.60-87.76

(continued)
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Level
Stage at Diagnosis

History of Condition

History of CVD

CVC

a

a

High-risk Surgery

Charlson Score

n

Person-Years

Incidence Rate

95% CI

Stage I

182

5,589.17

32.56

28.00-37.65

Stage II

25

832.25

30.04

19.44-44.34

Stage III

58

1,631.75

35.54

26.99-45.95

Stage IV

65

2,046.00

31.77

24.52-40.49

Stage Unknown

64

1,140.58

56.11

43.21-71.65

No

230

11,129.1

20.67

18.08-23.52

Yes

164

110.67

1,481.93

1,263.80-1,726.89

No

282

9,374.50

30.08

26.67-33.81

Yes

112

1,865.25

60.05

49.44-72.25

No

383

11,232.6

34.10

30.77 - 37.69

Yes

11

7.17

1,534.88

766.21 – 2,746.33

No

378

11,230.0

33.66

30.35 - 37.23

Yes

16

9.75

1,641.03

937.99 – 2,664.92

0

95

4,396.75

21.61

17.48-26.41

1

77

2,993.67

25.72

20.30-32.15

139

2,708.67

51.32

43.14-60.59

83

1,140.67

72.76

57.96-90.20

2 to 3
4+

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); RCC = renal cell
carcinoma; VTE = venous thromboembolic event.
a
More than 30 days before the outcome.

The incidence rate for DVT in the year prior to kidney cancer diagnosis was 21.71
per 1,000 p-y (Table 9). The pattern of rates was similar to the pattern in Table 8 for race,
geographic region, year of diagnosis, stage, history of condition, history of CVD, and
Charlson score. The incidence rates were similar for females 23.10 (95% CI 19.10-27.68)
and males, 20.59 (95% CI 17.19-24.47). There were very small numbers with DVT in the
Chromophobe and transitional cell tumors, leading to very wide confidence intervals
which included in the incidence rates of the other histology groups.
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Table 9
Incidence Rates per 1,000 p-y for DVT in the Year Prior to Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

246

11,329.6

21.71

19.08-24.60

66-69

35

1,920.92

18.22

12.69-25.34

70-74

62

3,108.58

19.94

15.29-25.57

75-79

59

2,835.58

20.81

15.84-26.84

80-84

39

2,049.00

19.03

13.53-26.02

85+

51

1,415.50

36.03

26.83-47.37

Black

38

870.67

43.64

30.89-59.91

Other/Unknown

14

774.25

18.08

9.89-30.34

White

194

9,684.67

20.03

17.31-23.06

Female

117

5,065.42

23.10

19.10-27.68

Male

129

6,264.17

20.59

17.19-24.47

Midwest

34

1,434.67

23.70

16.41-33.12

Northeast

58

2,357.25

24.60

18.68-31.81

South

68

3,062.00

22.21

17.25-28.15

West

86

4,475.67

19.22

15.37-23.73

2004

40

1,825.50

21.91

15.65-29.84

2005

47

1,930.08

24.35

17.89-32.38

2006

31

1,924.67

16.11

10.94-22.86

2007

44

1,974.58

22.28

16.19-29.91

2008

37

1,877.83

19.70

13.87-27.16

2009

47

1,796.92

26.16

19.22-34.78

< 11

-

14.61

5.36-31.79

Clear Cell

191

8,575.33

22.27

19.23-25.67

Other RCC

24

1,102.42

21.77

13.95-32.39

Papillary

17

969.00

17.54

10.22-28.09

< 11

-

29.40

12.69-57.94

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

History of Condition

History of CVD

CVC

a

a

High-risk Surgery

Charlson Score

n

Person-Years

Incidence Rate

95% CI

Stage I

120

5,630.50

21.31

17.67-25.48

Stage II

17

839.00

20.26

11.80-32.44

Stage III

33

1,643.00

20.09

13.83-28.21

Stage IV

41

2,056.17

19.94

14.31-27.05

Stage Unknown

35

1,160.92

30.15

21.00-41.93

No

159

11,259.5

14.12

12.01-16.49

Yes

87

70.08

1,241.38

994.29-1,531.24

No

168

9,440.50

17.80

15.21-20.70

Yes

78

1,889.08

41.29

32.64-51.53

No

235

11,322.4

20.76

18.19 - 23.59

Yes

11

7.17

1,534.88

766.21 – 2,746.33

No

230

11,318.9

20.32

17.78 - 23.12

Yes

16

10.67

1,500.00

857.38 – 2,435.91

0

53

4,420.50

11.99

8.98-15.68

1

37

3,016.00

12.27

8.64-16.91

2 to 3

90

2,742.17

32.82

26.39-40.34

4+

66

1,150.92

57.35

44.35-72.96

Note. Numbers less than 11 and the associated person-years have been suppressed.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); DVT = deep vein
thrombosis; RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rate for pulmonary embolism in the year prior to kidney cancer
diagnosis was 7.88 per 1,000 p-y (Table 10). There were a small number of patients with
the outcome in many categories making patterns and differences between groups difficult
to distinguish. Blacks and females had incidence rates approximately twice that of their
reference groups. In the two histology groups with 11 or more patients with pulmonary
embolism, clear cell carcinoma and other RCC, the incidence rates were similar - 7.98
(95% CI 6.21 – 10.10) and 9.91 (95% CI 4.95 – 17.73), respectively. Incidence rates were
much higher in the patients with a history of pulmonary embolism or a history of CVD.
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Table 10
Incidence Rates per 1,000 p-y for PE in the Year Prior to Kidney Cancer Diagnosis
Level

n

Person-Years

Incidence Rate

95% CI

TOTAL

TOTAL

90

11,417.2

7.88

6.34-9.69

Age at Diagnosis

66-69

19

1,931.17

9.84

5.92-15.36

70-74

17

3,130.33

5.43

3.16-8.70

75-79

22

2,854.58

7.71

4.83-11.67

80-84

16

2,063.58

7.75

4.43-12.59

85+

16

1,437.50

11.13

6.36-18.08

-

-

15.85

8.67-26.60

< 11

-

5.12

1.40-13.11

White

72

9,752.92

7.38

5.78-9.30

Female

56

5,102.00

10.98

8.29-14.25

Male

34

6,315.17

5.38

3.73-7.52

< 11

-

4.84

1.94-9.96

Northeast

-

-

8.84

5.47-13.52

South

-

-

7.11

4.46-10.77

West

40

4,502.33

8.88

6.35-12.10

2004

14

1,838.67

7.61

4.16-12.78

2005

-

-

5.64

2.82-10.10

2006

< 11

-

5.16

2.48-9.49

2007

17

1,994.25

8.52

4.97-13.65

2008

19

1,884.67

10.08

6.07-15.74

2009

19

1,813.75

10.48

6.31-16.36

< 11

-

4.85

0.59-17.51

Clear Cell

69

8,644.75

7.98

6.21-10.10

Other RCC

11

1,109.83

9.91

4.95-17.73

Papillary

< 11

-

7.19

2.89-14.82

Transitional cell
tumor

< 11

-

3.61

0.09-20.11

Race

Black
Other/Unknown

Gender

Geographic Region

Year of Diagnosis

Histology Group

Midwest

Chromophobe

(continued)
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Level
Stage at Diagnosis

History of Condition

History of CVD

CVC

a

Stage I

95% CI

9.35

7.00-12.23

Stage II

< 11

-

5.92

1.92-13.81

Stage III

< 11

-

5.43

2.48-10.31

Stage IV

< 11

-

4.34

1.98-8.23

Stage Unknown

14

1,171.33

11.95

6.53-20.05

No

63

11,402.4

5.53

4.25-7.07

Yes

27

14.75

1,830.51

1,206.32-2,663.29

No

66

9,494.75

6.95

5.38-8.84

Yes

24

1,922.42

12.48

8.00-18.58

-

-

7.71

6.18 - 9.50

< 11

-

1,500.00

181.66 – 5,418.52

-

-

7.62

6.10 - 9.40

< 11

-

1,440.00

296.96 – 4,208.29

0

18

4,437.58

4.06

2.40-6.41

1

23

3,024.00

7.61

4.82-11.41

2 to 3

32

2,778.25

11.52

7.88-16.26

4+

17

1,177.33

14.44

8.41-23.12

No
Yes

Charlson Score

Incidence Rate

5,668.50

Yes
High-risk Surgery

Person-Years
53

No
a

n

Note. Numbers less than 11 and the associated person-years have been suppressed.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); PE = pulmonary embolism;
RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

More kidney cancer patients had a diagnosis of other VTE than pulmonary
embolism, still some of the subgroups had very small counts (Table 11). The incidence
rate of other VTE was 11.33 per 1,000 p-y. The incidence rate for patients 66 to 69 at
diagnosis was 7.25, with higher rates for older patients at diagnosis, but there was no
apparent trend at the older ages. There were small numbers in nonwhite patients but the
rates appear similar for each group. Similarly, there were small numbers of patients with
the outcome for the chromophobe and transitional cell tumor patients. The incidence rates
for the other histology groups were similar. Incidence rates were higher in females than
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males, patients with history of other VTE or history of CVD, and increased with
increasing Charlson score. No clear patterns were visible for geographic region or year of
diagnosis.
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Table 11
Incidence Rates per 1,000 p-y for Other VTE in the Year Prior to Kidney Cancer
Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

129

11,385.9

11.33

9.46-13.46

66-69

14

1,930.92

7.25

3.96-12.17

70-74

39

3,118.33

12.51

8.89-17.10

75-79

37

2,841.83

13.02

9.17-17.95

80-84

22

2,060.58

10.68

6.69-16.16

85+

17

1,434.25

11.85

6.90-18.98

Black

< 11

-

10.14

4.63-19.24

Other/Unknown

< 11

-

9.00

3.62-18.53

White

113

9,719.83

11.63

9.58-13.98

Female

69

5,090.67

13.55

10.55-17.15

Male

60

6,295.25

9.53

7.27-12.27

Midwest

16

1,440.58

11.11

6.35-18.04

Northeast

35

2,369.00

14.77

10.29-20.55

South

31

3,084.50

10.05

6.83-14.27

West

47

4,491.83

10.46

7.69-13.91

2004

27

1,832.33

14.74

9.71-21.44

2005

19

1,944.50

9.77

5.88-15.26

2006

24

1,925.17

12.47

7.99-18.55

2007

27

1,985.25

13.60

8.96-19.79

2008

18

1,884.08

9.55

5.66-15.10

2009

14

1,814.58

7.72

4.22-12.94

< 11

-

14.66

5.38-31.91

Clear Cell

91

8,623.50

10.55

8.50-12.96

Other RCC

14

1,108.50

12.63

6.90-21.19

Papillary

11

970.92

11.33

5.66-20.27

< 11

-

25.57

10.28-52.69

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

Stage I

CVC

a

6.55-11.63

< 11

-

8.31

3.34-17.12

Stage III

24

1,645.25

14.59

9.35-21.70

Stage IV

25

2,066.25

12.10

7.83-17.86

-

-

19.78

12.54-29.68

No

61

11,339.7

5.38

4.11-6.91

Yes

68

46.25

1,470.27

1,141.72-1,863.92

No

100

9,467.25

10.56

8.59-12.85

Yes

29

1,918.67

15.11

10.12-21.71

-

-

11.16

9.30 - 13.27

< 11

-

1,263.16

152.97 – 4,562.96

-

-

10.81

8.98 - 12.89

< 11

-

1,674.42

614.48 – 3,644.50

0

35

4,425.25

7.91

5.51-11.00

1

30

3,019.92

9.93

6.70-14.18

2 to 3

47

2,762.42

17.01

12.50-22.63

4+

17

1,178.33

14.43

8.40-23.10

Yes
High-risk Surgery

No
Yes

Charlson Score

95% CI

8.82

No
a

Incidence Rate

5,668.92

Stage Unknown

History of CVD

Person-Years
50

Stage II

History of Condition

n

Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers
greater than 11 are also suppressed so that the counts for other cells cannot be derived.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); Other VTE = other venous
thromboembolic event; RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rate for any ATE (myocardial infarction or ischemic stroke) in the
year prior to kidney cancer diagnosis was 31.32 per 1,000 person-years (Table 12). With
wide confidence intervals, there was no clear trend due to age, year of diagnosis, or stage.
However, patients with unknown stage appeared to have higher incidence rates of any
ATE than patients whose tumors were staged at diagnosis. The incidence rates were
similar for Black and White patients, but lower for those with other or unknown race. The
rate for males was higher than the incidence rate for females. Incidence rates were lowest
in the West, but similar in the Midwest, Northeast and South. The incidence rates
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increased with increasing Charlson score, with history of any ATE, history of CVD,
recent placement of a CVC, and recent high-risk surgery. The incidence rates for the four
RCC histology groups (range 25.92 to 41.02) and these rates were not different than the
rate for transitional cell tumors, 29.15. However, the confidence intervals for the
incidence rates for all of the histology groups were very wide.
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Table 12
Incidence Rates per 1,000 p-y for Any ATE in the Year Prior to Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

354

11,303.5

31.32

28.14 - 34.76

66-69

40

1,921.25

20.82

14.87 - 28.35

70-74

83

3,104.33

26.74

21.30 - 33.14

75-79

104

2,818.75

36.90

30.15 - 44.71

80-84

68

2,041.08

33.32

25.87 - 42.24

85+

59

1,418.08

41.61

31.67 - 53.67

Black

31

879.33

35.25

23.95 - 50.04

Other/Unknown

19

775.83

24.49

14.74 - 38.24

White

304

9,648.33

31.51

28.07 - 35.26

Female

141

5,066.42

27.83

23.43 - 32.82

Male

213

6,237.08

34.15

29.72 - 39.06

Midwest

60

1,425.83

42.08

32.11 - 54.17

Northeast

83

2,351.00

35.30

28.12 - 43.76

South

99

3,056.75

32.39

26.32 - 39.43

West

112

4,469.92

25.06

20.63 - 30.15

2004

54

1,819.17

29.68

22.30 - 38.73

2005

61

1,925.58

31.68

24.23 - 40.69

2006

61

1,912.75

31.89

24.39 - 40.97

2007

53

1,975.83

26.82

20.09 - 35.09

2008

63

1,871.50

33.66

25.87 - 43.07

2009

62

1,798.67

34.47

26.43 - 44.19

-

-

26.96

13.46 - 48.23

Clear Cell

265

8,559.67

30.96

27.34 - 34.92

Other RCC

45

1,097.00

41.02

29.92 - 54.89

Papillary

25

964.33

25.92

16.78 - 38.27

< 11

-

29.15

12.59 - 57.44

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

History of Condition

History of CVD

CVC

a

High-risk Surgery

Charlson Score

Person-Years

Incidence Rate

95% CI

Stage I

178

5,624.42

31.65

27.17 - 36.65

Stage II

23

836.92

27.48

17.42 - 41.24

Stage III

42

1,639.17

25.62

18.47 - 34.63

Stage IV

55

2,052.00

26.80

20.19 - 34.89

Stage Unknown

56

1,151.00

48.65

36.75 - 63.18

No

309

1,1097.4

27.84

24.83 - 31.13

Yes

45

206.08

218.36

159.27 - 292.18

No

249

9,791.08

25.43

22.37 - 28.79

Yes

105

1,512.42

69.43

56.78 - 84.04

-

-

30.54

27.40 - 33.94

Yes

< 11

-

1,421.05

649.80 -2,697.60

No

339

11,293.9

30.02

26.91 - 33.39

Yes

15

9.58

1,565.22

876.04 – 2,581.59

0

57

5,246.42

10.86

8.23 - 14.08

1

85

3,147.00

27.01

21.57 - 33.40

141

2,268.42

62.16

52.32 - 73.31

71

641.67

110.65

86.42 - 139.57

No
a

n

2 to 3
4+

Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers
greater than 11 are also suppressed so that the counts for other cells cannot be derived.
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC = central venous catheter; CVD =
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina
or transient ischemic attack); IS = ischemic stroke; MI = myocardial infarction; RCC = renal cell
carcinoma.
a

More than 30 days before the outcome.

The incidence rate for myocardial infarction in the year prior to kidney cancer
diagnosis was 16.88 per 1,000 person-years (Table 13). The incidence rates were higher
for patients 70 years or older at diagnosis than patients 66 to 69 years of age. The
incidence rates were similar for Black and White patients, but less for those with other or
unknown race. The incidence rates were higher for males than females. There was no
clear trend in rates for geographic region, year of diagnosis, or histology group. The
incidence rates increased with increasing Charlson score, with history of myocardial
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infarction and with history of CVD. The rates were similar for the RCC histology groups,
but the confidence intervals were very wide. The numbers of patients with myocardial
infarction were less than 11 for the chromophobe and transitional cell tumor patients.
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Table 13
Incidence Rates per 1,000 p-y for MI in the Year Prior to Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Year of Diagnosis

Histology Group

Incidence Rate

95% CI

11,373.8

16.88

14.58-19.44

66-69

18

1,931.08

9.32

5.52-14.73

70-74

52

3,117.92

16.68

12.46-21.87

75-79

50

2,842.83

17.59

13.05-23.19

80-84

40

2,052.42

19.49

13.92-26.54

85+

32

1,429.58

22.38

15.31-31.60

-

-

15.79

8.63-26.49

< 11

-

12.83

6.15-23.60

White

168

9,707.83

17.31

14.79-20.13

Female

72

5,095.58

14.13

11.06-17.79

120

6,278.25

19.11

15.85-22.86

Midwest

24

1,441.67

16.65

10.67-24.77

Northeast

48

2,364.67

20.30

14.97-26.91

South

53

3,078.25

17.22

12.90-22.52

West

67

4,489.25

14.92

11.57-18.95

2004

33

1,827.42

18.06

12.43-25.36

2005

28

1,940.25

14.43

9.59-20.86

2006

33

1,923.75

17.15

11.81-24.09

2007

27

1,988.50

13.58

8.95-19.76

2008

36

1,883.58

19.11

13.39-26.46

2009

35

1,810.33

19.33

13.47-26.89

< 11

-

19.53

8.43-38.49

Clear Cell

144

8,614.33

16.72

14.10-19.68

Other RCC

20

1,105.25

18.10

11.05-27.95

Papillary

14

969.67

14.44

7.89-24.22

< 11

-

21.82

8.01-47.49

Black

Male
Geographic Region

Person-Years
192

Other/Unknown

Gender

n

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

History of Condition

History of CVD

CVC

a

High-risk Surgery

Charlson Score

Person-Years

Incidence
Rate

95% CI

Stage I

101

5,656.33

17.86

14.54-21.70

Stage II

13

840.17

15.47

8.24-26.46

Stage III

19

1,649.58

11.52

6.93-17.99

Stage IV

23

2,067.92

11.12

7.05-16.69

Stage Unknown

36

1,159.83

31.04

21.74-42.97

No

159

11,267.5

14.11

12.00-16.48

Yes

33

106.33

310.34

213.63-435.84

No

110

9,478.75

11.60

9.54-13.99

Yes

82

1,895.08

43.27

34.41-53.71

-

-

75.32

70.28 - 80.64

Yes

< 11

-

1,523.81

657.87 – 3,002.51

No

809

10,970.1

73.75

68.75 - 79.01

Yes

26

14.42

1,803.47

1,178.09 – 2,642.50

0

12

4,439.75

2.70

1.40-4.72

1

35

3,018.92

11.59

8.08-16.12

2 to 3

75

2,762.17

27.15

21.36-34.04

4+

70

1,153.00

60.71

47.33-76.70

No
a

n

Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers
greater than 11 are also suppressed so that the counts for other cells cannot be derived.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); MI = myocardial infarction;
RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rate for ischemic stroke in the year prior to kidney cancer diagnosis
was 15.19per 1,000 person-years (Table 14). There was no clear trend in incidence rates
for age at diagnosis, gender, year of diagnosis, or stage at diagnosis. The incidence rates
increased with increasing Charlson comorbidity score and were higher in patients with
history of ischemic stroke, history of CVD, recent placement of CVC, and recent highrisk surgery. Incidence rates appeared higher for regions other than the West and for the
Other RCC histology group, however there were very wide confidence intervals.
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Table 14
Incidence Rates per 1,000 p-y for IS in the Year Prior to Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Year of Diagnosis

Histology Group

Incidence Rate

95% CI

11,389.9

15.19

13.01 - 17.63

66-69

23

1,928.83

11.92

7.56 - 17.89

70-74

34

3,124.33

10.88

7.54 - 15.21

75-79

56

2,842.75

19.70

14.88 - 25.58

80-84

30

2,061.08

14.56

9.82 - 20.78

85+

30

1,432.92

20.94

14.13 - 29.89

-

-

19.21

11.19 - 30.76

< 11

-

11.55

5.28 - 21.92

White

147

9,725.75

15.11

12.77 - 17.76

Female

73

5,101.08

14.31

11.22 - 17.99

100

6,288.83

15.90

12.94 - 19.34

Midwest

38

1,434.50

26.49

18.75 - 36.36

Northeast

38

2,373.83

16.01

11.33 - 21.97

South

49

3,079.83

15.91

11.77 - 21.03

West

48

4,501.75

10.66

7.86 - 14.14

2004

22

1,836.67

11.98

7.51 - 18.14

2005

33

1,941.33

17.00

11.70 - 23.87

2006

30

1,928.42

15.56

10.50 - 22.21

2007

27

1,989.08

13.57

8.95 - 19.75

2008

34

1,882.08

18.07

12.51 - 25.24

2009

27

1,812.33

14.90

9.82 - 21.68

< 11

-

7.29

1.50 - 21.31

Clear Cell

129

8,621.08

14.96

12.49 - 17.78

Other RCC

26

1,108.67

23.45

15.32 - 34.36

Papillary

13

971.25

13.38

7.13 - 22.89

< 11

-

7.21

0.87 - 26.04

Black

Male
Geographic Region

Person-Years
173

Other/Unknown

Gender

n

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

Stage I

History of CVD

CVC

a

11.35 - 17.76

< 11

-

11.84

5.68 - 21.77

Stage III

25

1,647.08

15.18

9.82 - 22.41

Stage IV

34

2,061.25

16.49

11.42 - 23.05

Stage Unknown

-

-

19.67

12.47 - 29.51

No

-

-

14.54

12.40 - 16.94

Yes

< 11

-

83.46

38.16 - 158.44

No

135

9,839.83

13.72

11.50 - 16.24

Yes

38

1,550.08

24.51

17.35 - 33.65

-

-

14.93

12.77 - 17.35

< 11

-

1,800.00

371.20 – 5,260.36

-

-

14.49

12.37 - 16.88

< 11

-

1,811.32

782.00 – 3,569.02

0

35

5,258.33

6.66

4.64 - 9.26

1

44

3,167.75

13.89

10.09 - 18.65

2 to 3

65

2,302.33

28.23

21.79 - 35.98

4+

29

661.50

43.84

29.36 - 62.96

No
Yes

Charlson Score

95% CI

14.29

Yes
High-risk Surgery

Incidence Rate

5,667.33

No
a

Person-Years
81

Stage II

History of Condition

n

Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers
greater than 11 are also suppressed so that the counts for other cells cannot be derived.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); IS = ischemic stroke; RCC
= renal cell carcinoma.
a

More than 30 days before the outcome.

The follow-up period after kidney cancer diagnosis. In the follow-up period
after cancer diagnosis, the incidence rate for any VTE was 53.00 per 1,000 p-y (Table
15). The incidence rates increased with increasing age, year of diagnosis, stage at
diagnosis, and increasing Charlson score. The rates were higher in patients who were
Black, female, treated with chemotherapy, treated with immunotherapy, history of any
VTE, and history of CVD. Patients treated with nephrectomy had lower incidence rates
than patients without nephrectomy, however this may be due to nephrectomy being a
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treatment indicated for lower stage tumors. Lower stage tumors had lower incidence rates
than higher staged tumors. The incidence rates were highest in the Northeast and South,
followed by the Midwest and West region. Incidence rates also differed by histology
group. The incidence rates were highest in the patients with other RCC (76.03, 95% CI
63.52-90.17), followed by transitional cell tumors (64.37, 95% CI 43.74-91.37), clear cell
tumors (53.13, 95% CI 50.02-56.39), papillary (43.88, 95% CI 36.17- 52.76), and
chromophobe (33.39, 95% CI 24.07-45.14). However, some of the histology groups have
very wide confidence intervals and so some groups may not be different at a statistically
significant level.
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Table 15
Incidence Rates per 1,000 p-y for Any VTE After Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Year of Diagnosis

Histology Group

Incidence Rate

95% CI

26,452.7

53.00

50.26 -55.85

66-69

224

5,148.58

43.51

38.00 -49.59

70-74

394

7,965.67

49.46

44.70 -54.60

75-79

364

6,979.50

52.15

46.93 -57.80

80-84

255

4,247.00

60.04

52.90 -67.88

85+

165

2,112.00

78.13

66.66 -91.00

Black

138

1,813.33

76.10

63.94 -89.91

78

1,799.25

43.35

34.27 -54.10

1,186

22,840.2

51.93

49.01 -54.97

Female

676

11,840.2

57.09

52.87 -61.56

Male

726

14,612.5

49.68

46.13 -53.43

Midwest

175

3,354.25

52.17

44.73 -60.50

Northeast

346

5,881.83

58.83

52.79 -65.36

South

379

6,860.00

55.25

49.82 -61.10

West

502

10,356.7

48.47

44.32 -52.90

2004

266

6,239.17

42.63

37.66 -48.08

2005

254

5,703.83

44.53

39.22 -50.36

2006

249

5,076.58

49.05

43.15 -55.53

2007

233

4,366.42

53.36

46.73 -60.67

2008

213

3,112.92

68.42

59.54 -78.26

2009

187

1,953.83

95.71

82.48 -110.45

42

1,257.75

33.39

24.07 -45.14

1,084

20,402.3

53.13

50.02 -56.39

Other RCC

132

1,736.08

76.03

63.62 -90.17

Papillary

113

2,575.08

43.88

36.17 -52.76

31

481.58

64.37

43.74 -91.37

White

Geographic Region

Person-Years
1,402

Other/Unknown

Gender

n

Chromophobe
Clear Cell

Transitional cell
tumor
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Level
Stage at Diagnosis

Chemotherapy

Immunotherapy

Nephrectomy

History of Condition

CVC

33.45

30.71 -36.37

Stage II

88

2,364.33

37.22

29.85 -45.86

Stage III

328

3,802.75

86.25

77.17 -96.11

Stage IV

301

1,709.17

176.11

156.77 -197.17

Stage Unknown

135

2,134.25

63.25

53.03 -74.87

No

977

21,267.8

45.94

43.10 -48.91

Yes

425

5,185.00

81.97

74.36 -90.14

1,303

25,332.5

51.44

48.68 -54.31

Yes

99

1,120.25

88.37

71.83 -107.59

No

400

5,147.08

77.71

70.28 -85.72

Yes

1,002

21,305.7

47.03

44.16 -50.03

No

1,119

26,177.2

42.75

40.28 -45.33

283

275.50

1,027.22

911.02 -1,154.14

1,045

21,328.6

49.00

46.07 -52.06

357

5,124.17

69.67

62.63 -77.29

1,229

26,147.7

47.00

44.41 - 49.71

173

305.08

567.06

485.71 - 658.14

1,264

26,193.1

48.26

45.63 - 50.99

Yes

138

259.67

531.45

446.48 - 627.88

0

193

4,777.17

40.40

34.90 -46.52

1

210

4,435.75

47.34

41.16 -54.20

2 to 3

458

9,258.92

49.47

45.04 -54.21

4+

541

7,980.92

67.79

62.19 -73.75

No

No

Yes

Charlson Score

95% CI

16,442.3

No

High-risk Surgerya

Incidence Rate

550

Yes
a

Person-Years

Stage I

Yes
History of CVD

n

No

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); RCC = renal cell
carcinoma; VTE = venous thromboembolic event.
a

More than 30 days before the outcome.

The incidence rate for DVT in the follow-up period after kidney cancer diagnosis
was 35.56 per 1,000 p-y (Table 16). The incidence rates followed similar patterns as for
any VTE. Unlike in the period prior to cancer diagnosis (Table 9), incidence increased
with stage and year of diagnosis.
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Table 16
Incidence Rates per 1,000 p-y for DVT After Kidney Cancer Diagnosis
Level

n

Person-Years

Incidence Rate

95% CI

TOTAL

TOTAL

972

27,336.6

35.56

33.36 -37.86

Age at Diagnosis

66-69

144

5,313.08

27.10

22.86 -31.91

70-74

277

8,223.42

33.68

29.83 -37.89

75-79

236

7,265.50

32.48

28.47 -36.90

80-84

197

4,348.33

45.30

39.20 -52.09

85+

118

2,186.25

53.97

44.68 -64.64

Black

106

1,882.25

56.32

46.11 -68.11

47

1,869.50

25.14

18.47 -33.43

White

819

23,584.8

34.73

32.39 -37.19

Female

463

12,306.0

37.62

34.27 -41.21

Male

509

15,030.6

33.86

30.99 -36.94

Midwest

128

3,463.00

36.96

30.84 -43.95

Northeast

248

6,097.83

40.67

35.77 -46.06

South

262

7,093.25

36.94

32.60 -41.69

West

334

10,682.5

31.27

28.00 -34.81

2004

181

6,482.50

27.92

24.00 -32.30

2005

196

5,846.83

33.52

28.99 -38.56

2006

172

5,282.67

32.56

27.88 -37.81

2007

161

4,506.83

35.72

30.42 -41.69

2008

142

3,210.17

44.23

37.26 -52.14

2009

120

2,007.58

59.77

49.56 -71.47

27

1,308.17

20.64

13.60 -30.03

Clear Cell

750

21,059.0

35.61

33.11 -38.26

Other RCC

90

1,794.50

50.15

40.33 -61.65

Papillary

80

2,681.00

29.84

23.66 -37.14

Transitional cell
tumor

25

493.92

50.62

32.76 -74.72

Race

Other/Unknown

Gender

Geographic Region

Year of Diagnosis

Histology Group

Chromophobe

(continued)
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Level
Stage at Diagnosis

Immunotherapy

Nephrectomy

History of Condition

History of CVD

CVC

a

High-risk Surgerya

Charlson Score

Person-Years

Incidence Rate

95% CI

Stage I

374

16,879.8

22.16

19.97 -24.52

Stage II

64

2,414.08

26.51

20.42 -33.85

Stage III

224

4,048.00

55.34

48.33 -63.08

Stage IV

220

1,770.83

124.24

108.36 -141.78

90

2,223.92

40.47

32.54 -49.74

No

666

21,907.9

30.40

28.13 -32.80

Yes

306

5,428.67

56.37

50.23 -63.05

No

909

26,121.1

34.80

32.57 -37.14

Yes

63

1,215.50

51.83

39.83 -66.31

No

295

5,262.67

56.06

49.84 -62.83

Yes

677

22,073.9

30.67

28.40 -33.07

No

803

27,165.9

29.56

27.55 -31.68

Yes

169

170.67

990.23

846.57 -1,151.30

No

703

22,032.9

31.91

29.59 -34.36

Yes

269

5,303.67

50.72

44.84 -57.16

No

826

2,7074.4

30.51

28.46 - 32.66

Yes

146

262.17

556.90

470.23 - 654.91

No

856

27,127.7

31.55

29.48 - 33.74

Yes

116

208.83

555.47

458.99 - 666.23

0

122

4,908.50

24.85

20.64 -29.68

1

132

4,571.75

28.87

24.16 -34.24

2 to 3

314

9,551.00

32.88

29.34 -36.72

4+

404

8,305.33

48.64

44.02 -53.63

Stage Unknown
Chemotherapy

n

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); DVT = deep vein
thrombosis; RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rate for pulmonary embolism in the follow-up period after kidney
cancer diagnosis was 13.58 per 1,000 p-y (Table 17). There was no consistent trend in
incidence rates by age at diagnosis or geographic region. Incidence rates increased with
increasing year of diagnosis, stage at diagnosis, and Charlson score. The rates were
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higher in Black patients, females, patients treated with chemotherapy or immunotherapy,
history of pulmonary embolism, and history of CVD. Patients treated with nephrectomy
had lower rates of pulmonary embolism. Less than 11 patients with chromophobe or
transitional cell tumors had pulmonary embolism and so the incidence rates had very
wide confidence intervals. The incidence rates for the other histology groups ranged from
13.77 to 19.26, with overlapping confidence intervals.
Unlike the year prior to cancer diagnosis (Table 10), the incidence rates for
pulmonary embolism in females (14.88, 95% CI 12.84-17.15) was only slightly larger
than the incidence rate for males (12.52, 95% CI 10.83-14.40) in the period after cancer
diagnosis (Table 17).
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Table 17
Incidence Rates per 1,000 p-y for PE After Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

386

28,421.4

13.58

12.26 -15.01

66-69

84

5,425.33

15.48

12.35 -19.17

70-74

114

8,554.08

13.33

10.99 -16.01

75-79

96

7,514.08

12.78

10.35 -15.60

80-84

48

4,634.33

10.36

7.64 -13.73

85+

44

2,293.58

19.18

13.94 -25.75

Black

34

2,024.92

16.79

11.63 -23.46

Other/Unknown

16

1,926.08

8.31

4.75 -13.49

White

336

24,470.4

13.73

12.30 -15.28

Female

190

12,768.9

14.88

12.84 -17.15

Male

196

15,652.5

12.52

10.83 -14.40

Midwest

52

3,599.50

14.45

10.79 -18.94

Northeast

92

6,384.08

14.41

11.62 -17.67

South

94

7,396.50

12.71

10.27 -15.55

West

148

11,041.3

13.40

11.33 -15.75

2004

63

6,759.33

9.32

7.16 -11.92

2005

61

6,166.33

9.89

7.57 -12.71

2006

83

5,471.83

15.17

12.08 -18.80

2007

56

4,670.17

11.99

9.06 -15.57

2008

67

3,288.83

20.37

15.79 -25.87

2009

56

2,064.92

27.12

20.49 -35.22

< 11

-

5.17

2.08 -10.64

Clear Cell

302

21,932.6

13.77

12.26 -15.41

Other RCC

36

1,868.75

19.26

13.49 -26.67

Papillary

38

2,749.25

13.82

9.78 -18.97

< 11

-

5.81

1.20 -16.99

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

Chemotherapy

Immunotherapy

Nephrectomy

History of Condition

History of CVD

CVC

a

High-risk Surgerya

Charlson Score

n

Person-Years

Incidence Rate

95% CI

Stage I

163

17,349.6

9.40

8.01 -10.95

Stage II

30

2,489.00

12.05

8.13 -17.21

Stage III

67

4,364.83

15.35

11.90 -19.49

Stage IV

98

1,876.33

52.23

42.40 -63.65

Stage Unknown

28

2,341.67

11.96

7.95 -17.28

No

253

22,681.8

11.15

9.82 -12.62

Yes

133

5,739.58

23.17

19.40 -27.46

No

357

27,151.0

13.15

11.82 -14.59

Yes

29

1,270.42

22.83

15.29 -32.78

No

112

5,469.00

20.48

16.86 -24.64

Yes

274

22,952.4

11.94

10.57 -13.44

No

325

28,346.2

11.47

10.25 -12.78

Yes

61

75.25

810.63

620.07 -1,041.29

No

289

22,785.3

12.68

11.26 -14.23

Yes

97

5,636.08

17.21

13.96 -21.00

No

329

28,326.7

11.61

10.39 - 12.94

Yes

57

94.75

601.58

455.63 - 779.42

No

339

28,338.7

11.96

10.72 - 13.31

Yes

47

82.75

567.98

417.33 - 755.29

0

47

4,989.75

9.42

6.92 -12.53

1

56

4,682.00

11.96

9.03 -15.53

2 to 3

128

9,893.42

12.94

10.79 -15.38

4+

155

8,856.25

17.50

14.85 -20.48

Note. Numbers less than 11 and the associated person-years have been suppressed.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); PE = pulmonary embolism;
RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rates for other VTE in the period after kidney cancer diagnosis was
13.35 per 1,000 p-y (Table 18). There was no clear trend in incidence rates for age at
diagnosis, race, gender, treatment with nephrectomy, history of CVD, or Charlson score;
however, some of the groups had very wide confidence intervals. The incidence rates
were higher in patients diagnosed in 2008 or 2009 than in earlier years, diagnosed with
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other RCC, diagnosed with Stage III or IV kidney cancer, treated with chemotherapy or
immunotherapy, and patients with history of other VTE.
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Table 18
Incidence Rates per 1,000 p-y for Other VTE After Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

378

28,321.7

13.35

12.03 -14.76

66-69

58

5,461.00

10.62

8.06 -13.73

70-74

106

8,495.67

12.48

10.22 -15.09

75-79

117

7,480.17

15.64

12.94 -18.75

80-84

58

4,611.67

12.58

9.55 -16.26

85+

39

2,273.25

17.16

12.20 -23.45

Black

27

2,039.83

13.24

8.72 -19.26

Other/Unknown

26

1,886.42

13.78

9.00 -20.19

White

325

24,395.5

13.32

11.91 -14.85

Female

179

12,755.5

14.03

12.05 -16.25

Male

199

15,566.3

12.78

11.07 -14.69

Midwest

32

3,661.58

8.74

5.98 -12.34

Northeast

105

6,326.33

16.60

13.57 -20.09

South

100

7,355.17

13.60

11.06 -16.54

West

141

10,978.7

12.84

10.81 -15.15

2004

76

6,677.08

11.38

8.97 -14.25

2005

61

6,182.00

9.87

7.55 -12.68

2006

70

5,454.75

12.83

10.00 -16.21

2007

61

4,654.67

13.11

10.02 -16.83

2008

62

3,294.92

18.82

14.43 -24.12

2009

48

2,058.33

23.32

17.19 -30.92

< 15

-

9.74

5.19 -16.66

Clear Cell

297

21,862.8

13.58

12.08 -15.22

Other RCC

33

1,853.92

17.80

12.25 -25.00

Papillary

29

2,761.33

10.50

7.03 -15.08

< 11

-

11.79

4.33 -25.66

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

Chemotherapy

Immunotherapy

Nephrectomy

History of Condition

History of CVD

CVC

a

High-risk Surgerya

Charlson Score

n

Person-Years

Incidence Rate

95% CI

Stage I

131

17,407.8

7.53

6.29 -8.93

Stage II

19

2,491.42

7.63

4.59 -11.91

Stage III

123

4,223.50

29.12

24.20 -34.75

Stage IV

59

1,899.42

31.06

23.65 -40.07

Stage Unknown

46

2,299.67

20.00

14.64 -26.68

No

263

22,640.4

11.62

10.25 -13.11

Yes

115

5,681.33

20.24

16.71 -24.30

No

342

27,085.6

12.63

11.32 -14.04

Yes

36

1,236.17

29.12

20.40 -40.32

No

81

5,481.67

14.78

11.73 -18.37

Yes

297

22,840.1

13.00

11.57 -14.57

No

297

28,178.1

10.54

9.38 -11.81

Yes

81

143.67

563.81

447.74 -700.76

No

306

22,664.0

13.50

12.03 -15.10

Yes

72

5,657.75

12.73

9.96 -16.03

No

331

28,241.1

11.72

10.49 - 13.05

Yes

47

80.67

582.64

428.11 - 774.79

No

333

28,239.4

11.79

10.56 - 13.13

Yes

45

82.33

546.56

398.66 - 731.34

0

57

4,957.83

11.50

8.71 -14.90

1

66

4,676.50

14.11

10.92 -17.96

2 to 3

131

9,808.17

13.36

11.17 -15.85

4+

124

8,879.25

13.97

11.62 -16.65

Note. Numbers less than 11 and the associated person-years have been suppressed. Additional cells were
suppressed where necessary so that the number in an individual cell with counts less than 11 could not be
determined.
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); Other VTE = other venous
thromboembolic event; RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rate for any ATE in the period after kidney cancer diagnosis was
39.68 per 1,000 p-y (Table 19). Incidence rates increased with increasing age at diagnosis
and increasing Charlson score. Incidence rates were higher in Black patients, patients
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diagnosed outside of the West geographic region, diagnosed with Stage IV or unknown
stage, with other RCC, not treated with nephrectomy, with history of any ATE, history of
CVD, placement of CVC, and high-risk surgery. There was no clear difference in rates
across gender, year of diagnosis, treatment by chemotherapy or treatment by
immunotherapy.

128
Table 19
Incidence Rates per 1,000 p-y for Any ATE After Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Geographic Region

Year of Diagnosis

Histology Group

Person-Years

Incidence Rate

95% CI

1,083

27,290.4

39.68

37.36 - 42.12

66-69

151

5,277.75

28.61

24.23 - 33.56

70-74

272

8,267.58

32.90

29.11 - 37.05

75-79

309

7,164.67

43.13

38.45 - 48.22

80-84

209

4,381.58

47.70

41.45 - 54.62

85+

142

2,198.83

64.58

54.39 - 76.12

Black

108

1,944.50

55.54

45.56 - 67.06

58

1,865.42

31.09

23.61 - 40.19

White

917

23,480.5

39.05

36.57 - 41.67

Female

482

12,337.2

39.07

35.66 - 42.72

Male

601

14,953.3

40.19

37.04 - 43.54

Midwest

150

3,484.08

43.05

36.44 - 50.52

Northeast

263

6,054.25

43.44

38.35 - 49.02

South

306

7,055.83

43.37

38.64 - 48.51

West

364

10,696.3

34.03

30.62 - 37.71

2004

231

6,364.50

36.30

31.77 - 41.29

2005

235

5,839.00

40.25

35.27 - 45.73

2006

203

5,297.08

38.32

33.23 - 43.97

2007

161

4,545.58

35.42

30.16 - 41.33

2008

148

3,225.25

45.89

38.79 - 53.90

2009

105

2,019.00

52.01

42.54 - 62.96

44

1,305.67

33.70

24.49 - 45.24

Clear Cell

840

20,989.0

40.02

37.36 - 42.82

Other RCC

92

1,801.83

51.06

41.16 - 62.62

Papillary

88

2,702.50

32.56

26.12 - 40.12

Transitional cell
tumor

19

491.42

38.66

23.28 - 60.38

Other/Unknown

Gender

n

Chromophobe

(continued)
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Level
Stage at Diagnosis

Chemotherapy

Immunotherapy

Nephrectomy

History of Condition

History of CVD

CVC

a

High-risk Surgerya

Charlson Score

n

Person-Years

Incidence Rate

95% CI

Stage I

581

16,625.3

34.95

32.16 - 37.91

Stage II

92

2,395.67

38.40

30.96 - 47.10

Stage III

160

4,203.92

38.06

32.39 - 44.44

Stage IV

122

1,866.58

65.36

54.28 - 78.04

Stage Unknown

128

2,199.00

58.21

48.56 - 69.21

No

871

21,709.5

40.12

37.50 - 42.88

Yes

212

5,580.92

37.99

33.04 - 43.46

1,040

26,059.9

39.91

37.52 - 42.41

Yes

43

1,230.50

34.95

25.29 - 47.07

No

317

5,263.17

60.23

53.78 - 67.24

Yes

766

22,027.3

34.78

32.36 - 37.33

No

968

26,741.0

36.20

33.95 - 38.55

Yes

115

549.42

209.31

172.81 - 251.25

No

750

23,176.8

32.36

30.09 - 34.76

Yes

333

4,113.58

80.95

72.49 - 90.13

No

936

26,932.4

34.75

32.56 - 37.05

Yes

147

358.00

410.61

346.92 - 482.62

No

936

26,937.5

34.75

32.56 - 37.05

Yes

147

352.92

416.53

351.92 - 489.57

0

90

5,727.17

15.71

12.64 - 19.32

1

145

5,055.58

28.68

24.20 - 33.75

2 to 3

374

9,852.00

37.96

34.21 - 42.01

4+

474

6,655.67

71.22

64.95 - 77.93

No

Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC = central venous catheter; CVD =
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina
or transient ischemic attack); IS = ischemic stroke; MI = myocardial infarction; RCC = renal cell
carcinoma.
a

More than 30 days before the outcome.

The incidence rates for myocardial infarction in the period after kidney cancer
diagnosis was 21.91 per 1,000 p-y (Table 20). The incidence rates increased with
increasing age at diagnosis and Charlson score. The patterns for the incidence rates were
similar for the rates for any ATE (Table 19), except the highest incidence rates by
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histology group was for patients with Transitional cell tumors. The confidence intervals
for incidence rates by histology groups were very wide except for clear cell tumor which
was the most frequently type of histology diagnosed. The incidence rates for myocardial
infarction were higher than for pulmonary embolism and other VTE, which was
unexpected based on the assertion in the published literature at ATEs were rarer than
VTEs.
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Table 20
Incidence Rates per 1,000 p-y for MI After Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

615

28,065.1

21.91

20.22 -23.72

66-69

95

5,381.50

17.65

14.28 -21.58

70-74

150

8,478.75

17.69

14.97 -20.76

75-79

168

7,426.00

22.62

19.33 -26.31

80-84

122

4,516.25

27.01

22.43 -32.25

85+

80

2,262.58

35.36

28.04 -44.01

Black

63

1,999.25

31.51

24.21 -40.32

Other/Unknown

32

1,900.75

16.84

11.52 -23.77

White

520

24,165.1

21.52

19.71 -23.45

Female

256

12,713.5

20.14

17.74 -22.76

Male

359

15,351.6

23.39

21.03 -25.93

Midwest

88

3,575.42

24.61

19.74 -30.32

Northeast

157

6,246.17

25.14

21.36 -29.39

South

157

7,305.25

21.49

18.26 -25.13

West

213

10,938.3

19.47

16.95 -22.27

2004

135

6,589.17

20.49

17.18 -24.25

2005

126

6,055.75

20.81

17.33 -24.77

2006

115

5,454.67

21.08

17.41 -25.31

2007

93

4,627.08

20.10

16.22 -24.62

2008

85

3,286.08

25.87

20.66 -31.98

2009

61

2,052.33

29.72

22.74 -38.18

Chromophobe

25

1,332.25

18.77

12.14 -27.70

Clear Cell

469

21,633.4

21.68

19.76 -23.73

Other RCC

53

1,841.92

28.77

21.55 -37.64

Papillary

51

2,760.83

18.47

13.75 -24.29

Transitional cell
tumor

17

496.67

34.23

19.94 -54.80

(continued)
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Level
Stage at Diagnosis

Chemotherapy

Immunotherapy

Nephrectomy

History of Condition

History of CVD

CVC

a

Incidence Rate

95% CI

324

17,129.4

18.91

16.91 -21.09

Stage II

58

2,447.25

23.70

18.00 -30.64

Stage III

88

4,324.33

20.35

16.32 -25.07

Stage IV

67

1,899.92

35.26

27.33 -44.78

Stage Unknown

78

2,264.17

34.45

27.23 -42.99

No

502

22,325.9

22.49

20.56 -24.54

Yes

113

5,739.17

19.69

16.23 -23.67

No

589

26,799.7

21.98

20.24 -23.83

Yes

26

1,265.33

20.55

13.42 -30.11

No

180

5,398.17

33.34

28.65 -38.59

Yes

435

22,666.9

19.19

17.43 -21.08

No

543

27,773.2

19.55

17.94 -21.27

Yes

72

291.92

246.65

192.99 -310.61

No

373

22,666.0

16.46

14.83 -18.21

Yes

242

5,399.08

44.82

39.35 -50.84

1,349

25,498.4

52.91

50.12 - 55.81

205

349.42

586.69

509.12 - 672.74

1,370

25,491.0

53.74

50.94 - 56.67

184

356.83

515.65

443.83 - 595.78

0

24

5,029.42

4.77

3.06 -7.10

1

62

4,690.08

13.22

10.14 -16.95

2 to 3

155

9,868.92

15.71

13.33 -18.38

4+

374

8,476.67

44.12

39.76 -48.83

Yes
No
Yes
Charlson Score

Person-Years

Stage I

No

High-risk Surgerya

n

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); MI = myocardial infarction;
RCC = renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rate for ischemic stroke in the period after kidney cancer diagnosis
was 19.39 per 1,000 p-y (Table 21). The incidence rates by histology group were 15.59,
19.95, 24.11, and 16.60 for Chromophobe, Clear cell, Other RCC, and Papillary,
respectively. With wide confidence intervals, the differences in incidence rates may not
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be statistically significant. The incidence rates increased with increasing age at diagnosis
and increasing Charlson comorbidity score.
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Table 21
Incidence Rates per 1,000 p-y for IS After Kidney Cancer Diagnosis
Level
TOTAL

TOTAL

Age at Diagnosis

Race

Gender

Geographic Region

Year of Diagnosis

Histology Group

n

Person-Years

Incidence Rate

95% CI

548

28,256.5

19.39

17.80 - 21.09

66-69

71

5,451.00

13.03

10.17 - 16.43

70-74

144

8,521.33

16.90

14.25 - 19.90

75-79

165

7,435.75

22.19

18.93 - 25.85

80-84

97

4,573.75

21.21

17.20 - 25.87

85+

71

2,274.67

31.21

24.38 - 39.37

Black

55

2,039.58

26.97

20.31 - 35.10

Other/Unknown

28

1,909.50

14.66

9.74 - 21.19

White

465

24,307.4

19.13

17.43 - 20.95

Female

260

12,735.5

20.42

18.01 - 23.05

Male

288

15,521.0

18.56

16.47 - 20.83

Midwest

72

3,620.50

19.89

15.56 - 25.04

Northeast

127

6,340.67

20.03

16.70 - 23.83

South

171

7,290.08

23.46

20.07 - 27.25

West

178

11,005.3

16.17

13.89 - 18.73

2004

115

6,663.75

17.26

14.25 - 20.72

2005

131

6,058.92

21.62

18.08 - 25.66

2006

104

5,473.75

19.00

15.52 - 23.02

2007

75

4,678.75

16.03

12.61 - 20.09

2008

72

3,314.92

21.72

16.99 - 27.35

2009

51

2,066.42

24.68

18.38 - 32.45

-

-

15.59

9.65 - 23.83

Clear Cell

434

21,756.8

19.95

18.12 - 21.92

Other RCC

45

1,866.25

24.11

17.59 - 32.26

Papillary

46

2,771.08

16.60

12.15 - 22.14

< 11

-

3.88

0.47 - 14.02

Chromophobe

Transitional cell
tumor

(continued)
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Level
Stage at Diagnosis

Chemotherapy

Immunotherapy

Nephrectomy

History of Condition

History of CVD

CVC

a

High-risk Surgerya

Charlson Score

n

Person-Years

Incidence Rate

95% CI

Stage I

306

17,188.9

17.80

15.86 - 19.91

Stage II

36

2,481.83

14.51

10.16 - 20.08

Stage III

86

4,357.83

19.73

15.79 - 24.37

Stage IV

58

1,913.33

30.31

23.02 - 39.19

Stage Unknown

62

2,314.58

26.79

20.54 - 34.34

No

428

22,504.8

19.02

17.26 - 20.91

Yes

120

5,751.75

20.86

17.30 - 24.95

No

525

26,975.9

19.46

17.83 - 21.20

Yes

23

1,280.58

17.96

11.39 - 26.95

No

158

5,434.83

29.07

24.72 - 33.97

Yes

390

22,821.7

17.09

15.43 - 18.87

No

515

27,958.4

18.42

16.86 - 20.08

Yes

33

298.08

110.71

76.21 - 155.47

No

390

23,816.9

16.37

14.79 - 18.08

Yes

158

4,439.58

35.59

30.26 - 41.59

No

473

28,073.9

16.85

15.36 - 18.44

Yes

75

182.58

410.77

323.10 - 514.91

No

459

28,024.1

16.38

14.91 - 17.95

Yes

89

232.42

382.93

307.53 - 471.23

0

53

5,770.08

9.19

6.88 - 12.01

1

87

5,142.42

16.92

13.55 - 20.87

2 to 3

201

10,105.8

19.89

17.23 - 22.84

4+

207

7,238.17

28.60

24.83 - 32.77

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); IS = ischemic stroke; RCC
= renal cell carcinoma.
a

More than 30 days before the outcome.

The incidence rates of thromboembolic events were higher in the period after
cancer diagnosis than in the period before diagnosis for each outcome. Consistently,
incidence rates increased with history of the condition, history of CVD, and increasing
Charlson score. Ischemic stroke was the most common ATE and typically drove the
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patterns seen for the any ATE tables. The incidence rates of ATEs were higher than
expected, however appears to be due to the inclusion of ischemic stroke. The incidence
rate for ischemic stroke of 60.12 per 1,000 p-y was higher than the incidence rate for any
of the venous thromboembolic events.
Descriptive Analysis 2
The purpose of descriptive analysis 2 was to describe the incidence proportions of
thromboembolic events in the kidney cancer cohort in discrete periods after kidney
cancer diagnosis. Tables 21 to 23 contain the results for each outcome with incidence
proportions within 90 days, 91 to 180 days, 181 to 270 days, and 271 to 365 days after
the cancer diagnosis. The incidence proportions in the entire follow-up period were also
provided.
Within the first year after cancer diagnosis, the highest incidence proportions of
VTEs and ATEs occurred in the first 90 days (Tables 22 to 24). The trend was that the
incidence proportions decreased in later time periods for all outcomes except other VTE
and ATEs (any, myocardial infarction, or ischemic stroke); however there were wide,
overlapping confidence intervals and so the incidence proportions may not have been
different at a statistically significant level. The highest incidence proportions occurred in
the entire follow-up period.
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Table 22
Incidence Proportions for Any VTE and DVT After Kidney Cancer Diagnosis
Any VTE
DVT
Period
Incidence
95% CI
Incidence
95% CI
Proportion
Proportion
0 - 90 days

6.38%

5.94% - 6.84%

4.29%

3.93% - 4.68%

91 - 180 days

1.37%

1.15% - 1.62%

0.90%

0.72% - 1.10%

181 - 270 days

0.98%

0.79% - 1.21%

0.78%

0.61% - 0.99%

271 - 365 days

0.82%

0.64% - 1.04%

0.50%

0.36% - 0.67%

Entire Follow-up Period

12.2%

11.6% - 12.8%

8.48%

7.98% - 9.00%

Note. DVT = deep vein thrombosis; VTE = venous thromboembolic event.

Table 23
Incidence Proportions for PE and Other VTEs After Kidney Cancer Diagnosis
PE
Other VTE
Period
Incidence
95% CI
Incidence
95% CI
Proportion
Proportion
0 - 90 days

1.64%

1.42% - 1.89%

1.57%

1.35% - 1.81%

91 - 180 days

0.41%

0.29% - 0.55%

0.44%

0.32% - 0.59%

181 - 270 days

0.30%

0.20% - 0.43%

0.19%

0.11% - 0.30%

271 - 365 days

0.20%

0.12% - 0.32%

0.27%

0.17% - 0.40%

Entire Follow-up Period

3.37%

3.04% - 3.71%

3.30%

2.98% - 3.64%

Note. Other VTE = other venous thromboembolic event; PE = pulmonary embolism.
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Table 24
Incidence Proportions for ATEs After Kidney Cancer Diagnosis
Any ATE
MI
Period
IP
95% CI
IP
95% CI

IP

IS
95% CI

0 - 90 days

3.19%

2.88% - 3.53%

1.82%

1.59% - 2.09%

1.47%

1.26% - 1.71%

91 - 180 days

0.90%

0.72% - 1.10%

0.58%

0.45% - 0.75%

0.36%

0.25% - 0.49%

181 - 270 days

0.67%

0.51% - 0.86%

0.34%

0.23% - 0.48%

0.36%

0.25% -0.50%

271 - 365 days

0.78%

0.61% - 0.99%

0.41%

0.28% - 0.56%

0.40%

0.28% - 0.56%

Entire Follow-up Period

9.45%

8.92% - 10.0%

5.37%

4.96% - 5.79%

4.78%

4.40% - 5.19%

Note. Any ATE = any arterial thromboembolic event (MI or IS); IS = ischemic stroke; MI = myocardial
infarction.

Research Question 1
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly
exposed (kidney cancer) patients 12 months before index date compare to a matched
unexposed (noncancer) Medicare population during the same 12-month timeframe?
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are
statistically significantly greater in the exposed patients than in the unexposed patients.
H01: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the year prior to the index date in the exposed patients and in the matched
unexposed patients.
The purpose of Research Question 1 was to compare the incidence rates in the
exposed to unexposed cohorts in the year prior to index date. The incidence rate ratios
were estimated by the hazard ratio and all models were adjusted for the matching factors.
Adjusted models were run twice, first using kidney disease and diabetes as potential
confounders and effect measure modifiers; second, using the Charlson score as a
potential confounder. Kidney disease and diabetes are two conditions which are
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components of the Charlson comorbidity score. Using backward selection, variables were
retained in the model if they had a p-value of less than 0.05. The hazard ratios were
stratified by variables whose interaction terms with gender had a p-value less than 0.05 in
the full model.
The incidence rate for any VTE was higher in the exposed cohort than in the
unexposed cohort in the crude and adjusted models (Table 25). The crude hazard ratio
comparing the incidence rate in the exposed to the unexposed was 1.44 (95% CI 1.23 –
1.69). After adjusting for other factors, the hazard ratio increased. Using the first method,
the hazard ratio was 1.65 (95% CI 1.30 - 2.09) after adjusting by atherosclerosis, varicose
veins, placement of central venous catheter more than 30 days prior to the outcome,
kidney disease and history of VTE. Using the Charlson comorbidity score instead of
kidney disease and diabetes variables in the full model, the adjusted hazard ratio was 1.81
(95% CI 1.42 – 2.28) and the adjusting factors were Charlson score, varicose veins,
central venous catheter and history of VTE.
The incidence rate for DVT was higher in the exposed cohort than the unexposed
cohort in the year prior to index date (Table 25). The crude hazard ratio was 1.69 (95%
CI 1.38 – 2.08), but decreased slightly after adjusting for confounders. The confounders
in the first adjusted model were atherosclerosis, varicose veins, kidney disease and
history of CVD and the hazard ratio was 1.50 (95% CI 1.19-1.89). The model adjusted by
the Charlson score yielded a hazard ratio of 1.57 (95% CI 1.24 – 1.98) and was adjusted
by atherosclerosis and varicose veins. After adjusting for the Charlson score, history of
CVD was no longer a confounder for the relationship.
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The incidence rate for pulmonary embolism in the year prior to index date was
higher in the exposed cohort than the unexposed cohort for all models (Table 25). The
crude hazard ratio (HR = 1.62, 95% CI 1.16 – 2.27) was between the two adjusted hazard
ratios.
Unlike any VTE, DVT, and pulmonary embolism, the incidence rate for other
VTEs in the year prior to index date was not consistently higher for the exposed than the
unexposed at a statistically significant level (Table 25). The crude hazard ratio was 1.32
(95% CI 1.01 - 1.71). However, in the first model the history of CVD was an EMM and
the incidence rate ratio was greater than one in the population without history of CVD
(HR = 1.41, 95% CI 1.02 – 1.96). The hazard ratio for patients with a history of CVD was
0.83 (95% CI 0.38 – 1.80) and was not statistically significant at the 0.05 level. The
hazard ratio for the model adjusted by the Charlson score was greater than 1 (HR = 1.23,
95% CI 0.93 – 1.62), but it was also not statistically significant at the 0.05 level.
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Table 25
Incidence Rate Ratios for Venous Thromboembolic Events in the Year Prior to Index
Date (N = 22,926)
Crude HR (95% CI)a

Adjusted HR (95%
CI)

Adjusted HR (95%
CI)

Any VTE
(n = 394 events in cancer cohort; n = 271 events in noncancer cohort)
Cancer vs. noncancer
1.44 (1.23 - 1.69)*** 1.65 (1.30 - 2.09)b***

1.81 (1.42 - 2.28)c***

DVT
(n = 246 events in cancer cohort; n = 147 events in noncancer cohort)
Cancer vs. noncancer
1.69 (1.38 - 2.08)*** 1.50 (1.19 -1.89) d***

1.57 (1.24 - 1.98)e***

PE
(n = 90 events in cancer cohort; n = 55 events in noncancer cohort)
Cancer vs. noncancer
1.62 (1.16 - 2.27)**
1.52 (1.07 - 2.18)f*

1.84 (1.24 - 2.74)g**

Other VTE
(n = 129 events in cancer cohort; n = 98 events in noncancer cohort)
Cancer vs. noncancer
1.32 (1.01 - 1.71)*
Without history of
1.41 (1.02 - 1.96)h*
CVD
With history of CVD
0.83 (0.38 - 1.80)h

1.23 (0.93 - 1.62)i

Note. CVD = cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart
failure, angina or transient ischemic attack); DVT = deep vein thrombosis; Other VTE = other venous
thromboembolic event; PE = pulmonary embolism; VTE = venous thromboembolic event.
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a

Model adjusted only for matching

b

Model adjusted for matching and atherosclerosis, varicose veins, central venous catheter, kidney disease,

and history of VTE. Placement of central venous catheter was more than 30 days before outcome.
c

Model adjusted for matching and Charlson Comorbidity Score, varicose veins, central venous catheter,

and history of VTE. Placement of central venous catheter was more than 30 days before outcome.
d

Model adjusted for matching and atherosclerosis, varicose veins, kidney disease and history of CVD.

e

Model adjusted for matching and Charlson Comorbidity Score, atherosclerosis, and varicose veins.

f

Model adjusted for matching, type 2 diabetes and kidney disease.

g

Model adjusted for matching and Charlson Comorbidity Score.

h

Model adjusted for matching and type 2 diabetes and varicose veins. Stratified by history of CVD.

i

Model adjusted for matching and Charlson Comorbidity Score and varicose veins.

* p < .05. ** p < .01. *** p < .001.

The incidence rate ratio was greater than 1.0 comparing the exposed to unexposed
cohorts for any ATE in the year prior to index date, but only for the crude model (Table
26). After adjusting for other factors including type 2 diabetes, kidney disease, Charlson
Comorbidity Score, atherosclerosis, varicose veins, high-risk surgery, history of CVD,
and history of ATE, there was no statistically significant difference in the incidence rates
of any ATE for cancer patients and noncancer patients.
The incidence rate ratio for myocardial infarction in the year prior to index date
differed by history of CVD (Table 26). Although the hazard ratio was greater than 1 for
the crude model (HR = 1.26, 95% CI 1.20 – 1.56), the hazard ratio was not significantly
different than 1.0 for the model adjusted by the Charlson score (HR = 1.18, 95% CI 0.88

143
– 1.59). In patients without a history of CVD, the hazard ratio was greater than 1 (HR =
1.46, 95% CI 1.05 – 2.05). The hazard ratio was less than 1.0 for patients with a history
of CVD (HR = 0.48, 95% CI 0.24 – 0.97).
Elderly kidney cancer patients did not have a higher incidence rate of ischemic
stroke than the matched, noncancer comparison group. Although the hazard ratios were
greater than 1.0, for neither the crude nor adjusted models were the results statistically
different from 1.0 (Table 26). The crude hazard ratio was 1.20, but after adjusting for
other risk factors the hazard ratio decreased to 1.04 to 1.09 for the two multivariate
models.
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Table 26
Incidence Rate Ratios for Arterial Thromboembolic Events in the Year Prior to Index
Date (N = 22,926)
Crude HR (95% CI)a

Adjusted HR (95%
CI)

Adjusted HR (95%
CI)

(n = 354 events in cancer cohort; n = 291 events in noncancer cohort)
Cancer vs. noncancer
1.23 (1.05 - 1.43)*
1.11 (0.92 - 1.34) b

1.14 (0.93 - 1.39) c

Any ATE

MI
(n = 192 events in cancer cohort; n = 153 events in noncancer cohort)
Cancer vs. noncancer
1.26 (1.02 - 1.56)*
Without history of
1.46 (1.05 - 2.04)d**
CVD
With history of CVD
0.48 (0.24 - 0.97) d**
IS
(n = 173 events in cancer cohort; n = 145 events in noncancer cohort)
Cancer vs. noncancer
1.20 (0.96 - 1.50)
1.04 (0.81 - 1.34)f

1.18 (0.88 - 1.59)e

1.09 (0.84 - 1.42)g

Note. Any ATE = any arterial thromboembolic event (MI or IS); CVD = cardiovascular disease
(myocardial infarction, ischemic stroke, new onset congestive heart failure, angina or transient ischemic
attack); MI = myocardial infarction; IS = ischemic stroke.
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a

Model adjusted only for matching

b

Model adjusted for matching and type 2 diabetes, atherosclerosis, high-risk surgery, kidney disease,

history of CVD, and history of ATE. High-risk surgery was more than 30 days before outcome.
c

Model adjusted for matching and Charlson Comorbidity Score, atherosclerosis, high-risk surgery and

history of ATE. High-risk surgery was more than 30 days before outcome.
d

Model adjusted for matching and type 2 diabetes and kidney disease. Stratified by history of CVD.

e

Model adjusted for matching and Charlson Comorbidity Score and history of MI .

f

Model adjusted for matching and type 1 diabetes, atherosclerosis, history of ischemic stroke, and kidney

disease. High-risk surgery was more than 30 days before outcome.
g

Model adjusted for matching and Charlson Comorbidity Score, atherosclerosis, and history of IS.

* p < .05. ** p < .01. *** p < .001.

For most outcomes, the incidence rate of thromboembolic events was higher in
the exposed cohort than the unexposed cohort in the year prior to index date. For other
VTEs, any ATE, myocardial infarction, and ischemic stroke, history of CVD was an
EMM with the incidence rate of events higher in the exposed cohort for patients without
a history of CVD. In patients with a history of CVD, the incidence rate was lower in the
exposed cohort or not statistically significantly different than the unexposed cohort.
Thus, the null hypothesis was rejected for any VTE, DVT and pulmonary
embolism after adjusting for other factors in the model. The null hypothesis could not be
rejected for other VTEs and myocardial infarction in patients with a history of CVD
when the models did not adjust for the Charlson comorbidity score. The null hypothesis
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could also not be rejected for other VTEs, any ATE, myocardial infarction, and ischemic
stroke after adjusting by the Charlson comorbidity score.
Research Question 2
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in
elderly exposed (kidney cancer) patients after index date compare to a matched
unexposed (noncancer) Medicare population during the same timeframe?
HA2: In the follow-up period after the index date, the incidence rates of VTEs or
of ATEs are statistically significantly greater in the exposed patients than in the
unexposed patients.
H02: There is no statistically significant difference in the incidence rates of VTEs
or ATEs in the period after index date in the exposed patients and in the matched
unexposed patients. The purpose of Research Question 2 was to compare the incidence
rates in the exposed to unexposed cohorts in the follow-up period after index date. The
methodology was the same as for Research Question 1.
The incidence rate for any VTE was higher in the exposed cohort than the
unexposed cohort in the follow-up period (Table 27). In the first model, Type 2 diabetes
and kidney disease were EMMs. The rate was more than five times higher in the exposed
population than the unexposed population in patients who had neither type 2 diabetes nor
kidney disease (5.42, 95% CI 4.18 – 7.02). The incidence rate was twice as high in the
exposed population in patients with type 2 diabetes only or kidney disease only. The
incidence rate was not statistically significantly different for the exposed to the
unexposed cohort in patients with both type 2 diabetes and kidney disease (1.15, 95% CI
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0.78 – 1.68). In the second model, the incidence rate was more than three times as high in
the exposed population (HR = 3.44, 95% CI 2.97 – 3.99) and no factors were EMMs.
The incidence rate for DVT in the exposed cohort was higher than in the
unexposed cohort in the follow-up period after index date (Table 27). In the first model,
atherosclerosis and kidney disease were EMMs. The incidence rate ratios were higher in
the exposed cohort for patients without both disease and for patients with only
atherosclerosis or kidney disease. The hazard ratio was 0.88 (95% CI 0.53 – 1.49) for
patients with both atherosclerosis and kidney disease. In the second model,
atherosclerosis was an EMM. The incidence rate ratio estimates were greater than 1.0 in
patients without atherosclerosis (HR = 3.56, 95% CI 2.88 – 4.41) and in patients with
atherosclerosis (HR = 1.75, 95% CI 1.13 – 2.72).
The incidence rate ratio for pulmonary embolism was approximately three times
higher in the exposed cohort than the unexposed cohort in the follow-up period (Table
27). Both adjusted models yielded similar hazard ratios. The first model hazard ratio was
2.95 (95% CI 2.31 – 3.77) and the second model adjusted hazard ratio was 3.28 (95% CI
2.60 – 4.14). Both models were adjusted by atherosclerosis, with the first model also
adjusted by kidney disease and the second model also adjusted by the Charlson score.
The incidence rate ratio for other VTEs differed by type 2 diabetes and kidney
disease in the first model (Table 27). In patients without diabetes and kidney disease, the
hazard ratio was 4.31 (95% CI 2.89 – 6.43); in patients with kidney disease the hazard
ratio was 1.80 (95% CI 0.90 – 3.57); in patients with type 2 diabetes the hazard ratio was
2.08 (95% CI 1.19 – 3.64); and in patients with both type 2 diabetes and kidney disease,
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the hazard ratio was 0.87 (95% CI 0.47 – 1.61). In the second model, there were no
EMMs and the incidence rate ratio in the exposed cohort was 2.6 times that of the
unexposed cohort after adjusting for Charlson score, varicose veins, and placement of
central venous catheter more than 30 days prior to VTE (HR = 2.66, 95% CI 2.11 – 3.36).
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Table 27
Incidence Rate Ratios for Venous Thromboembolic Events in Follow-up Period After
Index Date (N = 22,926)
Crude HR (95% CI)a

Adjusted HR (95% CI)
Any VTE
(n = 1,402 events in cancer cohort; n = 441 events in noncancer cohort)
Cancer vs. noncancer
3.41 (3.05 - 3.81)***
Without type 2 diabetes or kidney
5.42 (4.18 - 7.02) b***
disease.
Without type 2 diabetes, with kidney
2.19 (1.48 - 3.23) b ***
disease.
With type 2 diabetes, without kidney
2.84 (2.00 - 4.04) b ***
disease.
With type 2 diabetes and kidney
1.15 (0.78 - 1.68) b
disease.

Adjusted HR (95% CI)
3.44 (2.97 - 3.99) c***

DVT
(n = 972 events in cancer cohort; n = 289 events in noncancer cohort)
Cancer vs. noncancer
3.55 (3.10 - 4.06) ***
Without atherosclerosis or kidney
4.45 (3.37 - 5.89)d***
disease.
Without atherosclerosis, with kidney
1.57 (1.04 - 2.38) d *
disease.
With atherosclerosis, without kidney
2.51 (1.48 - 4.23) d **
disease.
With atherosclerosis and kidney
0.88 (0.53 - 1.49) d
disease.
Without atherosclerosis
With atherosclerosis

3.56 (2.88 - 4.41)e**
1.75 (1.13 - 2.72) e**

PE
(n = 386 events in cancer cohort; n = 100 events in noncancer cohort)
Cancer vs. noncancer
3.88 (3.11 - 4.84) ***
2.95 (2.31 - 3.77) f***

3.28 (2.60 - 4.14) g***

Other VTE
(n = 378 events in cancer cohort; n = 127 events in noncancer cohort)
Cancer vs. noncancer
3.07 (2.50 - 3.76) ***
Without type 2 diabetes or kidney
4.31 (2.89 - 6.43)h**
disease.
Without type 2 diabetes, with kidney
1.80 (0.90 - 3.57) h
disease.
With type 2 diabetes, without kidney
2.08 (1.19 - 3.64) h**
disease.
With type 2 diabetes and kidney
0.87 (0.47 - 1.61) h
disease.

2.66 (2.11 - 3.36)i***

Note. DVT = deep vein thrombosis; Other VTE = other venous thromboembolic event; PE = pulmonary
embolism; VTE = venous thromboembolic event.
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a

Model adjusted only for matching.

b

Model adjusted for matching and type 1 diabetes, atherosclerosis, varicose veins, high-risk surgery,

central venous catheter, and history of VTE. Stratified by type 2 diabetes and kidney disease. High-risk
surgery was more than 30 days before outcome.
c

Model adjusted for matching and Charlson Comorbidity Score, varicose veins, high-risk surgery, central

venous catheter, and history of VTE. High-risk surgery was more than 30 days before outcome.
d

Model adjusted for matching and. Stratified by atherosclerosis and kidney disease.

e

Model adjusted for matching and Charlson Comorbidity Score, varicose veins, high-risk surgery, central

venous catheter, and history of DVT. Stratified by atherosclerosis. High-risk surgery and central venous
catheter were more than 30 days before outcome.
f

Model adjusted for matching and atherosclerosis and kidney disease.

g

Model adjusted for matching and Charlson Comorbidity Score and atherosclerosis.

h

Model adjusted for matching and varicose veins and central venous catheter. Stratified by type 2 diabetes

and kidney disease. Placement of central venous catheter was more than 30 days before outcome.
i

Model adjusted for matching and Charlson Comorbidity Score, varicose veins, and central venous

catheter. Placement of central venous catheter was more than 30 days before outcome.
* p < .05. ** p < .01. *** p < .001.

The incidence rate ratio for any ATE comparing the exposed to unexposed cohort
was 1.81 (95% CI 1.64 – 2.01) for the crude model (Table 28). After adjusting for other
factors, the incidence rate was higher for the exposed cohort in patients without
atherosclerosis and without kidney disease for the first model; and in patients without
atherosclerosis for the second model. Conversely, the incidence rate for any ATE was
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lower for the exposed cohort in patients who had both atherosclerosis and kidney disease
(HR = 0.59, 95% CI 0.40 - 0.86).
The incidence rate ratios for myocardial infarction in the follow-up period
differed in the exposed and unexposed cohorts by history of myocardial infarction (Table
28). In the first model, presence of atherosclerosis also impacted the incidence rate ratio.
In patients without atherosclerosis or history of myocardial infarction, the exposed cohort
had higher incidence rates of myocardial infarction (HR = 1.42, 95% CI 1.10 – 1.84). In
patients with history of myocardial infarction or atherosclerosis, the incidence rate was
lower in the unexposed cohort than the exposed cohort. In the second model, patients in
the exposed cohort with a history of myocardial infarction had a higher incidence rate
than the unexposed cohort without a history of myocardial infarction (HR = 1.35, 95% CI
1.11 – 1.65). Patients in the exposed cohort with history of had a much lower incidence
rate than patients in the unexposed cohort (HR = 0.05, 95% CI 0.00 – 0.72).
The incidence rate ratio for ischemic stroke in the follow-up period comparing the
exposed to unexposed differed by presence of kidney disease in the first model, and by
the presence of atherosclerosis in the second model which also adjusted by the Charlson
comorbidity score (Table 28). In the first model, the incidence rates for ischemic stroke
were higher for the exposed cohort in patients without kidney disease, but lower for the
exposed cohort in patients with kidney disease. The second model results were similar in
that the incidence rate was lower for the exposed cohort in patients with atherosclerosis.
The incidence rate ratio was not statistically different from 1.0 for patients without
atherosclerosis.
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Table 28
Incidence Rate Ratios for Arterial Thromboembolic Events in Follow-up Period After
Index Date (N = 22,926)
Crude HR (95% CI)a

Adjusted HR (95% CI)
Any ATE
(n = 1,083 events in cancer cohort; n = 625 events in noncancer cohort)
Cancer vs. noncancer
1.81 (1.64 - 2.01)***
Without atherosclerosis
1.47 (1.21 - 1.79) b*
and without kidney
disease
Without atherosclerosis,
0.96 (0.71 - 1.31) b
with kidney disease
With atherosclerosis,
0.89 (0.61 - 1.30) b
without kidney disease
With atherosclerosis and
0.59 (0.40 - 0.86) b*
kidney disease
Without atherosclerosis
With atherosclerosis
MI
(n = 615 events in cancer cohort; n = 291 events in noncancer cohort)
Cancer vs. noncancer
2.17 (1.89 - 2.51)***
Without atherosclerosis
1.42 (1.10 - 1.84) d*
or history of MI.
Without atherosclerosis,
0.03 (0.00 - 0.44) d**
with history of MI.
With atherosclerosis,
0.80 (0.50 - 1.27) d
without history of MI.
With atherosclerosis and
0.02 (0.00 - 0.25) d**
history of MI.
Without history of MI
With history of MI

Adjusted HR (95% CI)

1.27 (1.08 - 1.49) c*
0.77 (0.55 - 1.08) c

1.35 (1.11 - 1.65) e**
0.05 (0.00 - 0.72) e**

IS
(n = 548 events in cancer cohort; n = 370 events in noncancer cohort)
Cancer vs. noncancer
1.47 (1.29 - 1.68)***
Without kidney disease
1.34 (1.06 - 1.70) f*
With kidney disease
0.52 (0.35 - 0.78) f***
Without atherosclerosis
1.04 (0.84 - 1.29) g
With atherosclerosis
0.55 (0.34 - 0.90) g*
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVD = cardiovascular disease
(myocardial infarction, ischemic stroke, new onset congestive heart failure, angina or transient ischemic
attack); IS = ischemic stroke; MI = myocardial infarction.
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a

Model adjusted only for matching

b

Model adjusted for matching and type 2 diabetes, high-risk surgery, central venous catheter, kidney

disease, history of ATE and history of CVD. Stratified by atherosclerosis and kidney disease. Central
venous catheter and high-risk surgery were more than 30 days before outcome.
c

Model adjusted for matching and Charlson Comorbidity Score, high-risk surgery, central venous

catheter, and history of ATE. Stratified by atherosclerosis. Central venous catheter and high-risk surgery
were more than 30 days before outcome.
d

Model adjusted for matching, Type 2 diabetes, high-risk surgery, central venous catheter, kidney disease,

and history of CVD. Stratified by atherosclerosis and history of MI. Central venous catheter and high-risk
surgery were more than 30 days before outcome.
e

Model adjusted for matching and Charlson Comorbidity Score, high-risk surgery and central venous

catheter. Stratified by history of MI. Central venous catheter and high-risk surgery were more than 30 days
before outcome.
f

Model adjusted for matching and type 2 diabetes, atherosclerosis, high-risk surgery, central venous

catheter, and history of IS. Stratified by kidney disease. Central venous catheter and high-risk surgery were
more than 30 days before outcome.
g

Model adjusted for matching and Charlson Comorbidity Score, high-risk surgery, central venous

catheter, and history of IS. Stratified by atherosclerosis. Central venous catheter and high-risk surgery
were more than 30 days before outcome.
* p < .05. ** p < .01. *** p < .001.

In the follow-up period after index date, the incidence rate was higher in the
exposed cohort than the unexposed cohort for thromboembolic events. The null
hypothesis was rejected for any VTE, DVT, pulmonary embolism, and other VTEs after
adjusting for the Charlson comorbidity score. In the models stratified by EMMs, the
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higher incidence rates in the exposed cohort were mostly limited to the patients without
the EMM condition (e.g., type 2 diabetes, kidney disease, or atherosclerosis). The null
hypothesis was rejected for any ATE in patients without atherosclerosis and without
kidney disease in the first model, and in patients without atherosclerosis in the second
model which adjusted for Charlson comorbidity score. The null hypothesis was rejected
for myocardial infarction in patients after adjusting for the Charlson comorbidity score,
and rejected for ischemic stroke in patients without atherosclerosis after adjusting for the
Charlson comorbidity score. The null hypothesis could not be rejected for any ATE in
patients with atherosclerosis or kidney disease but not both; for myocardial infarction in
patients with atherosclerosis but without a history of myocardial infarction; and for
ischemic stroke in patients without atherosclerosis after adjusting for the Charlson
comorbidity score. In outcomes where both models contained EMMs or no models
contained EMMS, the two models yielded similar results.
Research Question 3
Research Question 3: In the follow-up period after kidney cancer diagnosis, what
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE,
or OTE)?
HA3: No factors are statistically significantly associated with the time to newly
diagnosed VTEs in the period after kidney cancer diagnosis.
H03: Tumor histology and other factors are statistically significantly associated
with the time to newly diagnosed VTEs after kidney cancer diagnosis.

156
The purpose of Research Question 3 was to identify risk factors for venous
thromboembolic events in the exposed cohort in the follow-up period after kidney cancer
diagnosis. A Cox proportional hazard model was used for each outcome to identify
factors associated with time to event at the 0.05 significance level. Backward selection
was used to determine which variables were kept in the model. In both models, histology
group was kept in regardless of statistical significance.
The risk factors associated with incidence of any VTE in the follow-up period
were the oldest age group at diagnosis (80 years or older); Black race; Northeast region;
Stage III, IV or unknown; history of any VTE; placement of CVC more than 30 days
prior to VTE; varicose veins; treatment by chemotherapy; and being male without highrisk surgery more than 30 days prior to VTE (Table 29). In the first model transitional
cell tumor, kidney disease and type 1 diabetes were also identified as risk factors. In the
second model Charlson score of 2 or greater, year of diagnosis, and history of CVD were
also identified as risk factors for any VTE in this population.
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Table 29
Risk Factors Associated With Incidence of Any VTE in Follow-up Period After Kidney
Cancer Diagnosis (N = 11,463)
Age at Diagnosis

Histology Group

Level

Adjusted HR (95% CI)a

66-69

(Ref)

Race

1.06 (0.89, 1.25)

1.06 (0.90, 1.26)

75-79

1.11 (0.93, 1.32)

1.14 (0.95, 1.35)

80-84

1.22 (1.01, 1.47)*

1.26 (1.04, 1.53)*

85+

1.26 (1.01, 1.56)*

1.32 (1.06, 1.64)*

Clear Cell

0.93 (0.78, 1.10)

Papillary

1.08 (0.88, 1.32)

1.08 (0.88, 1.32)

0.67 (0.46, 0.97)*

0.70 (0.48, 1.02)

0

-

1

-

1.20 (0.98, 1.46)

2 to 3

-

1.26 (1.06, 1.50)*

4+

-

1.49 (1.24, 1.80)***

White

West

(Ref)

(Ref)

(Ref)

1.23 (1.02, 1.48)*

1.22 (1.01, 1.47)*

0.79 (0.62, 1.02)

0.77 (0.60, 0.99)*

(Ref)

(Ref)

Midwest

1.02 (0.85, 1.23)

1.01 (0.84, 1.21)

Northeast

1.20 (1.04, 1.39)*

1.20 (1.04, 1.39)*

1.06 (0.92, 1.23)

1.06 (0.92, 1.22)

South
Year of Diagnosis

Stage I
Stage II

(Ref)

1.04 (1.00, 1.08)*
(Ref)

1.09 (0.87, 1.38)

1.11 (0.89, 1.40)

Stage III

2.26 (1.95, 2.61)***

2.26 (1.96, 2.61)***

Stage IV

2.62 (2.24, 3.07)***

2.65 (2.26, 3.11)***

1.24 (1.01, 1.52)*

1.28 (1.04, 1.57)*

Stage Unknown
History of Condition

(Ref)

0.92 (0.77, 1.09)

Other/Unknown

Stage at Diagnosis

(Ref)

Chromophobe/Other
RCC

Black

Geographic Region

(Ref)

70-74

Transitional cell tumor
Charlson Score

Adjusted HR (95%
CI)b

No
Yes

(Ref)
14.08(12.13,16.35)***

(Ref)
14.12(12.19,16.52)***

(continued)
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Level
History of CVD

CVC

c

Adjusted HR (95%
CI)a

No

(Ref)

Yes

-

No

(Ref)

Yes
Varicose veins

No
Yes

Kidney Disease

No
Yes

Chemotherapy

Type 1 Diabetes

Gender

4.34 (3.40, 5.54)***
(Ref)
1.92 (1.45, 2.53)***
(Ref)
1.33 (1.19, 1.50)***

Adjusted HR (95%
CI)b
(Ref)
0.79 (0.69, 0.92)**
(Ref)
4.45 (3.49, 5.68)***
(Ref)
1.87 (1.41, 2.47)***
(Ref)
-

No

(Ref)

(Ref)

Yes

1.33 (1.17, 1.52)***

1.33 (1.17, 1.51)***

No

(Ref)

(Ref)

Yes

0.80 (0.67, 0.95)*

-

(Ref)

(Ref)

Female
Male without highrisk surgery

0.82 (0.73, 0.92)*

0.82 (0.73, 0.92)*

Male with high-risk
surgery

1.29 (0.86, 1.92)

1.32 (0.88, 1.96)

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); RCC = renal cell
carcinoma; VTE = venous thromboembolic event.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
More than 30 days before the outcome.

* p < .05. ** p < .01. *** p < .001.

The risk factors associated with incidence of DVT in the follow-up period were
other or unknown race; Stage III, IV, or unknown stage; history of DVT; high risk
surgery; placement of central venous catheter; varicose veins; and treatment by
chemotherapy (Table 30). In the first model, type I diabetes, kidney disease, and female
gender were also identified as risk factors. In the second model, Charlson score and
Northeast region were also risk factors.
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Table 30
Risk Factors Associated With Incidence of DVT in Follow-up Period After Kidney
Cancer Diagnosis (N = 11,463)
Level
Age at Diagnosis

66-69

Charlson Score

Race

1.17 (0.95, 1.45)

75-79

1.15 (0.92, 1.42)

1.14 (0.92, 1.41)

80-84

1.55 (1.24, 1.94)***

1.54 (1.23, 1.93)***

1.44 (1.11, 1.87)**

1.46 (1.12, 1.89)**

Clear Cell

(Ref)

1.00 (0.81, 1.22)

0.99 (0.81, 1.22)

Papillary

1.16 (0.91, 1.47)

1.16 (0.91, 1.48)

Transitional cell tumor

0.87 (0.57, 1.33)

0.91 (0.60, 1.39)

0

(Ref)

1

-

1.22 (0.95, 1.57)

2 to 3

-

1.32 (1.06, 1.63)*

4+

-

1.54 (1.24, 1.91)***

White

West

(Ref)

(Ref)

(Ref)

1.24 (1.00, 1.54)

1.23 (0.98, 1.53)

0.63 (0.46, 0.85)**

0.63 (0.46, 0.86)**

(Ref)

(Ref)

Midwest

-

0.93 (0.75, 1.16)

Northeast

-

1.20 (1.01, 1.43)*

South

-

1.01 (0.85, 1.20)

Stage I

(Ref)

Stage II

(Ref)

1.19 (0.90, 1.56)

1.22 (0.93, 1.60)

Stage III

2.25 (1.89, 2.68)***

2.27 (1.91, 2.71)***

Stage IV

2.74 (2.28, 3.31)***

2.83 (2.34, 3.42)***

1.43 (1.12, 1.82)**

1.41 (1.11, 1.80)**

Stage Unknown
History of Condition

(Ref)

Chromophobe/Other
RCC

Other/Unknown

Stage at Diagnosis

(Ref)

1.18 (0.96, 1.46)

Black

Geographic Region

(Ref)

Adjusted HR (95%
CI)b

70-74

85+
Histology Group

Adjusted HR (95%
CI)a

No

(Ref)

(Ref)

Yes

22.36(18.48,27.05)***

21.41(17.66,25.95)***

(continued)
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Level
High-risk surgeryc

No
Yes

Type 1 Diabetes

CVC

c

Chemotherapy

4.11 (3.03, 5.57)***

(Ref)
4.00 (2.95, 5.43)***
(Ref)

Yes

0.78 (0.63, 0.96)*

-

No

(Ref)

(Ref)

No

6.26 (4.73, 8.30)***
(Ref)
1.87 (1.35, 2.60)***

6.30 (4.76, 8.33)***
(Ref)
1.75 (1.26, 2.42)***

No

(Ref)

(Ref)

Yes

1.44 (1.25, 1.66)***

-

No

(Ref)

(Ref)

Yes
Gender

(Ref)

(Ref)

Yes
Kidney Disease

Adjusted HR (95%
CI)b

No

Yes
Varicose veins

Adjusted HR (95%
CI)a

Female
Male

1.31 (1.13, 1.52)***
(Ref)
0.83 (0.73, 0.95)**

1.33 (1.14, 1.54)***
(Ref)
0.85 (0.75, 0.98)*

Note. CVC= central venous catheter; DVT = deep vein thrombosis; RCC = renal cell carcinoma.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
More than 30 days before the outcome.

* p < .05. ** p < .01. *** p < .001.

The risk factors for incidence of pulmonary embolism in the follow-up period
were age; papillary and transition cell tumor histology; Stage III or IV; history of
pulmonary embolism; high-risk surgery more than 30 days prior to event; placement of
central venous catheter more than 30 days prior to event; treatment by chemotherapy or
nephrectomy; and gender (Table 31). Type 1 diabetes and kidney disease were also
associated with pulmonary embolism in the first model, whereas the Charlson score was
associated with pulmonary embolism in the second model.
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Table 31
Risk Factors Associated With Incidence of PE in Follow-up Period After Kidney Cancer
Diagnosis (N = 11,463)
Level
Age at Diagnosis

66-69

0.86 (0.64, 1.16)

75-79

0.67 (0.49, 0.92)*

0.67 (0.49, 0.91)*

80-84

0.63 (0.43, 0.91)*

0.62 (0.43, 0.90)*

0.83 (0.56, 1.23)

0.84 (0.56, 1.25)

Chromophobe/Other
RCC

Stage at Diagnosis

High-risk surgery

Papillary

1.50 (1.06, 2.14)*

1.53 (1.08, 2.18)*

Transitional cell tumor

0.28 (0.09, 0.90)*

0.30 (0.09, 0.96)*

0

(Ref)

1

-

1.28 (0.86, 1.90)

2 to 3

-

1.51 (1.07, 2.12)*

4+

-

1.68 (1.19, 2.38)**

Stage I

CVC

Type 1 Diabetes

(Ref)
0.98 (0.64, 1.50)

Stage III

1.53 (1.13, 2.06)**

1.52 (1.12, 2.05)**

Stage IV

2.43 (1.80, 3.28)***

2.50 (1.85, 3.38)***

0.75 (0.47, 1.18)

0.78 (0.50, 1.23)

No

(Ref)

(Ref)

Yes

38.08(27.19,53.32)***

34.65(24.76,48.51)***

No

(Ref)

(Ref)

5.14 (3.04, 8.70)***

5.42 (3.18, 9.23)***

No

(Ref)

(Ref)

Yes

9.04 (5.52, 14.80)***

8.42 (5.13, 13.82)***

No

(Ref)

(Ref)

Yes
Kidney Disease

(Ref)

(Ref)

0.98 (0.64, 1.49)

Yes
c

(Ref)
0.96 (0.69, 1.33)

Stage Unknown

c

(Ref)
0.95 (0.68, 1.32)

Stage II

History of Condition

(Ref)

0.89 (0.66, 1.19)

Clear Cell

Charlson Score

(Ref)

Adjusted HR (95%
CI)b

70-74

85+
Histology Group

Adjusted HR (95%
CI)a

No
Yes

0.70 (0.50, 1.00)*
(Ref)
1.61 (1.29, 2.00)***

(Ref)
-

(continued)
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Level
Chemotherapy

Nephrectomy

Gender

Adjusted HR (95%
CI)a

Adjusted HR (95%
CI)b

No

(Ref)

(Ref)

Yes

1.56 (1.23, 1.96)***

1.57 (1.24, 1.98)***

No

(Ref)

(Ref)

Yes

0.71 (0.54, 0.94)*

0.75 (0.57, 0.99)*

(Ref)

(Ref)

Female
Male

0.75 (0.60, 0.93)**

0.75 (0.61, 0.93)**

Note. CVC = central venous catheter; PE = pulmonary embolism; RCC = renal cell carcinoma.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
More than 30 days before the outcome.

* p < .05. ** p < .01. *** p < .001.

The risk factors associated with other VTE in the follow-up period were age at
diagnosis; Northeast region; year of diagnosis; Stage III, IV, and unknown Stage; history
of other VTE; history of CVD; high-risk surgery; and central venous catheter (Table 32).
In the first model, treatment by chemotherapy was also a risk factor and a diagnosis of
varicose veins was an EMM. Histology group was not a statistically significant risk factor
in either model. Charlson score was also not associated with other VTE in the second
model.
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Table 32
Risk Factors Associated With Incidence of Other VTE in Follow-up Period After Kidney
Cancer Diagnosis (N = 11,463)
Level
Age at Diagnosis

66-69

Histology Group

Geographic Region

1.02 (0.73, 1.43)

75-79

1.41 (1.01, 1.96)*

1.41 (1.02, 1.96)*

80-84

0.97 (0.66, 1.44)

0.86 (0.59, 1.27)

85+

1.42 (0.92, 2.19)

1.36 (0.89, 2.09)

0.94 (0.67, 1.30)

Papillary

0.98 (0.66, 1.46)

0.98 (0.66, 1.45)

Transitional cell tumor

0.58 (0.26, 1.33)

0.61 (0.27, 1.39)

0

(Ref)

(Ref)

1

-

0.97 ( 0.67, 1.42 )

2 to 3

-

1.19 ( 0.86, 1.63 )

4+

-

1.22 ( 0.87, 1.73 )

(Ref)

(Ref)

West
Midwest

0.77 (0.52, 1.14)

0.81 (0.54, 1.19)

Northeast

1.40 (1.07, 1.83)*

1.47 (1.12, 1.91)**

1.16 (0.89, 1.51)

1.20 (0.92, 1.56)

1.07 (1.00, 1.15)*

1.09 (1.02, 1.17)*

Stage I

(Ref)
0.94 (0.57, 1.52)

Stage III

3.12 (2.42, 4.04)***

3.13 (2.42, 4.04)***

Stage IV

1.66 (1.18, 2.34)**

1.57 (1.11, 2.22)*

1.62 (1.11, 2.36)*

1.73 (1.20, 2.50)**

No

(Ref)

(Ref)

Yes

28.94 (21.46, 39.04)***

26.33 (19.62, 35.33)***

No

(Ref)

(Ref)

Yes
High-risk surgery

(Ref)
0.92 (0.57, 1.50)

Stage Unknown

c

(Ref)

0.93 (0.67, 1.30)

Stage II

History of CVD

(Ref)

Chromophobe/Other RCC

Year of Diagnosis

History of Condition

(Ref)

1.05 (0.75, 1.47)

South

Stage at Diagnosis

(Ref)

Adjusted HR (95% CI)b

70-74

Clear Cell

Charlson Score

Adjusted HR (95%
CI)a

0.63 (0.48, 0.84)**

No

(Ref)

Yes

12.41 (7.29, 21.14)***

0.62 (0.46, 0.83)**
(Ref)
10.26 (6.06, 17.36)***
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Level
CVCc

No
Yes

Chemotherapy

No
Yes

Gender

Female
Male without varicose veins
Male with varicose veins

Adjusted HR (95%
CI)a
(Ref)
3.82 (2.29, 6.38)***
(Ref)
1.31 (1.02, 1.67)*
(Ref)

Adjusted HR (95%
CI)b
(Ref)
3.88 (2.31, 6.52)***
(Ref)
1.26 (0.99, 1.62)
(Ref)

0.97 (0.78, 1.20)

-

0.13 (0.04, 0.38)***

-

Note. CVC= central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); Other VTE = other venous
thromboembolic event; RCC = renal cell carcinoma.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
More than 30 days before the outcome.

* p < .05. ** p < .01. *** p < .001.

The null hypotheses could not be rejected for any of the venous thromboembolic
events as at least one factor was associated with the occurrence of a new event after
kidney cancer diagnosis. With regards to histology group, the null hypothesis was not
rejected for any VTE, except when the model was adjusted by the Charlson comorbidity
score. It was also not rejected for pulmonary embolism in either model. The null
hypothesis would have been rejected for DVT and other VTEs if only considering
histology.
Post-hoc analyses. Because the number of patients with ATEs was larger than
expected, models to assess the risk factors associated with these outcomes were produced
in the post-hoc analyses. The risk factors associated with any ATE were age of 75 or
older at diagnosis, geographic region (Northeast or South versus West), year of diagnosis,
history of any ATE, history of CVD, high-risk surgery, placement of CVC,
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atherosclerosis, chemotherapy and nephrectomy (Table 33). Receipt of chemotherapy or
nephrectomy were associated with a decreased risk of ATE. In the first model, type 1
diabetes and kidney disease were also risk factors for any ATE. In the second model, the
risk increased with Charlson comorbidity score (HR = 1.97 for a score of 1, HR = 3.01
for a score of 2 -3, HR = 4.50 for a score of 4 or greater).
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Table 33
Risk Factors Associated With Incidence of Any ATE in Follow-up Period After Kidney
Cancer Diagnosis (N = 11,463)
Level
Age at Diagnosis

66-69

Geographic Region

1.04 (0.85 - 1.28)

75-79

1.30 (1.06 - 1.58)*

1.27 (1.04 - 1.55)*

80-84

1.36 (1.10 - 1.69)**

1.32 (1.06 - 1.63)*

1.53 (1.20 - 1.96)***

1.50 (1.17 - 1.91)**

(Ref)

(Ref)

Chromophobe/Other RCC

1.00 (0.83 - 1.21)

1.00 (0.83 - 1.20)

Papillary

0.99 (0.79 - 1.24)

0.99 (0.79 - 1.24)

Transitional cell tumor

0.75 (0.47 - 1.21)

0.78 (0.48 - 1.26)

0

(Ref)

1

-

1.97 (1.43 - 2.72)***

2 to 3

-

3.01 (2.26 - 4.00)***

4+

-

4.50 (3.39 - 5.99)***

West

(Ref)

(Ref)

(Ref)

Midwest

1.25 (1.03 - 1.52)*

1.19 (0.98 - 1.44)

Northeast

1.22 (1.04 - 1.44)*

1.20 (1.02 - 1.41)*

1.30 (1.11 - 1.51)**

1.25 (1.07 - 1.45)**

South
Stage at Diagnosis

(Ref)

1.05 (0.86 - 1.29)

Clear Cell

Charlson Score

(Ref)

Adjusted HR (95%
CI)b

70-74

85+
Histology Group

Adjusted HR (95%
CI)a

Stage I

(Ref)

(Ref)

Stage II

1.18 (0.94 - 1.48)

1.18 (0.94 - 1.48)

Stage III

1.09 (0.91 - 1.30)

1.10 (0.92 - 1.32)

Stage IV

1.38 (1.11 - 1.71)**

1.44 (1.16 - 1.78)***

Stage Unknown

1.08 (0.88 - 1.33)

Year of Diagnosis

(continuous)

1.05 (1.01 - 1.09)*

1.05 (1.01 - 1.09)*

History of Condition

No

(Ref)

(Ref)

Yes
History of CVD

No
Yes
c

High-risk surgery

No
Yes

2.93 (2.31 - 3.71)***
(Ref)
1.30 (1.11 - 1.52)**
(Ref)
3.97 (3.06 - 5.14)***

1.10 (0.90 - 1.36)

2.99 (2.43 - 3.68)***
(Ref)
(Ref)
3.70 (2.85 - 4.81)***

(continued)
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Level
CVCc

No
Yes

Type 1 Diabetes

No
Yes

Kidney Disease

No
Yes

Atherosclerosis

No
Yes

Chemotherapy

Nephrectomy

Adjusted HR (95%
CI)a
(Ref)
4.31 (3.32 - 5.60)***
(Ref)
1.45 (1.24 - 1.71)***
(Ref)
1.65 (1.44 - 1.89)***
(Ref)
1.40 (1.23 - 1.60)***

Adjusted HR (95%
CI)b
(Ref)
4.38 (3.37 - 5.69)***
(Ref)
(Ref)
(Ref)
1.26 (1.10 - 1.45)***

No

(Ref)

(Ref)

Yes

0.84 (0.72 - 0.98)*

0.81 (0.70 - 0.95)**

No

(Ref)

(Ref)

Yes

0.76 (0.65 - 0.89)***

0.75 (0.64 - 0.88)***

Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC= central venous catheter; CVD =
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina
or transient ischemic attack); IS = ischemic stroke; MI = myocardial infarction; RCC = renal cell
carcinoma.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
More than 30 days before the outcome.

* p < .05. ** p < .01. *** p < .001.

The risk factors associated with myocardial infarction were region (Midwest or
Northeast where West was the reference), year of diagnosis, stage IV (versus stage I) at
diagnosis, history of myocardial infarction, high-risk surgery and placement of CVD
(Table 34). Chemotherapy and nephrectomy were protective against myocardial
infarction with hazard ratios ranging from 0.75 to 0.77. In the first model, history of
CVD, Type 1 diabetes, atherosclerosis, and kidney disease were associated with greater
rates of myocardial infarction. In the second model, the hazard ratio increased with
increasing Charlson score.
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Table 34
Risk Factors Associated With Incidence of MI in Follow-up Period After Kidney Cancer
Diagnosis (N = 11,463)
Level
Age at Diagnosis

66-69

Histology Group

Geographic Region

0.97 (0.75, 1.26)

75-79

1.01 (0.78, 1.31)

1.01 (0.78, 1.30)

80-84

1.23 (0.93, 1.62)

1.20 (0.91, 1.58)

85+

1.36 (0.99, 1.88)

1.35 (0.98, 1.86)

1.05 (0.82, 1.35)

Papillary

1.05 (0.78, 1.41)

1.06 (0.79, 1.42)

Transitional cell tumor

1.03 (0.60, 1.75)

1.04 (0.61, 1.78)

0

(Ref)

1

-

2.63 (1.64, 4.22)***

2 to 3

-

3.35 (2.18, 5.16)***

4+

-

6.95 (4.56, 10.59)***

(Ref)

(Ref)

West

High-risk surgery

(Ref)

Midwest

1.40 (1.09, 1.81)**

1.33 (1.03, 1.71)*

Northeast

1.24 (1.00, 1.54*

1.26 (1.02, 1.55)*

Stage I

1.17 (0.95, 1.44)

1.12 (0.91, 1.38)

1.08 (1.02, 1.14)**

1.08 (1.02, 1.14)**

(Ref)

(Ref)

Stage II

1.34 (1.01, 1.80)*

1.31 (0.98, 1.74)

Stage III

1.07 (0.84, 1.37)

1.08 (0.85, 1.37)

Stage IV

1.48 (1.11, 1.98)**

1.50 (1.12, 1.99)**

1.13 (0.86, 1.48)

1.14 (0.87, 1.50)

No

(Ref)

Yes

4.80 (3.55, 6.48)***

No

(Ref)

Yes
c

(Ref)

1.06 (0.83, 1.36)

Stage Unknown

History of CVD

(Ref)

Chromophobe/Other RCC

Year of Diagnosis

History of Condition

(Ref)

0.98 (0.76, 1.28)

South

Stage at Diagnosis

(Ref)

Adjusted HR (95%
CI)b

70-74

Clear Cell

Charlson Score

Adjusted HR (95%
CI)a

No
Yes

1.36 (1.12, 1.64)**
(Ref)
4.99 (3.50, 7.11)***

(Ref)
5.01 (3.81, 6.60)***
(Ref)
(Ref)
4.69 (3.27, 6.74)***

(continued)
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Level
CVCc

No
Yes

Diabetes Type 1

No
Yes

Atherosclerosis

No
Yes

Kidney Disease

No
Yes

Chemotherapy

No
Yes

Nephrectomy

No
Yes

Adjusted HR (95%
CI)a

Adjusted HR (95%
CI)b

(Ref)
4.87 (3.40, 6.96)***

(Ref)
5.23 (3.64, 7.51)***

(Ref)

(Ref)

1.54 (1.25, 1.89)***

-

(Ref)

(Ref)

1.24 (1.03, 1.49)*

-

(Ref)

(Ref)

2.30 (1.89, 2.80)***

-

(Ref)
0.77 (0.62, 0.95)*

(Ref)
0.76 (0.61, 0.94)*

(Ref)
0.75 (0.61, 0.93)**

(Ref)
0.76 (0.62, 0.94)*

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); MI = myocardial infarction;
RCC = renal cell carcinoma.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
More than 30 days before the outcome.

* p < .05. ** p < .01. *** p < .001.

Age at diagnosis 75 years or older, history of ischemic stroke, history of CVD,
atherosclerosis, CVC, high-risk surgery and diagnoses in the South region were
associated with greater risk of ischemic stroke after kidney cancer diagnosis (Table 35).
ischemic stroke occurred less frequently in patients with transitional cell tumors
compared to patients with clear cell tumors (HR = 0.22 for model 1; HR = 0.21 in model
2). The risk of ischemic stroke was also lower in patients who had a nephrectomy
compared to patients who did not. In the first model, males with Type 1 were at greater
risk of ischemic stroke. In the second model, the risk increased with increasing Charlson
score and with Stage IV cancer at diagnosis (compared to Stage I).
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Table 35
Risk Factors Associated With Incidence of IS in Follow-up Period After Kidney Cancer
Diagnosis (N = 11,463)
Level
Age at Diagnosis

66-69

1.05 (0.78 - 1.40)

75-79

1.38 (1.04 - 1.83)*

1.34 (1.01 - 1.78)*

80-84

1.41 (1.04 - 1.93)*

1.33 (0.98 - 1.82)

1.68 (1.19 - 2.37)**

1.61 (1.14 - 2.27)**

Stage at Diagnosis

History of Condition

1.00 (0.76 - 1.30)

Papillary

0.97 (0.71 - 1.32)

1.01 (0.74 - 1.38)

0.22 (0.05 - 0.87)*

0.21 (0.05 - 0.85)*

0

(Ref)

1

-

1.61 (1.04 - 2.49)*

2 to 3

-

2.83 (1.95 - 4.11)***

4+

-

3.02 (2.07 - 4.41)***

West

(Ref)

Midwest

1.10 (0.84 - 1.46)

1.07 (0.81 - 1.41)

Northeast

1.05 (0.83 - 1.33)

1.04 (0.82 - 1.31)

South

1.52 (1.23 - 1.88)***

1.49 (1.20 - 1.84)***

Stage I

(Ref)

(Ref)

Stage II

-

0.96 (0.67 - 1.36)

Stage III

-

1.17 (0.91 - 1.50)

Stage IV

-

1.38 (1.02 - 1.87)*

Stage Unknown

-

1.14 (0.85 - 1.53)

No

Yes
High-risk surgery

(Ref)

(Ref)

No
c

(Ref)

1.01 (0.78 - 1.31)

Yes
History of CVD

(Ref)

Chromophobe/Other RCC

Transitional cell tumor

Geographic Region

(Ref)

1.04 (0.78 - 1.39)

Clear Cell

Charlson Score

(Ref)

Adjusted HR (95%
CI)b

70-74

85+
Histology Group

Adjusted HR (95%
CI)a

(Ref)
2.23 (1.48 - 3.36)***
(Ref)
1.29 (1.04 - 1.59)*

(Ref)
2.44 (1.67 - 3.58)***
(Ref)
-

No

(Ref)

(Ref)

Yes

8.08 (5.34 - 12.21)***

7.82 (5.18 - 11.80)***

(continued)
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Level
CVCc

Adjusted HR (95%
CI)a

No
Yes

Atherosclerosis

4.30 (2.76 - 6.70)***

No
Yes

Type 1 Diabetes

(Ref)

(Ref)
1.57 (1.31 - 1.90)***

No

(Ref)

Yes
Nephrectomy

1.38 (1.10 - 1.74)**

No

(Ref)

Yes

0.74 (0.60 - 0.90)**

Adjusted HR (95%
CI)b
(Ref)
4.05 (2.61 - 6.29)***
(Ref)
1.45 (1.20 - 1.75)***
(Ref)
(Ref)
0.72 (0.58 - 0.90)**

Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic
stroke, new onset congestive heart failure, angina or transient ischemic attack); IS = ischemic stroke; RCC
= renal cell carcinoma.
a

Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier
(EMM).
b
Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and
diabetes were components of the Charlson score and were not assessed in the model.
c
Central venous catheter and high-risk surgery were more than 30 days before outcome.

* p < .05. ** p < .01. *** p < .001.

Summary
After applying inclusion criteria, exclusion criteria, and matching the exposed
kidney cancer cohort to the unexposed noncancer cohort, 11,463 patients in each cohort
were included in this study. The first descriptive analysis objectives were to describe the
incidence rates of venous and arterial thromboembolic events in the exposed cohort.
Tables 8 to 14 described the incidence rates of VTEs and ATEs in the year prior to
kidney cancer diagnosis in the exposed cohort. The incidence rates varied greatly across
type of thromboembolic event. For VTEs, the lowest incidence rate occurred for
pulmonary embolism (7.88 per 1,000 p-y) and the highest rate occurred for DVT (21.71
per 1,000 p-y). The incidence rate for any VTE (pulmonary embolism, DVT, or other
VTEs) was 35.05 per 1,000 p-y. The incidence rate for myocardial infarction was 16.88
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per 1,000 p-y while the rate for ischemic stroke was 76.02 per 1,000 p-y. The incidence
rate for any ATE (myocardial infarction or ischemic stroke) was 31,32 per 1,000 p-y. The
incidence rates varied across strata and outcome, however consistently the incidence rates
were higher in patients who had a history of the condition in the year prior to the period
start and increased with increasing Charlson score.
The second objective of the first descriptive analysis was to describe the incidence
rates of thromboembolic events in the follow-up period after kidney cancer diagnosis.
Tables 15 to 21 describe the incidence rates in this period overall and by patient
characteristics and covariates. For any VTE, DVT, and PVT the incidence rates after
kidney cancer diagnosis were higher than the rates in the year prior to kidney cancer
diagnosis. The incidence rates for other VTE and for myocardial infarction were slightly
higher in the follow-up period than in the year prior to kidney cancer diagnosis. The
incidence rate for ischemic stroke was lower in the year prior to kidney cancer diagnosis
(15.19 per 1,000 p-y) than in the period after kidney cancer diagnosis (19.39 per 1,000 py). Similar to the period prior to kidney cancer diagnosis, for each outcome the incidence
rate was much higher in patients with a history of the condition in the year prior and
increased with increasing Charlson score.
The objective of the second descriptive analysis was to describe the incidence
proportions of thromboembolic events in discrete periods after kidney cancer diagnosis.
Table 22 to 24 show the incidence rates within 90 days, 91 to 181 days, 181 to 270 days,
271 to 365 days, and for the entire follow-up period. Within the first year after the
incidence proportions were highest in the first three months after kidney cancer diagnosis
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and decreased in later periods. The incidence proportions were highest for the entire
follow-up period.
The first research question modeled the incidence rate ratios for thromboembolic
events in the exposed cohort compared to the unexposed cohort in the year prior to index
date. Tables 25 and 26 show the results for the crude and adjusted models. For every
thromboembolic event except ischemic stroke, the crude hazard ratio was significantly
greater than 1.0 at the 0.05 level. After adjusting the models, the incidence rate ratios
were greater than 1.0 for any VTE, DVT, and pulmonary embolism. For other VTEs, the
incidence rate was higher in the exposed cohort than the unexposed cohort in patients
without a history of CVD (HR = 1.41, 95% CI 1.02 – 1.96) after adjusting for matching,
type 2 diabetes and a diagnosis of varicose veins. For any arterial thromboembolic events
and ischemic stroke, the adjusted hazard ratios were not statistically different from 1.0.
The second research question modeled the incidence rate ratios for
thromboembolic events in the exposed cohort compared to the unexposed cohort in the
follow-up period after the index date. Tables 27 and 28 show the results for the crude and
adjusted models. The crude incidence rates for venous thromboembolic events in the
exposed cohort were three times the incidence rates in the unexposed cohort (Table 27).
After adjusting the models, for most patients the incidence rates for VTEs in the exposed
cohort were 57% to 542% greater than the rates in the unexposed cohort. For arterial
thromboembolic events, the crude hazard ratios ranged from 1.47 to 2.17 and were
statistically significant at the 0.05 level (Table 28). After adjusting, the incidence rate
ratio for the exposed cohort was only statistically different from 1.0 for any ATE for
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patients without atherosclerosis and without kidney disease (HR = 1.47, 95% CI 1.21 –
1.79); and without atherosclerosis (HR = 1.27, 95% CI 1.08 – 1.49) in the second model
adjusted for the Charlson score and other factors. For myocardial infarction, the adjusted
incidence rate ratio was greater than 1.0 in patients without atherosclerosis and without
history of myocardial infarction (HR = 1.42, 95% CI 1.10 – 1.84) in the first model; in
the second model, the incidence rate ratio was greater than 1.0 in patients without history
of myocardial infarction (HR = 1.35, 95% CI 1.11 – 1.65). In patients with a history of
myocardial infarction, the incidence rate ratio was 0.05 or less in both models (Table 28).
For ischemic stroke, the adjusted incidence rate ratio was statistically greater than 1.0 in
patients without kidney disease in the first model (HR = 1.34, 95% CI 1.06-1.70). The
incidence rate ratio was 0.52 for patients with kidney disease. In the second model,
patients with atherosclerosis had an adjusted hazard ratio of 0.55 (95% CI 0.34 – 0.90)
which was statistically significant at the 0.05 level (Table 28).
Research question 3 assessed potential risk factors for venous thromboembolic
events in kidney cancer patients after kidney cancer diagnosis. Histology group was only
statistically significantly associated with incidence of pulmonary embolism (Table 31).
Placement of a CVC, Stage III, and Stage IV tumors at diagnosis were risk factors for any
VTE, DVT, pulmonary embolism, and other VTEs. Other characteristics were not
consistent risk factors across the types of venous thromboembolic events.
Due to sufficient numbers of patients with myocardial infarction and ischemic
stroke, the risk factors for these arterial thromboembolic events were also assessed
(Tables 33 to 35). Increasing Charlson score, history of condition, placement of CVC,
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high-risk surgery, and Stage IV tumors at diagnosis were risk factors for any ATE,
myocardial infarction, and ischemic stroke. Nephrectomy appeared protective against the
arterial outcomes.
The incidence rates and risk factors for venous and arterial thromboembolic
events differed by each type of event as well as demographic and patient characteristics
in kidney cancer patients. In the year prior to index date, the incidence rates were higher
for the exposed cohort than the unexposed cohort for any VTE, DVT, and pulmonary
embolism. For other VTEs and myocardial infarction the incidence rates for the outcomes
were higher in the exposed cohort than the unexposed cohort in patients without a history
of CVD. In the follow-up period after index date, the incidence rates were higher in the
exposed cohort than the unexposed cohort for all of the venous thromboembolic events;
but the relationship was less consistent for the arterial thromboembolic events. In chapter
5, I discuss the interpretations of the findings, the limitations of the study,
recommendations for future study, and the implications for positive social change.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this study was to describe the incidence rates of venous and
arterial thromboembolic events in elderly kidney cancer patients; describe incidence
proportions of thromboembolic events in elderly kidney cancer patients in the period
following cancer diagnosis; compare the incidence rates of thromboembolic events in
elderly kidney cancer patients to matched noncancer patients in the year prior to index
date and in the follow-up period after index date; and assess risk factors for venous
thromboembolic events in elderly kidney cancer patients after cancer diagnosis. Because
there were sufficient number of patients with myocardial infarction and ischemic stroke,
risk factors for those arterial thromboembolic events in elderly kidney cancer patients
were also assessed as post-hoc analyses. I conducted a retrospective cohort study using
linked cancer registry and administrative claims data in elderly patients with Medicare
coverage to achieve the study objectives. Use of the linked database provided populationbased data containing cancer-specific information including histology type and stage
along with demographic, treatment, outcome, and potential confounder information.
The incidence rates of VTEs and ATEs differed by patient and tumor
characteristics in the period before and period after kidney cancer diagnosis. In the period
after cancer diagnosis, the incidence rates for most thromboembolic events were higher
than in the year prior to the cancer diagnosis. Within the first year after cancer diagnosis,
the incidence proportions were highest in the first three months for each thromboembolic
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event (Tables 22 to 24). It was hypothesized that the incidence rates of VTEs and ATEs
in the kidney cancer patients would be higher than rates in the noncancer patients. In the
year prior to the index date, the null hypothesis could not be rejected for any VTE, DVT,
or pulmonary embolism. The incidence rates for these outcomes were higher in kidney
cancer patients than in the noncancer patients in the year prior to the index date. In the
period after the index date, the null hypothesis could also not be rejected for any VTE,
DVT, or pulmonary embolism. For these outcomes, the incidence rates were higher in the
kidney cancer patients than in the noncancer patients in the follow-up period after the
index date. Several factors were identified which affected the risk of VTEs or ATEs after
kidney cancer diagnosis. This chapter interprets the findings for each of the descriptive
analyses and research questions, describes the study limitations, and provides
recommendations for further research. The implications for positive social change are
discussed and the study conclusion stated.
Interpretation of the Findings
Descriptive Analysis 1
The year prior to kidney cancer diagnosis. The incidence rates of DVT,
pulmonary embolism, and other VTEs in the year prior to kidney cancer diagnosis were
21.7, 7.9 and 11.3 per 1,000 p-y, respectively (Tables 9 to 11). These rates are much
lower than the rates for RCC patients reported by Connelly-Frost et al. (2013) of 32.2,
8.0, and 23.7 per 1,000 p-y in their analysis of RCC patients diagnosed between 1991 and
2003. Walker et al. (2013) reported that the incidence rates for venous thromboembolic
events in cancer patients have been increasing since 1997. Since the patients in this study
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were diagnosed with kidney cancer in later years than patients in the Connelly-Frost et al.
(2013) study, it would have been expected for the incidence rates to be higher than
previously reported, not lower. The inclusion of other kidney cancer histology groups
does not explain the difference in rates. One possible reason for the lower incidence rates
is that possible invalid diagnoses or rule-out diagnoses were removed from the analysis
data prior to identifying the outcomes and comorbid conditions. Diagnoses were included
if they were on inpatient claims, or there were at least two different physician or
outpatient claims that were more than 30 days apart. The program to do this was
publically available from the SEER-Medicare web site
(http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html).
Connelly-Frost et al. (2013) did not apply these exclusions to the claims data. If those
exclusions had not been applied, the incidence rates for DVT, pulmonary embolism, and
other VTEs were 39.1, 11.5, and 19.2 per 1,000 p-y, respectively. Those rates are more
similar to those reported by Connelly-Frost et al. (2013) in the 12 months prior to the
cancer diagnosis.
The incidence rates for any ATE (myocardial infarction or ischemic stroke),
myocardial infarction, and ischemic stroke in the year prior to cancer diagnosis were
31.3, 16.9, and 15.2 per 1,000 p-y (Tables 12 to 14). The incidence rates for these
conditions in kidney cancer patients prior to the cancer diagnosis were not identified in
the published literature. For Medicare beneficiaries, the incidence rates of hospitalization
for acute myocardial infarction decreased from 10.2 per 1,000 p-y in 2004 to 8.7 per
1,000 p-y in 2007 (Chen et al., 2010). The incidence rate of 16.9 per 1,000 p-y for
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myocardial infarction from this study is higher than the incidence rate for acute
myocardial infarction in Medicare patients in general, which is not surprising as the
definition of myocardial infarction used for this study was not restricted to only acute
events.
The incidence rate for ischemic stroke in cancer patients in this study (15.2 per
1,000 p-y) was higher than the rate of ischemic stroke in the general Medicare
population. The annual incidence rate for ischemic stroke in Medicare beneficiaries in
2008 was 11.5 per 1,000 (Casper, Nwaise, Crost, & Nilasena, 2008).
The follow-up period after kidney cancer diagnosis. The incidence rate of DVT
in the follow-up period after kidney cancer diagnosis, 53.0 per 1,000 person-years (Table
15), was higher than the rate of any VTE (14.0 per 1,000 person-years) reported by
Walker et al. (2013) but less than the rate for DVT of 108.2 per 1,000 person-years
reported by Connelly-Frost et al. (2013). Part of the reason for the discrepancy was
differences in methodologies used including not excluding patients with a history of the
condition, use of entire follow-up period even if longer than 12 months, and removing
potential rule-out diagnoses prior to calculating the incidence rates. Walker et al. (2013)
excluded patients with a VTE prior to cancer; however, the incidence rate in patients
without a history of any VTE was 42.75 (Table 15) which is still much higher than the
rate reported by Walker et al. (2013). One difference is that only 12 months prior to the
study period of interest were included for identifying history of VTE, whereas Walker et
al. (2013) excluded patients if they had a VTE any time prior to the first cancer diagnosis.
The difference in the period prior to cancer diagnosis which was assessed for history of
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VTE may be a contributing factor for the differences in reported incidence rates. Another
factor may be this study population included American patients whereas Walker et al.
(2013) reported rates in patients in the United Kingdom. Walker et al. (2013) reported an
incidence rate of 4.3 per 1,000 p-y for VTEs in the noncancer cohort age 60 or older. The
incidence rates for VTEs in a U.S. population by age group ranged from 1.69 to 8.49 per
1,000 p-y for females, and 1.63 to 9.84 per 1,000 p-y for males (Silverstein et al., 1998).
Both Walker et al. (2013) and I allowed for follow-up periods of longer than 12 months.
Connelly-Frost et al. (2013) included patients with a history of VTE prior to cancer
diagnosis but restricted follow-up to 12 months. Without the rule-out diagnosis exclusion
applied, the incidence rates for DVT, pulmonary embolism, and other VTEs in the
follow-up period after cancer diagnosis were 66.5, 21.7, and 27.7, respectively as
compared to 108.2, 30.0, and 49.0 as reported by Connelly-Frost et al. (2013). The
combination of the removal of the rule-out diagnoses and the longer follow-up period is
the probable reason for the lower incidence rates in this study as compared with
Connelly-Frost et al. (2013).
The incidence rates of any ATE, myocardial infarction, and ischemic stroke were
39.7, 21.9, and 19.4 per 1,000 p-y, respectively (Table 19 to Table 21). These incidence
rates were higher than expected based on the literature found, however that may be due to
differences in the real world population included in this study and clinical trial
populations. Arterial events were rare in clinical trial patients of chemotherapy-treated
RCC patients (Bayer HealthCare Pharmaceuticals, 2013; Choueiri et al., 2010;
GlaxoSmithKline, 2014; Qi et al., 2014). Ischemic stroke was not included in the
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definition of ATE for several studies (Choueiri et al., 2010; Petrelli et al., 2012). The
number of clinical trial participants was small compared to this population-based study,
include stricter inclusion and exclusion criteria for the study participants, and were not
restricted solely to elderly patients with Medicare coverage.
Descriptive Analysis 2
The incidence proportions of venous thromboembolic events were higher in the
period closest to cancer diagnosis then decreased in later periods. These findings were
consistent with other published studies (Chew et al., 2008; Connelly-Frost et al., 2013;
Moore et al., 2011; Walker et al., 2013). None of these studies reported the incidence
proportions for the entire follow-up period so that could not be compared. Incidence
proportions of arterial thromboembolic events in cancer patients were not identified in the
published literature.
Research Question 1
The incidence rate ratios estimates for DVT and pulmonary embolism in the year
prior to the index date were not dissimilar from the relative risks presented by ConnellyFrost et al. (2013). Connelly-Frost et al. (2013) reported a relative risk of 1.6 (95% CI 1.3
– 1.9) for DVT, while the two models in this study estimated the incidence rate ratio to be
1.50 to 1.57 (Table 25). Connelly-Frost et al. (2013) reported a relative risk of 1.8 (95%
CI 1.3 – 2.6) for pulmonary embolism; the estimates from this study were 1.5 and 1.8
(Table 25). I did not find a statistically significant difference in the incidence rate ratios
for other VTEs after adjusting for other factors (Table 28), however Connelly-Frost et al.
(2013) reported a relative risk of 1.5 (95% CI 1.2 – 1.8). Both studies reported the
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incidence rate ratios for other VTEs stratified by history of CVD. The incidence rate ratio
was higher in cancer patients than the noncancer patients for patients without a history of
CVD. Connelly-Frost et al. (2013) reported 1.7 (95% CI 1.3 – 2.1) and this analysis
resulted in an incidence rate ratio of 1.4 (95% CI 1.0 – 2.0) (Table 25). Neither study
found a significant difference in the incidence rates for the patients with a history of CVD
(HR = 0.8, 95% CI 0.4 – 1.8 from this study; OR = 1.0, 95% CI 0.7 – 1.4 from ConnellyFrost et al., 2013).
The incidence rate ratios estimated in this study for venous thromboembolic
events were in the same direction, but lower than the standardized incidence ratio
reported for kidney cancer patients diagnosed in California. White et al. (2005) reported a
standardized incidence ratio of 2.5 (95% CI 1.5 – 3.9) for the year prior to cancer
diagnosis. The difference in the estimates may be due to the differences in the
populations as the White et al. (2005) study analyzed adults aged 18 or older diagnosed
with cancer in California prior to 2000. The participants in this study were 66 years or
older at first cancer diagnosis, more geographically distributed and diagnosed in later
years. Another difference is in the measures used by the two studies. While White et al.
(2005) calculated a standardized incidence ratio, I calculated hazard ratios to estimate
incidence rate ratios.
No studies were found in the published literature of the incidence rate ratios of
myocardial infarction or ischemic stroke comparing kidney cancer cohort to a noncancer
cohort in the year prior to the index date. After adjusting for other factors, the incidence
rates of any ATE and ischemic stroke were not statistically significantly different

184
between the two cohorts. For myocardial infarction the incidence rates were higher in the
kidney cancer cohort than the noncancer cohort in the patients without a history of CVD.
Conversely, in patients with a history of CVD the first model (which assessed diabetes
and kidney disease instead of the Charlson score as potential confounders and effect
measure modifiers) found that the incidence rates were lower in the kidney cancer
patients. The second model, which adjusted by the Charlson score, produced a hazard
ratio of 1.18; however it was not statistically significant at the 0.05 level. This is
consistent with the findings of lung cancer patients in the Netherlands who did not have a
statistically significant increased incidence of myocardial infarction or ischemic stroke in
the year prior to cancer diagnosis (van Herk-Sukel et al., 2013). While the incidence rates
of ATEs may be higher in cancer patients than in the general Medicare population, it does
not appear that kidney tumors are the reason for the higher rates. Other factors in the
cancer population such as comorbidity score are more likely the drivers for the incidence
rates of ATEs in this population.
Research Question 2
The incidence rate ratios for venous thromboembolic events in the follow-up
period after index date were higher in the kidney cancer cohort than the noncancer cohort
(Table 27). Blom et al. (2005) also reported a higher risk of VTE after kidney cancer
diagnosis compared to noncancer patients (adjusted OR = 6.2, 95% CI 0.8 – 46.5), even
though it was not statistically significant at the 0.05 level. Connelly-Frost et al. (2013)
reported higher incidence rate ratios in the cancer cohort than the noncancer cohort for
DVT (HR = 3.6), pulmonary embolism (HR = 4.3), and other VTE (HR = 2.4). I found
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higher incidence rates of DVT in the cancer cohort than noncancer cohort in patients
without atherosclerosis (HR = 3.6, 95% CI 2.9 – 4.4) and with atherosclerosis (HR = 1.8,
95% CI 1.1 – 2.7) (Table 27). The first model in this study included higher incidence
rates in the cancer cohort except for those with both atherosclerosis and kidney disease
(Table 27). Although Connelly-Frost et al. (2013) restricted their maximum duration of
follow-up to 12 months, their study similarly reported higher incidence rates for DVT in
the cancer cohort stratified by atherosclerosis (HR = 2.0, 95% CI 1.5 – 2.6 for patients
with atherosclerosis; HR = 4.1, 95% CI 3.5 – 4.9 for patients without atherosclerosis)
(Connelly-Frost et al., 2013).
The incidence rate ratio for pulmonary embolism was approximately three fold
higher in the kidney cancer patients than the noncancer cohort (Table 27). Connelly-Frost
et al. (2013) reported a hazard ratio of 4.3 (95% CI 3.2 – 5.7) for pulmonary embolism in
the year after index date. The incidence rate ratio for other VTE was higher for the cancer
cohort as well. The second model yielded an adjusted hazard ratio of 2.7 (95% CI 2.1 –
3.4) (Table 27). The hazard ratio for other VTE reported by Connelly-Frost et al. (2013)
was very similar (HR = 2.4, 95% CI 2.0 – 2.8). The first model reported higher incidence
rates in the cancer cohort for patients without type 2 diabetes and without kidney disease
(HR = 4.3, 95% CI 2.9 – 6.4). There was a two-fold increase for patients with only one of
kidney disease or type 2 diabetes, but the result was only statistically significant for
patients without kidney disease (Table 27).
In the follow-up period after the kidney cancer diagnosis, the results for arterial
thromboembolic events were inconsistent as to whether they were higher for the cancer
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cohort. For any ATE, the first adjusted model yielded an adjusted hazard ratio of 1.5 for
patients without atherosclerosis and without kidney disease (Table 28). For patients with
both atherosclerosis and kidney disease, the adjusted hazard ratio was 0.6. The second
model similarly reported an adjusted hazard ratio greater than 1.0 for patients without
atherosclerosis (HR = 1.3), but a lower hazard ratio of 0.77 for patients with
atherosclerosis. For myocardial infarction, the incidence rate for the cancer cohort was
higher than the noncancer cohort for patients without a history of atherosclerosis or
history of myocardial infarction (the first model) or patients without a history of
myocardial infarction (second model). For ischemic stroke, the incidence rates were
higher in the cancer cohort in patients who did not have kidney disease; incidence rates
were lower in the cancer cohort in patients with kidney disease. After adjusting for the
comorbidity score and other factors, the incidence rates of ischemic stroke were similar
for the cancer and noncancer cohorts in patients without atherosclerosis (Table 28). For
patients with atherosclerosis, the incidence rate for ischemic stroke was lower in the
cancer cohort after adjusting for the Charlson comorbidity score and other factors (HR =
0.6) (Table 28). The incidence rates for ATEs in cancer patients were higher than
noncancer patients in the absence of atherosclerosis and kidney disease. In patients with
atherosclerosis and kidney disease, the incidence rates of ATEs in cancer patients were
half or less than the rates in noncancer patients. Cancer patients with more chronic
conditions have greater healthcare utilization, including more primary care or specialist
visits and hospitalizations, than cancer patients with less chronic conditions (Legler,
Bradley, & Carlson, 2011; Yu, Ravelo, Wagner, & Barnett, 2004; Zulman et al., 2015).
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Timing may also be a factor in whether or not the incidence rates were higher in cancer
patients compared to noncancer patients. The hazard ratios for myocardial infarction and
for ischemic stroke comparing lung cancer to noncancer patients were 1.0 or greater in
the first six months after cancer diagnosis, but less than 1.0 for more than six months
after diagnosis (van Herk-Sukel et al., 2011).
Research Question 3
Age was a risk factor for some venous thromboembolic events in the follow-up
period after kidney cancer diagnosis. Age of 80 or older increased the risk of any VTE
and DVT in kidney cancer patients compared to ages 66 to 69 at diagnosis (Tables 29 to
30). For other VTEs, only age of 75 to 79 increased the risk of the event while age 80 or
older at diagnosis was not a statistically significant predictor (Table 32). For pulmonary
embolism, the risk of event decreased with increasing age at diagnosis (Table 31). Chew
et al. (2006) nor Connelly-Frost et al. (2013) found age to be a statistically significant
predictor for venous thromboembolic events in kidney cancer or elderly RCC patients.
The differences in the study populations and duration of follow-up after cancer diagnosis
may be the reasons some association with age was reported from this analyses but Chew
et al. (2006) did not find the same association. Where age was assessed by 5-year age
increments in this study and the population was elderly patients, the population studied
by Chew et al. (2006) included patients of all ages and was younger (median age of 64
years). Chew et al. (2006) also looked for an association of venous thromboembolic
events in the 12 months after cancer diagnosis with 10-year age increments. I did not
restrict follow-up after cancer diagnosis to a maximum of 12 months. Connelly-Frost et
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al. (2013) also assessed age as a risk factor in the 12 months after cancer diagnosis. I and
Connelly-Frost et al. (2013) used the same 5-year age increments; however this study
reported very different incidence rates due to the differences in duration of follow-up and
use of the algorithm to remove potential rule-out diagnoses as discussed earlier. The
percent changes in incidence rates from the 66 to 69 year olds to the 85 years or older in
the Connelly-Frost et al. (2013) study were 38%, 2%, and 58% for DVT, pulmonary
embolism, and other VTEs respectively. The percent changes for the incidence rates in
this study were 99%, 24%, and 62%. So I may have found some association with age
even though Connelly-Frost et al. (2006) did not due to the differences in the observed
incidence rates and the pattern of rates by age group. Age was also not a risk factor for
pulmonary embolism in lung cancer patients in the first six months after lung cancer
diagnosis (van Herk-Sukel et al., 2013). However, age of 65 years or older at diagnosis
was associated with higher risk of myocardial infarction and ischemic stroke in lung
cancer patients compared to lung cancer patients less than 65 years old (van Herk-Sukel
et al., 2013).
Research on the risk of venous thromboembolism by histology group in kidney
cancer patients was not found in the published literature. Histology was not a statistically
significant risk factor for DVT or other VTEs in elderly kidney cancer patients (Tables 30
and 32). The risk of any VTE was lower in transitional cell tumors compared to patients
with clear cell tumors (Table 29). The hazard ratio from the second model (0.70) was
very similar to the hazard ratio from the first model (0.67), however it was not
statistically significant at the 0.05 level. Transitional cell tumors also appeared protective
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against pulmonary embolism as well, with hazard ratios of 0.28 to 0.30. The risk of
pulmonary embolism was increased in patients with papillary tumors as compared to
clear cell tumors (Table 31). This is the first known study to examine this relationship in
kidney cancer patients. This is the first evidence of any difference in risk of venous and
thromboembolic events by histology type in kidney cancer patients. In other tumors, any
difference in risk of thromboembolic events by histology type is inconsistent (Alcalay et
al., 2006; Blom et al., 2004; Chew et al., 2007, 2008; Matsuo et al., 2015; van HerkSukel et al., 2013). The findings from this study of elderly kidney cancer patients
suggests that the thromboembolism preventive measures or care for these patients do not
need to differ based on histology type.
Compared to patients with Stage I tumors at diagnosis, patients diagnosed with
Stage III or IV were at higher risk of any VTE, DVT, pulmonary embolism, and other
VTEs (Tables 29 to 32). Unknown and unstaged tumors also increased the risk for any
VTE, DVT and other VTEs, but not pulmonary embolism. Connelly-Frost et al. (2013)
also found that later stage (regional or distant) tumors increased the risk of venous
thromboembolism compared to localized tumors in elderly RCC patients. Other studies
also reported higher risk of venous thromboembolic events in patients with metastatic or
Stage IV tumors of other cancer types (Agnelli et al, 2006; Blom et al., 2005; ChavezMacGregor et al., 2011; Hall et al., 2009).
History of the event in the 12 months prior to kidney cancer diagnosis was a
significant risk factor for all types of venous thromboembolic events. The hazard ratios
ranged from 14.08 for any VTE (first model, Table 29) to 38.08 for pulmonary embolism
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(first model, Table 31). These estimates consistent with the findings but higher than
reported by previous studies (Agnelli et al., 2006; Connelly-Frost et al., 2013).
Conversely, history of cardiovascular disease decreased the risk of any VTE and of other
VTEs (Tables 29 and 32). As discussed below for the post hoc analysis, history of CVD
increased the risk for any ATE, myocardial infarction and ischemic stroke (Tables 33 to
35). One hypothesis as to why history of CVD would decrease the risk of VTEs is that
those patients were more likely to die before having a venous event. Alternatively, the
patients with a history of CVD may have been given medical therapy or therapeutic
lifestyle changes as secondary prevention of coronary artery disease. These secondary
prevention techniques include smoking cessation, physical activity regimens, dietary
modification, weight management and pharmacologic treatments (Hall & Lorenc, 2010).
These techniques may improve patient health and reduce the risk of not only coronary
artery disease but also thromboembolic events. However, assessing that hypothesis is
beyond the scope and capabilities of this study methodology. Additionally, as cardiac
surgeries is one type of surgical procedure which can increase the risk of thromboembolic
events, the healthcare provider may be more likely to give cardiac surgery patients
prophylactic therapy or keep the patients under closer observation for thromboembolic
events.
Nephrectomy decreased the risk of pulmonary embolism, but was not a risk factor
for the other venous thromboembolic events (Table 31). Connelly-Frost et al. (2013) did
not find nephrectomy to be a risk factor for any venous thromboembolic event, but the
incidence rates were lower in patients who had a nephrectomy. Researchers of other
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tumor types also reported that cancer-directed surgery was not associated with venous
thromboembolic events after adjusting for other factors (Blom et al., 2006; Hall et al.,
2009). I also found that nephrectomy was protective against any ATE, myocardial
infarction, and ischemic stroke. One researcher reported that cancer-directed surgery in
lung cancer patients was not associated with myocardial infarction or ischemic stroke
(van Herk-Sukel et al., 2013). However, cancer-directed surgeries for different tumor
types vary in body system affected, in type of surgery, and invasiveness. Thus, even
though the findings from this study are consistent with findings in other tumor types, the
comparison of findings across tumor types may not be appropriate.
Chemotherapy however increased in the risk of all types of venous
thromboembolic events in this study (Tables 29 to 32). This is consistent with the finding
by Connelly-Frost et al. (2013) for DVT and other VTEs, but the Connelly-Frost et al.
(2013) study did not find chemotherapy to be a risk factor for pulmonary embolism. The
difference in findings may be due to different chemotherapy treatments used to treat RCC
and kidney cancer patients prior to 2004. Chemotherapy was protective against any ATE
and myocardial infarction. A study of lung cancer patients found no association between
receipt of chemotherapy and myocardial infarction or ischemic stroke (van Herk-Sukel et
al., 2013). Doyle et al. (2005) also did not find an association between receipt of
chemotherapy and myocardial infarction in a study of elderly breast cancer patients.
High-risk cardiac and vascular surgeries were not risk factors for DVT, but
greatly increased the risk for pulmonary embolism and for other VTEs (Tables 30 to 32).
High-risk surgery was a risk factor for any VTE in males compared to females, but the
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result was not statistically significant (Table 29). Compared to females, men without
high-risk surgery were at lower risk of any VTE (Table 29). Placement of a central
venous catheter before an event significantly increased the risk of all venous
thromboembolic events by 3.8 to 9-fold (Tables 29 to 32). These findings are the opposite
of those reported by Connelly-Frost et al. (2013) where high-risk surgery or CVC before
an event was a protective factor. The Chavez-MacGregor et al. (2011) study reported
higher risk of VTEs in the year after breast cancer diagnosis with placement of a CVC. It
is unclear why I found results the opposite of the Connelly-Frost et al. (2013) study.
However, similar to other findings of this study which contradicted the results of the
Connelly-Frost et al. (2013) study, the answer may lie in the difference in the follow-up
period and the removal of the potential rule-out diagnoses.
A Charlson score of two or greater, compared to a Charlson score of zero, was a
risk factor for any VTE, DVT, and pulmonary embolism (Tables 29 to 31). For these
events, in the first model which assessed diabetes and kidney disease instead, kidney
disease increased the risk of the event however type 1 diabetes decreased the risk. Type 2
diabetes was not a statistically significant risk factor for any of the venous
thromboembolic events. The increased risk of DVT due to kidney disease is consistent
with Connelly-Frost et al. (2013); however the risk of DVT was higher in patients
without kidney disease. The risk of pulmonary embolism and other VTEs was not
increased in patients with kidney disease (Connelly-Frost et al., 2013).
I reported differences in the risks of any VTE and DVT by race and differences of
thromboembolic event risks (other than pulmonary embolism) by geographic region.
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Neither race, year of diagnosis, nor geographic region was reported to be statistically
significant predictors of venous thromboembolic events in the study by Connelly-Frost et
al. (2013). Several researchers adjusted for race and did not report the risk for events by
racial groups (Chew et al., 2006; Doyle et al., 2005; Moore et al., 2011).
A diagnosis of varicose veins was a risk factor for DVT in the Connelly-Frost et
al. (2013) study and in this study (Table 30). A varicose veins diagnosis was also a risk
factor in this study for any VTE (Table 29). Similar to Connelly-Frost et al. (2013), male
gender was protective against DVT and pulmonary embolism (Tables 30 to 31). One
model in this study also found that male gender was protective against other VTEs,
however only in male patients with a diagnosis of varicose veins (Table 32). When an
association is found, the presence of varicose veins and male gender are generally found
to increase the risk of thromboembolic events in cancer patients compared to patients
without varicose veins and female gender, respectively (Khorana & Connolly, 2009;
Konigsbrugge et al., 2013). However, I and Connelly-Frost et al. (2013) reported
opposite findings for an association with gender. The unexpected finding of lower risk of
any VTE in males with varicose veins may be an artifact of the study population or the
model. Further research will be needed to determine whether the result can be replicated.
Post-hoc Analysis
As the number of any ATE, myocardial infarction, and ischemic stroke were
higher than expected, the risk factors for these events were also assessed. Kidney cancer
patients with age at diagnosis of 70 or older were at higher risk of any ischemic stroke
than patients aged 66 to 69 at diagnosis (Table 35). Patients in age groups 75 and older
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were at increased risk for any ATE (myocardial infarction or ischemic stroke) (Table 33).
Increased risk for ischemic stroke in the older cancer patients is consistent with studies in
other cancer types (Chen et al., 2011; van Herk-Sukel et al., 2011, 2013). Although I did
not find age to be a statistically significant risk factor for myocardial infarction, another
researcher and colleagues reported increased risk for myocardial infarction in older
cancer patients (van Herk-Sukel et al., 2011, 2013).
Patients with transitional cell tumors were at decreased risk for ischemic stroke
compared to patients with clear cell tumors (Table 35). Histology group was not at risk
factor for myocardial infarction or any ATE. van Herk-Sukel et al. (2013) found that the
subtype of lung cancer did not increase the risk for myocardial infarction or ischemic
stroke. However, the histology types were specific to lung cancer and are not
generalizable to the histology groupings for kidney cancer.
Patients with a history of the arterial event were at greater risk for any ATE,
myocardial infarction and ischemic stroke (Tables 33 to 35). This finding is consistent
with the findings in lung cancer patients as reported by van Herk-Sukel et al. (2013). A
history of CVD was also still an independent risk factor for these arterial events after
adjusting for history of the event and other factors.
Patients with Stage IV tumors at diagnosis, Charlson score of one or greater, had a
diagnosis of atherosclerosis, a diagnosis of kidney disease, or who had a CVC inserted
were also at higher risk for any ATE, myocardial infarction, and ischemic stroke (Tables
33 to 35). Geographic region other than the West was a risk factor for myocardial
infarction and any ATE. Patients in the Midwest and Northeast were at higher risk for
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myocardial infarction (Table 34). Patients in the Northeast were also at higher risk for
any ATE (Table 33). Males were at higher risk than females for any ATE and ischemic
stroke if they also had a diagnosis of diabetes or high-risk surgery (Tables 33 and 35).
Nephrectomy was protective against myocardial infarction or any ATE in kidney cancer
patients (Tables 33 to 34). Chemotherapy was protective against myocardial infarction as
well (Table 34).
Theoretical Framework
The advanced epidemiologic triangle as described by Merrill (2009) was the
theoretical framework used to interpret the association between incident VTEs and ATEs
with causative factors, environment and lifestyle factors, and population characteristics.
In this study, the causative factors were kidney cancer, cancer stage and cancer
treatments. The environment and lifestyle factors were high-risk surgeries and placement
of central venous catheter. The population characteristics were age, region of diagnosis,
race, Charlson comorbidity score and individual comorbidities. Time is also considered
in the advanced epidemiologic triangle.
The first research question examined the incidence rate ratios of thromboembolic
events in cancer patients compared to noncancer patients in the year prior to the index
date. In the advanced epidemiologic triangle used for this study, being diagnosed with
kidney cancer was a causative factor. Because this time period is prior to diagnosis, the
framework seemed to suggest that there should not be any difference in incidence rates of
thromboembolic events in the cancer patients and noncancer patients. However, the
patients who will be diagnosed with cancer most likely had cancer in this period but it
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was not diagnosed yet. Kidney cancer can be asymptomatic and there are no routine
screening tests specific for kidney cancer (American Cancer Society, 2014). Thus, the
framework is still applicable during this period and the findings of increased incidence of
any VTE, DVD, and pulmonary embolism in the cancer cohort are not inconsistent with
the framework (Table 25).
The second research question examined the incidence rate ratios of
thromboembolic events in the follow-up period after the index date. The incidence rates
of events were higher in the cancer patients than the noncancer patients (Tables 27 and
28). This finding is consistent with the theoretical framework as kidney cancer diagnosis
and cancer characteristics were characterized as causative factors. The incidence rate
ratios differed by the diagnosis of other comorbidities, and the environmental and other
population characteristics were statistically significant confounders in most of the
models.
The third research question was analyzed in the cancer patient cohort only. Other
than the cancer itself, the causative factors included cancer stage and treatments. Stage,
particularly late stage, and chemotherapy were associated with increased risk of venous
thromboembolic events (Tables 29 to 32). Nephrectomy, another cancer treatment, was
associated with a decreased risk of pulmonary embolism (Table 31). The population
characteristics and environment and lifestyle factors including older age, comorbidities,
geographic region, race, and history of other conditions also impacted the risk of venous
thromboembolic events.
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In each research question, the effect of cancer diagnosis differed by type of
thromboembolic event, comorbidities (i.e., population factors), high-risk surgery and
placement of central venous catheter (i.e., environment and lifestyle factors). The
differences in findings across the three research questions suggest that within the
framework the relationships of the factors to the events may be different for venous and
arterial events. Before the index date, the incidence rates of most venous thromboembolic
events were higher in cancer patients than noncancer patients, but that was not the case
for ischemic stroke. After the index date, the incidence rates of venous thromboembolic
events were higher in the kidney cancer patients, while they were higher in arterial
thromboembolic events but only in patients without certain comorbidities (Tables 25 to
28). Within the kidney cancer patient cohort receipt of chemotherapy increased the risk of
venous thromboembolic events, whereas it was protective for myocardial infarction and
not statistically significant for ischemic stroke (Tables 29 to 35). Future frameworks
developed for studies of venous and arterial thromboembolic events in cancer patients
may benefit from developing two frameworks which model differences in the
relationships of factors such as chemotherapy and outcome.
Limitations of the Study
The main limitation of this study as discussed in chapters 1 and 3 are that there
are potential confounders and other factors which we cannot measure such as smoking
status, platelet counts, lab values of other conditions, or severity of conditions. That data
is simply not available in the administrative claims database utilized for this study. The
advantages of using the SEER-Medicare database are that it is population-based, has a
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large sample size, and contains high-quality and detailed cancer data. For the objectives
of this study, these advantages outweigh the limitations of the unmeasured factors.
Another limitation is that the study is limited to the diagnoses and procedures indicated in
the claims data. Conditions, procedures, and medications which were not submitted and
reimbursed by Medicare were missed. Although rule-out diagnoses were removed as
much as possible, it is still possible that some rule-out diagnoses or diagnoses which were
follow-up visits were included in the study data. Conversely, some legitimate diagnoses
and procedures may have been removed during the data cleaning process. Other studies
of thromboembolic events in cancer patients which use administrative claims databases
have similar limitations.
Recommendations
I reported incidence rates, incidence proportions and risk factors for venous and
arterial thromboembolic events in elderly kidney cancer patients and incidence rate ratios
for the events comparing the cancer cohort to a matched noncancer cohort. New
contributions to the research include incidence rates stratified by histology type,
assessment of histology group as a risk factor for thromboembolic events, incidence rates
and proportions for myocardial infarction and ischemic stroke, and assessment of risk
factors for arterial thromboembolic events in kidney cancer patients. Future studies
should include assessment of kidney cancer histology type as a risk factor for venous and
arterial thromboembolic events in other populations and age groups. Given the incidence
rates of myocardial infarction and ischemic stroke were as high as incidence rates of
venous thromboembolic events and these outcomes can impact patient quality of life and
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patient prognosis; more studies are needed of myocardial infarction and ischemic stroke
in cancer patients of all cancer types including kidney cancer.
Differences in cancer stage at diagnosis, healthcare utilization, and cancer
survival have been shown in studies of different cancer types within the United States
(Farkas, Greenbaum, Singhal, & Cosgrove, 2012; Niu, Roche, Pawlish,& Henry, 2013;
Ward et al., 2008). Thus the findings from this study, which used a Medicare population
who did not participate in a managed care plan, may not apply to the elderly who have
different insurance coverage or are uninsured. It would be beneficial to determine
whether these findings and relationships would be found in kidney cancer patients with
other insurance coverage and in different age groups. If the associations between factors
and thromboembolic events are different for patients with payers other than Medicare,
who have a Medicare managed-care plan, or who are nonelderly; then applying the
evidence generated by this study could lead to sub-optimal care and risk assessment for
these other patient groups.
The difference in risk by age group across thromboembolic event type was
unexpected, and in future studies, risk factors for venous thromboembolic events should
be assessed for any VTE as well as each VTE individually. By conducting studies which
just report findings for the group of thromboembolic events, differences in trends and risk
factors may be missed or incorrectly generalized to each individual event.
In general, the models performed similarly when using the Charlson score versus
using kidney disease and diabetes variables individually. Future studies may reasonably
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use the Charlson score instead of running separate models which include the selected
conditions which are components of the Charlson comorbidity score.
Implications for Positive Social Change
The findings from study have several implications for positive social change.
Better understanding of the factors which affect the risk of venous and arterial
thromboembolic events can inform patients and healthcare providers. This information
can aid healthcare providers in determining which patients may benefit from closer
observation or prophylaxis to prevent or minimize morbidity from these events. The risk
of arterial thromboembolic events was not previously researched in kidney cancer
patients and so the findings from this study provide additional information to patients,
healthcare providers, and other researchers. I also contributed research on incidence rates
by histology type in kidney cancer patients and whether histology type impacted the risk
of venous and arterial thromboembolic events. Based on the findings of this study,
healthcare providers have no reason to believe the risks of venous and arterial
thromboembolic events differ by histology group within RCC patients with Clear cell,
Chromophobe, Papillary or other RCC. For the outcomes other than pulmonary embolism
and ischemic stroke, there was no difference in incidence of thromboembolic events in
kidney cancer patients with RCC or transitional cell tumors. Thus healthcare providers
would not need any change in observation, prophylaxis, or treatment in this regard based
on histologic type of RCC. Similarly the lower risk of VTEs in patients with transitional
cell tumors compared to patients with clear cell tumors indicates that no additional care
would be needed for this group, beyond the usual thromboembolic risk assessment and
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care for elderly kidney cancer patients. The increased risk of pulmonary embolism in
patients with papillary histology may warrant additional consideration by the healthcare
provider during the risk assessment for thromboembolic events.
Conclusion
This population-based, retrospective cohort study of elderly Medicare
beneficiaries with and without kidney cancer provided new and useful information on the
incidence and risk factors for venous and arterial thromboembolic events. Incidence rates
of myocardial infarction were calculated, and were as high as the incidence rates of the
venous thromboembolic events. I confirmed that incidence rates of thromboembolic
events are higher in kidney cancer patients in the follow-up period after cancer diagnosis
than in the year prior to diagnosis. Similar to other studies the incidence proportions in
the first year after cancer diagnosis were highest in the first three months. Prior to the
index date, the incidence rates of venous thromboembolic events were higher in the
cancer (exposed) cohort than the noncancer comparator cohort. For any ATE and
ischemic stroke, there were no statistically significant differences in incidence rates
between the two cohorts. In the follow-up period after index date, the incidence rates of
most thromboembolic events were different in the cancer cohort than in the noncancer
cohort when the patients were stratified by kidney disease, type 2 diabetes, or
atherosclerosis. Unexpectedly, the incidence rate ratios were greater than 1.0 for patients
without kidney disease, type 2 diabetes, or atherosclerosis. More research is needed to
understand why the presence of these comorbidities would differentially impact the
incidence rates of thromboembolic events in cancer and noncancer patients. This study
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was the first study (to my knowledge) in which the relationship of histology groups of
kidney cancer and thromboembolic events were assessed and to report that kidney cancer
patients with transitional cell tumors appear to be at lower risk for pulmonary embolism
and ischemic stroke compared to patients diagnosed with clear cell tumors. A better
understanding of the risk factors for thromboembolic events in elderly kidney cancer
patients may inform patients and healthcare providers, in turn proving beneficial for
patient care.
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Appendix A: Abbreviations
Definition
AJCC
AMI
ATE
CCI
CDC
CMS
CPT
CVC
CVD
DVT
EMM
FDA
HCPCS
HF
HIPAA
HR
ICD-9-CM
ICD-10-CM
ICD-O
IL-2
IRB
IRR
IS
mTOR
MeSH
MHSA
MVT
NCCN
NDC
NEC
OR
OS
OTE
PE
PFS
OS
PH
RCC
RR
SEER
SES
US
VEGF
VHL
VTE

American Joint Committee on Cancer
Acute Myocardial Infarction
Arterial Thromboembolic Event
Charlson Comorbidity Index
Centers for Disease Control and Prevention
Centers for Medicare & Medicaid Services
Current Procedural Terminology
Central Venous Catheter
Cardiovascular Disease
Deep Venous Thrombosis
Effect Measure Modifier
United States Food and Drug Administration
Healthcare Common Procedure Coding System
Heart Failure
Health Insurance Portability and Accountability Act
Hazard Ratio
International Classification of Diseases, Ninth Revision, Clinical Modification
International Classification of Diseases, Tenth Revision, Clinical Modification
International Classification of Diseases for Oncology
Interleukin-2
Institutional Review Board
Incidence Rate Ratio
Ischemic Stroke
Mammalian Target Of Rapamycin
Medical Subject Headings
Mental Health and Substance Abuse
Motor Vehicle Traffic
National Comprehensive Cancer Network
National Drug Code
Not Elsewhere Classified
Odds Ratio
Overall Survival
Other Thromboembolic Event
Pulmonary Embolism
Progression-free Survival
Overall Survival
Proportional Hazard
Renal Cell Carcinoma
Relative Risk
Surveillance, Epidemiology, and End Results Program
Socioeconomic Status
United States
Vascular Endothelial Growth Factor
von Hippel-Lindau
Venous Thromboembolic Event
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Appendix B. Operational Definitions
Kidney cancer
Transitional cell
tumors of the
kidney
RCC
RCC Histology

Age at diagnosis
(index date)
Race
Geographic region

Coverage by
Medicare plans
Part A and Part B
Participation in
Medicare managed
care plans

DVT
PE
OTE
MI

Coding Definitions
ICD-O-3 site code C64.9, excluding histology codes for hematopoietic cancers
(9590-9989), with malignant behavior.
ICD-O-3 site code C64.9 and histology codes 8050-8130 (inclusive), with
malignant behavior.
ICD-O-3 site code C64.9, excluding histology codes 8050-8130 (inclusive) and
histology codes for hematopoietic cancers (9590-9989), with malignant behavior.
Clear Cell: ICD-O-3 and histology codes 8310, 8312
Papillary: ICD-O-3 site code C64.9 and histology code 8260
Chromophobe: ICD-O-3 site code C64.9 and histology codes 8317, 8270
Other: ICD-O-3 site code C64.9, excluding histology codes 8050-8130 (inclusive)
and 8310, 8312, 8317, and 8270
The integer number of years between the year of birth and the year of diagnosis
(index date).
Use the race variable from the Medicare entitlement file. Exclude patients with
unknown race. The race categories were combined into three race groups - White,
Black, and other races.
This variable was categorized into the four United States Census regions of
Northeast, Midwest, South and West. The states which make up the Northeast
region are Maine, New Hampshire, Vermont, Massachusetts, Connecticut, Rhode
Island, New Jersey, New York, Pennsylvania; the states in the Midwest region are
North Dakota, South Dakota, Nebraska, Kansas, Missouri, Iowa, Minnesota,
Wisconsin, Illinois, Michigan, Indiana, Ohio; the states in the South region are
Maryland, Delaware, West Virginia, Virginia, Kentucky, Tennessee, North
Carolina, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas,
Louisiana, Oklahoma, Texas, and District of Columbia; the states in the West region
are Washington, Idaho, Montana, Wyoming, Oregon, California, Nevada, Utah,
Colorado, Arizona, New Mexico, Alaska, and Hawaii (United States Census
Bureau, 2013).
For each month, the variable (mon1-mon264) is coded as 0 = Not entitled, 1= Part
A only, 2 = Part B only, or 3 = Part A and B. The number of months of coverage
was the total number of consecutive months with Part A and B coverage (where the
indicator variable has a value of 3).
For each month, the variable (gho1-gho264) is coded as 0 = Not a member of
HMO, 1 = Non-Lock-in, CMS to process provider claims , 2 = Non-Lock-in, GHO
to process in-plan Part A & in-area Part B claims, 4 = Chronic care disease
management organizations-FFS plan , A = Lock-in, CMS to process provider
claims, B = Lock-in, GHO to process in-plan Part A & in-area Part B claims, C =
Lock-in, GHO to process all Part A and Part B claims.
Participation in a managed care plan was identified by a month where the GHO
variable has a value which is not 0.
ICD-9-CM diagnosis codes 451.11, 451.19, 451.2, 451.81, 451.83, 451.84, 453.1,
453.2, 453.40, 453.41, 453.42, 453.8, 453.9
ICD-9-CM diagnosis codes 415.1 and 415.19
ICD-9-CM diagnosis codes 362.35, 362.36, 437.6, 451.0, 451.82, 451.89
ICD-9-CM diagnosis codes 410.0, 410.00, 410.01, 410.02, 410.1, 410.10, 410.11,
410.12, 410.2, 410.20, 410.21, 410.22, 410.3, 410.30, 410.31, 410.32, 410.4,
410.40, 410.41, 410.42, 410.5, 410.50, 410.51, 410.52, 410.6, 410.60, 410.61,
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IS

Any chemotherapy

Coding Definitions
410.62, 410.7, 410.70, 410.71, 410.72, 410.8, 410.80, 410.81, 410.82, 410.9,
410.90, 410.91, 410.92, 451.9 453.0, 453.3.
ICD-9-CM diagnosis codes 433.0, 433.00, 433.01, 433.1, 433.10, 433.11, 433.2,
433.20, 433.21, 433.3, 433.30, 433.31, 433.8, 433.80, 433.81, 433.9, 433.90,
433.91, 434.0, 434.00, 434.01, 434.1, 434.10, 434.11, 434.9, 434.90, 434.91, 437.1
Restrict to diagnoses captured on hospitalizations only.
Use of any chemotherapy was defined by ICD-9-CM diagnosis codes V58.1,
V58.11, V66.2, and V67.2; ICD-9-CM procedure codes 00.10, 99.25; a HCPCS
code indicating chemotherapy or chemotherapy administration (96400-96549,
C8953, C8954, C8955, C9214, C9239, C9257, J8999-J9999, Q2024, S0088, S0116,
and for 2005 only, G0355-G0362 and Q0083-Q0085, excluding J9015, J9214);
NDC codes in the Durable Medical Equipment or prescription drug event files
indicating chemotherapy drugs (listed below); and revenue codes 0331, 0332, and
0335 (Applied Research Program, 2013; Lund et al., 2013).
NDC Code, Generic Name, Brand Name
00008117901, TEMSIROLIMUS, TORISEL
00008117905, TEMSIROLIMUS, TORISEL
00026848858, SORAFENIB, NEXAVAR
00069014501, AXITINIB, INLYTA
00069015111, AXITINIB, INLYTA
00069055030, SUNITINIB, SUTENT
00069055038, SUNITINIB, SUTENT
00069077030, SUNITINIB, SUTENT
00069077038, SUNITINIB, SUTENT
00069098030, SUNITINIB, SUTENT
00069098038, SUNITINIB, SUTENT
00078056651, EVEROLIMUS, AFINITOR
00078056661, EVEROLIMUS, AFINITOR
00078056751, EVEROLIMUS, AFINITOR
00078056761, EVEROLIMUS, AFINITOR
00078059451, EVEROLIMUS, AFINITOR
00078059461, EVEROLIMUS, AFINITOR
00078062051, EVEROLIMUS, AFINITOR
00078062651, EVEROLIMUS, AFINITOR DISPERZ
00078062851, EVEROLIMUS, AFINITOR DISPERZ
00173080409, PAZOPANIB, VOTRIENT
50242006001, BEVACIZUMAB, AVASTIN
50242006002, BEVACIZUMAB, AVASTIN
50242006101, BEVACIZUMAB, AVASTIN
50242006201, ERLOTINIB, TARCEVA
50242006301, ERLOTINIB, TARCEVA
50242006401, ERLOTINIB, TARCEVA
50419048858, SORAFENIB, NEXAVAR
54569598300, SUNITINIB, SUTENT
54868544700, ERLOTINIB, TARCEVA
54868547400, ERLOTINIB, TARCEVA
68817013450, PACLITAXEL, ABRAXANE
00013128683, DOXORUBICIN, ADRIAMYCIN PFS
00013126683, DOXORUBICIN, ADRIAMYCIN PFS
00013123691, DOXORUBICIN, ADRIAMYCIN PFS
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00013124691, DOXORUBICIN, ADRIAMYCIN PFS
00013125679, DOXORUBICIN, ADRIAMYCIN PFS
00013116683, DOXORUBICIN, ADRIAMYCIN PFS
00013113691, DOXORUBICIN, ADRIAMYCIN PFS
00013114694, DOXORUBICIN, ADRIAMYCIN PFS
00013114691, DOXORUBICIN, ADRIAMYCIN PFS
00013115679, DOXORUBICIN, ADRIAMYCIN PFS
00013117687, DOXORUBICIN, ADRIAMYCIN PFS
00013111683, DOXORUBICIN, ADRIAMYCIN RDF
00013108691, DOXORUBICIN, ADRIAMYCIN RDF
00013109694, DOXORUBICIN, ADRIAMYCIN RDF
00013109691, DOXORUBICIN, ADRIAMYCIN RDF
00013110679, DOXORUBICIN, ADRIAMYCIN RDF
00013104694, FLUOROURACIL, ADRUCIL
00703301812, FLUOROURACIL, ADRUCIL
00013105694, FLUOROURACIL, ADRUCIL
00703301912, FLUOROURACIL, ADRUCIL
00703301513, FLUOROURACIL, ADRUCIL
00013103691, FLUOROURACIL, ADRUCIL
50242006001, BEVACIZUMAB, AVASTIN
50242006101, BEVACIZUMAB, AVASTIN
50242006002, BEVACIZUMAB, AVASTIN
00009752902, IRINOTECAN, CAMPTOSAR
00009752904, IRINOTECAN, CAMPTOSAR
00009752901, IRINOTECAN, CAMPTOSAR
55390015101, CARBOPLATIN, CARBOPLATIN
63323016721, CARBOPLATIN, CARBOPLATIN
10019091601, CARBOPLATIN, CARBOPLATIN
10019091615, CARBOPLATIN, CARBOPLATIN
50111096676, CARBOPLATIN, CARBOPLATIN
00591222011, CARBOPLATIN, CARBOPLATIN
00703327601, CARBOPLATIN, CARBOPLATIN
00703326601, CARBOPLATIN, CARBOPLATIN
55390015201, CARBOPLATIN, CARBOPLATIN
63323016800, CARBOPLATIN, CARBOPLATIN
10019091701, CARBOPLATIN, CARBOPLATIN
50111096776, CARBOPLATIN, CARBOPLATIN
00703326801, CARBOPLATIN, CARBOPLATIN
00703327801, CARBOPLATIN, CARBOPLATIN
00703326871, CARBOPLATIN, CARBOPLATIN
55390015001, CARBOPLATIN, CARBOPLATIN
63323016610, CARBOPLATIN, CARBOPLATIN
10019091501, CARBOPLATIN, CARBOPLATIN
50111096576, CARBOPLATIN, CARBOPLATIN
00703327401, CARBOPLATIN, CARBOPLATIN
00591221911, CARBOPLATIN, CARBOPLATIN
00703326401, CARBOPLATIN, CARBOPLATIN
66758004702, CARBOPLATIN, CARBOPLATIN
10139006015, CARBOPLATIN, CARBOPLATIN
63323016915, CARBOPLATIN, CARBOPLATIN
63323017215, CARBOPLATIN, CARBOPLATIN
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00409112911, CARBOPLATIN, CARBOPLATIN
10019091202, CARBOPLATIN, CARBOPLATIN
00591333712, CARBOPLATIN, CARBOPLATIN
00703424601, CARBOPLATIN, CARBOPLATIN
55390022101, CARBOPLATIN, CARBOPLATIN
61703036022, CARBOPLATIN, CARBOPLATIN
66758004703, CARBOPLATIN, CARBOPLATIN
10139006045, CARBOPLATIN, CARBOPLATIN
15210006612, CARBOPLATIN, CARBOPLATIN
63323016945, CARBOPLATIN, CARBOPLATIN
63323017245, CARBOPLATIN, CARBOPLATIN
00409112912, CARBOPLATIN, CARBOPLATIN
10019091203, CARBOPLATIN, CARBOPLATIN
00591333889, CARBOPLATIN, CARBOPLATIN
00703424801, CARBOPLATIN, CARBOPLATIN
61703036050, CARBOPLATIN, CARBOPLATIN
66758004701, CARBOPLATIN, CARBOPLATIN
10139006005, CARBOPLATIN, CARBOPLATIN
15210006112, CARBOPLATIN, CARBOPLATIN
63323016905, CARBOPLATIN, CARBOPLATIN
63323017205, CARBOPLATIN, CARBOPLATIN
00409112910, CARBOPLATIN, CARBOPLATIN
10019091201, CARBOPLATIN, CARBOPLATIN
00591333626, CARBOPLATIN, CARBOPLATIN
00703424401, CARBOPLATIN, CARBOPLATIN
61703036018, CARBOPLATIN, CARBOPLATIN
66758004704, CARBOPLATIN, CARBOPLATIN
15210006712, CARBOPLATIN, CARBOPLATIN
67817006712, CARBOPLATIN, CARBOPLATIN
55390015601, CARBOPLATIN, CARBOPLATIN
63323017260, CARBOPLATIN, CARBOPLATIN
61703033956, CARBOPLATIN, CARBOPLATIN
00703324911, CARBOPLATIN, CARBOPLATIN
00591345460, CARBOPLATIN, CARBOPLATIN
00015323111, CARBOPLATIN, CARBOPLATIN
00015323211, CARBOPLATIN, CARBOPLATIN
00015323011, CARBOPLATIN, CARBOPLATIN
00015323311, CARBOPLATIN, CARBOPLATIN
61703033922, CARBOPLATIN, CARBOPLATIN
00703324611, CARBOPLATIN, CARBOPLATIN
61703033950, CARBOPLATIN, CARBOPLATIN
00703324811, CARBOPLATIN, CARBOPLATIN
61703033918, CARBOPLATIN, CARBOPLATIN
00703324411, CARBOPLATIN, CARBOPLATIN
55390015401, CARBOPLATIN, CARBOPLATIN
55390015501, CARBOPLATIN, CARBOPLATIN
55390015301, CARBOPLATIN, CARBOPLATIN
55390011299, CISPLATIN, CISPLATIN
55390041499, CISPLATIN, CISPLATIN
63323010365, CISPLATIN, CISPLATIN
10019091002, CISPLATIN, CISPLATIN
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63323010364, CISPLATIN, CISPLATIN
63323010351, CISPLATIN, CISPLATIN
10019091001, CISPLATIN, CISPLATIN
55390009901, CISPLATIN, CISPLATIN
55390011250, CISPLATIN, CISPLATIN
55390041450, CISPLATIN, CISPLATIN
00703574811, CISPLATIN, CISPLATIN-AQ
00703574711, CISPLATIN, CISPLATIN-AQ
00955102001, DOCETAXEL, DOCETAXEL
00955102104, DOCETAXEL, DOCETAXEL
61471029512, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL
17314960001, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL
59676096001, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL
17314960002, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL
59676096002, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL
10019092001, DOXORUBICIN, DOXORUBICIN HCL
55390023110, DOXORUBICIN, DOXORUBICIN HCL
55390024110, DOXORUBICIN, DOXORUBICIN HCL
55390023210, DOXORUBICIN, DOXORUBICIN HCL
55390023301, DOXORUBICIN, DOXORUBICIN HCL
10019092102, DOXORUBICIN, DOXORUBICIN HCL
55390024301, DOXORUBICIN, DOXORUBICIN HCL
63323010161, DOXORUBICIN, DOXORUBICIN HCL
55390023801, DOXORUBICIN, DOXORUBICIN HCL
55390024801, DOXORUBICIN, DOXORUBICIN HCL
00703504001, DOXORUBICIN, DOXORUBICIN HCL
53905023606, DOXORUBICIN, DOXORUBICIN HCL
63323088310, DOXORUBICIN, DOXORUBICIN HCL
55390023610, DOXORUBICIN, DOXORUBICIN HCL
55390024610, DOXORUBICIN, DOXORUBICIN HCL
55390023701, DOXORUBICIN, DOXORUBICIN HCL
00186153261, DOXORUBICIN, DOXORUBICIN HCL
00703504601, DOXORUBICIN, DOXORUBICIN HCL
00469883250, DOXORUBICIN, DOXORUBICIN HCL
63323088330, DOXORUBICIN, DOXORUBICIN HCL
55390024701, DOXORUBICIN, DOXORUBICIN HCL
00074504601, DOXORUBICIN, DOXORUBICIN HCL
00703504303, DOXORUBICIN, DOXORUBICIN HCL
63323088305, DOXORUBICIN, DOXORUBICIN HCL
55390023510, DOXORUBICIN, DOXORUBICIN HCL
55390024510, DOXORUBICIN, DOXORUBICIN HCL
00009509301, EPIRUBICIN, ELLENCE
00009509101, EPIRUBICIN, ELLENCE
00024059704, OXALIPLATIN, ELOXATIN
00024059602, OXALIPLATIN, ELOXATIN
00024059120, OXALIPLATIN, ELOXATIN
00024059240, OXALIPLATIN, ELOXATIN
00024059010, OXALIPLATIN, ELOXATIN
61703034735, EPIRUBICIN, EPIRUBICIN HCL
66758004202, EPIRUBICIN, EPIRUBICIN HCL
63323015100, EPIRUBICIN, EPIRUBICIN HCL
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55390020801, EPIRUBICIN, EPIRUBICIN HCL
61703035902, EPIRUBICIN, EPIRUBICIN HCL
61703035959, EPIRUBICIN, EPIRUBICIN HCL
00703306911, EPIRUBICIN, EPIRUBICIN HCL
59762509301, EPIRUBICIN, EPIRUBICIN HCL
66758004201, EPIRUBICIN, EPIRUBICIN HCL
63323015125, EPIRUBICIN, EPIRUBICIN HCL
25021020325, EPIRUBICIN, EPIRUBICIN HCL
55390020701, EPIRUBICIN, EPIRUBICIN HCL
61703035993, EPIRUBICIN, EPIRUBICIN HCL
00703306711, EPIRUBICIN, EPIRUBICIN HCL
59762509101, EPIRUBICIN, EPIRUBICIN HCL
63323015175, EPIRUBICIN, EPIRUBICIN HCL
66733094823, CETUXIMAB, ERBITUX
66733095823, CETUXIMAB, ERBITUX
00015340420, ETOPOSIDE, ETOPOPHOS
54868535500, ETOPOSIDE, ETOPOSIDE
51079096501, ETOPOSIDE, ETOPOSIDE
51079096505, ETOPOSIDE, ETOPOSIDE
00378326694, ETOPOSIDE, ETOPOSIDE
55390029301, ETOPOSIDE, ETOPOSIDE
55390049301, ETOPOSIDE, ETOPOSIDE
55390029101, ETOPOSIDE, ETOPOSIDE
55390049101, ETOPOSIDE, ETOPOSIDE
00703566701, ETOPOSIDE, ETOPOSIDE
63323010425, ETOPOSIDE, ETOPOSIDE
00074564601, ETOPOSIDE, ETOPOSIDE
00703564601, ETOPOSIDE, ETOPOSIDE
00703565601, ETOPOSIDE, ETOPOSIDE
63323010450, ETOPOSIDE, ETOPOSIDE
00074148503, ETOPOSIDE, ETOPOSIDE
00703565701, ETOPOSIDE, ETOPOSIDE
10019093001, ETOPOSIDE, ETOPOSIDE
00074148501, ETOPOSIDE, ETOPOSIDE
00074564301, ETOPOSIDE, ETOPOSIDE
00703564301, ETOPOSIDE, ETOPOSIDE
00703565301, ETOPOSIDE, ETOPOSIDE
63323010405, ETOPOSIDE, ETOPOSIDE
55390029201, ETOPOSIDE, ETOPOSIDE
55390049201, ETOPOSIDE, ETOPOSIDE
51927277200, Etoposide, ETOPOSIDE
00004190406, FLUOROURACIL, FLUOROURACIL
38779002509, FLUOROURACIL, FLUOROURACIL
38779002505, FLUOROURACIL, FLUOROURACIL
38779002510, FLUOROURACIL, FLUOROURACIL
38779002501, FLUOROURACIL, FLUOROURACIL
51927108500, FLUOROURACIL, FLUOROURACIL
49452317501, FLUOROURACIL, FLUOROURACIL
38779002525, FLUOROURACIL, FLUOROURACIL
38779002504, FLUOROURACIL, FLUOROURACIL
49452317503, FLUOROURACIL, FLUOROURACIL
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49452317502, FLUOROURACIL, FLUOROURACIL
63370009535, FLUOROURACIL, FLUOROURACIL
51552073305, FLUOROURACIL, FLUOROURACIL
62991148604, FLUOROURACIL, FLUOROURACIL
49452317504, FLUOROURACIL, FLUOROURACIL
51552073301, FLUOROURACIL, FLUOROURACIL
63370009525, FLUOROURACIL, FLUOROURACIL
51552073304, FLUOROURACIL, FLUOROURACIL
62991148602, FLUOROURACIL, FLUOROURACIL
63370009515, FLUOROURACIL, FLUOROURACIL
51552073302, FLUOROURACIL, FLUOROURACIL
10139006301, FLUOROURACIL, FLUOROURACIL
63323011761, FLUOROURACIL, FLUOROURACIL
10139006350, FLUOROURACIL, FLUOROURACIL
61703040932, FLUOROURACIL, FLUOROURACIL
39769001210, FLUOROURACIL, FLUOROURACIL
00004197701, FLUOROURACIL, FLUOROURACIL
00187395364, FLUOROURACIL, FLUOROURACIL
66758004401, FLUOROURACIL, FLUOROURACIL
66758004403, FLUOROURACIL, FLUOROURACIL
10139006310, FLUOROURACIL, FLUOROURACIL
10139006311, FLUOROURACIL, FLUOROURACIL
63323011710, FLUOROURACIL, FLUOROURACIL
63323011720, FLUOROURACIL, FLUOROURACIL
10139006312, FLUOROURACIL, FLUOROURACIL
63323011751, FLUOROURACIL, FLUOROURACIL
00182306863, FLUOROURACIL, FLUOROURACIL
62991148601, Fluorouracil, FLUOROURACIL
68152010100, LEVOLEUCOVORIN, FUSILEV
63323012550, GEMCITABINE, GEMCITABINE HCL
00781328379, GEMCITABINE, GEMCITABINE HCL
00781328275, GEMCITABINE, GEMCITABINE HCL
00409018701, GEMCITABINE, GEMCITABINE HCL
00002750201, GEMCITABINE, GEMZAR
00002750101, GEMCITABINE, GEMZAR
00078037366, IMATINIB, GLEEVEC
00078043815, IMATINIB, GLEEVEC
54868528901, IMATINIB, GLEEVEC
00078040105, IMATINIB, GLEEVEC
54868528903, IMATINIB, GLEEVEC
54868528900, IMATINIB, GLEEVEC
54868528902, IMATINIB, GLEEVEC
00078040134, IMATINIB, GLEEVEC
54868542701, IMATINIB, GLEEVEC
54868542700, IMATINIB, GLEEVEC
00078040215, IMATINIB, GLEEVEC
50242005656, TRASTUZUMAB, HERCEPTIN
50242013468, TRASTUZUMAB, HERCEPTIN
50242013460, TRASTUZUMAB, HERCEPTIN
66758004802, IRINOTECAN, IRINOTECAN HCL
10518010311, IRINOTECAN, IRINOTECAN HCL
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63323019305, IRINOTECAN, IRINOTECAN HCL
55390029601, IRINOTECAN, IRINOTECAN HCL
61703034909, IRINOTECAN, IRINOTECAN HCL
00781306675, IRINOTECAN, IRINOTECAN HCL
00591318926, IRINOTECAN, IRINOTECAN HCL
00703443411, IRINOTECAN, IRINOTECAN HCL
59762752902, IRINOTECAN, IRINOTECAN HCL
61703034962, IRINOTECAN, IRINOTECAN HCL
00703443491, IRINOTECAN, IRINOTECAN HCL
66758004801, IRINOTECAN, IRINOTECAN HCL
63323019302, IRINOTECAN, IRINOTECAN HCL
10518010310, IRINOTECAN, IRINOTECAN HCL
55390029501, IRINOTECAN, IRINOTECAN HCL
61703034916, IRINOTECAN, IRINOTECAN HCL
10019093401, IRINOTECAN, IRINOTECAN HCL
00781306672, IRINOTECAN, IRINOTECAN HCL
00591318902, IRINOTECAN, IRINOTECAN HCL
00703443211, IRINOTECAN, IRINOTECAN HCL
59762752901, IRINOTECAN, IRINOTECAN HCL
49452403601, LEUCOVORIN, LEUCOVORIN CA
51927269200, LEUCOVORIN, LEUCOVORIN CA
49452403602, LEUCOVORIN, LEUCOVORIN CA
00054849706, LEUCOVORIN, LEUCOVORIN CA
00054449705, LEUCOVORIN, LEUCOVORIN CA
00054449710, LEUCOVORIN, LEUCOVORIN CA
67263034583, LEUCOVORIN, LEUCOVORIN CA
00054849806, LEUCOVORIN, LEUCOVORIN CA
00054449805, LEUCOVORIN, LEUCOVORIN CA
58406062674, LEUCOVORIN, LEUCOVORIN CA
00054449810, LEUCOVORIN, LEUCOVORIN CA
00054849906, LEUCOVORIN, LEUCOVORIN CA
62584076701, LEUCOVORIN, LEUCOVORIN CA
51079058205, LEUCOVORIN, LEUCOVORIN CA
00555048527, LEUCOVORIN, LEUCOVORIN CA
51309074225, LEUCOVORIN, LEUCOVORIN CA
62701090125, LEUCOVORIN, LEUCOVORIN CA
00781122263, LEUCOVORIN, LEUCOVORIN CA
00182187024, LEUCOVORIN, LEUCOVORIN CA
00536414904, LEUCOVORIN, LEUCOVORIN CA
00603418435, LEUCOVORIN, LEUCOVORIN CA
00054449911, LEUCOVORIN, LEUCOVORIN CA
51079058201, LEUCOVORIN, LEUCOVORIN CA
49884023701, LEUCOVORIN, LEUCOVORIN CA
00555048402, LEUCOVORIN, LEUCOVORIN CA
58406062467, LEUCOVORIN, LEUCOVORIN CA
51309074191, LEUCOVORIN, LEUCOVORIN CA
62701090099, LEUCOVORIN, LEUCOVORIN CA
00781122001, LEUCOVORIN, LEUCOVORIN CA
00182186901, LEUCOVORIN, LEUCOVORIN CA
00904231560, LEUCOVORIN, LEUCOVORIN CA
00603418321, LEUCOVORIN, LEUCOVORIN CA
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00054449625, LEUCOVORIN, LEUCOVORIN CA
62584076601, LEUCOVORIN, LEUCOVORIN CA
51079058101, LEUCOVORIN, LEUCOVORIN CA
00555048401, LEUCOVORIN, LEUCOVORIN CA
58406062462, LEUCOVORIN, LEUCOVORIN CA
62701090030, LEUCOVORIN, LEUCOVORIN CA
00781122031, LEUCOVORIN, LEUCOVORIN CA
00536414807, LEUCOVORIN, LEUCOVORIN CA
00054449613, LEUCOVORIN, LEUCOVORIN CA
54868331001, LEUCOVORIN, LEUCOVORIN CA
00054849619, LEUCOVORIN, LEUCOVORIN CA
51079058106, LEUCOVORIN, LEUCOVORIN CA
54868331000, LEUCOVORIN, LEUCOVORIN CA
66479024725, LEUCOVORIN, LEUCOVORIN CA
58406062307, LEUCOVORIN, LEUCOVORIN CA
00074514001, LEUCOVORIN, LEUCOVORIN CA
00703514001, LEUCOVORIN, LEUCOVORIN CA
55390005210, LEUCOVORIN, LEUCOVORIN CA
55390081810, LEUCOVORIN, LEUCOVORIN CA
55390005301, LEUCOVORIN, LEUCOVORIN CA
61703041050, LEUCOVORIN, LEUCOVORIN CA
55390082401, LEUCOVORIN, LEUCOVORIN CA
55390005401, LEUCOVORIN, LEUCOVORIN CA
00703514501, LEUCOVORIN, LEUCOVORIN CA
55390082501, LEUCOVORIN, LEUCOVORIN CA
55390005110, LEUCOVORIN, LEUCOVORIN CA
00074454102, LEUCOVORIN, LEUCOVORIN CA
00517860525, LEUCOVORIN, LEUCOVORIN CA
00074454104, LEUCOVORIN, LEUCOVORIN CA
55390000901, LEUCOVORIN, LEUCOVORIN CA
55390082601, LEUCOVORIN, LEUCOVORIN CA
00641236441, LEUCOVORIN, LEUCOVORIN CA
63323071100, LEUCOVORIN, LEUCOVORIN CA
00641236941, LEUCOVORIN, LEUCOVORIN CA
38779017806, Leucovorin Calcium, LEUCOVORIN CALCIUM
49452403604, Leucovorin Calcium, LEUCOVORIN CALCIUM
38779003506, METHOTREXATE, METHOTREXATE
38779003511, METHOTREXATE, METHOTREXATE
63370015410, METHOTREXATE, METHOTREXATE
62991120001, METHOTREXATE, METHOTREXATE
38779003504, METHOTREXATE, METHOTREXATE
63370015425, METHOTREXATE, METHOTREXATE
38779003503, METHOTREXATE, METHOTREXATE
63370015415, METHOTREXATE, METHOTREXATE
62991120002, METHOTREXATE, METHOTREXATE
51552105409, METHOTREXATE, METHOTREXATE
49452460003, METHOTREXATE, METHOTREXATE
49452460101, METHOTREXATE, METHOTREXATE
51552105401, METHOTREXATE, METHOTREXATE
51927156500, METHOTREXATE, METHOTREXATE
49452460102, METHOTREXATE, METHOTREXATE
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49452460002, METHOTREXATE, METHOTREXATE
38779003510, Methotrexate Sodium, METHOTREXATE
38779003515, Methotrexate Sodium, METHOTREXATE
38779003525, Methotrexate Sodium, METHOTREXATE
61703040804, METHOTREXATE, METHOTREXATE LPF
58406068318, METHOTREXATE, METHOTREXATE LPF
66479013613, METHOTREXATE, METHOTREXATE LPF
58406068312, METHOTREXATE, METHOTREXATE LPF
66479013619, METHOTREXATE, METHOTREXATE LPF
58406068316, METHOTREXATE, METHOTREXATE LPF
58406068315, METHOTREXATE, METHOTREXATE LPF
66479013611, METHOTREXATE, METHOTREXATE LPF
61703040807, METHOTREXATE, METHOTREXATE LPF
54868382601, METHOTREXATE, METHOTREXATE SOD
54868382600, METHOTREXATE, METHOTREXATE SOD
54868382602, METHOTREXATE, METHOTREXATE SOD
00677161001, METHOTREXATE, METHOTREXATE SOD
54868382605, METHOTREXATE, METHOTREXATE SOD
00378001401, METHOTREXATE, METHOTREXATE SOD
21695011100, METHOTREXATE, METHOTREXATE SOD
52959024400, METHOTREXATE, METHOTREXATE SOD
67253032010, METHOTREXATE, METHOTREXATE SOD
00555057202, METHOTREXATE, METHOTREXATE SOD
51285050902, METHOTREXATE, METHOTREXATE SOD
68115063200, METHOTREXATE, METHOTREXATE SOD
62701094099, METHOTREXATE, METHOTREXATE SOD
00781107601, METHOTREXATE, METHOTREXATE SOD
00182153901, METHOTREXATE, METHOTREXATE SOD
00904174960, METHOTREXATE, METHOTREXATE SOD
00536399801, METHOTREXATE, METHOTREXATE SOD
00364249901, METHOTREXATE, METHOTREXATE SOD
00603449921, METHOTREXATE, METHOTREXATE SOD
00005450723, METHOTREXATE, METHOTREXATE SOD
00054455025, METHOTREXATE, METHOTREXATE SOD
00405464301, METHOTREXATE, METHOTREXATE SOD
59911587401, METHOTREXATE, METHOTREXATE SOD
00904601260, METHOTREXATE, METHOTREXATE SOD
00054855025, METHOTREXATE, METHOTREXATE SOD
00555057246, METHOTREXATE, METHOTREXATE SOD
51079067086, METHOTREXATE, METHOTREXATE SOD
00054855005, METHOTREXATE, METHOTREXATE SOD
00555057247, METHOTREXATE, METHOTREXATE SOD
51079067087, METHOTREXATE, METHOTREXATE SOD
00054855006, METHOTREXATE, METHOTREXATE SOD
00555057248, METHOTREXATE, METHOTREXATE SOD
54868382603, METHOTREXATE, METHOTREXATE SOD
00054855007, METHOTREXATE, METHOTREXATE SOD
49999038024, METHOTREXATE, METHOTREXATE SOD
00555057249, METHOTREXATE, METHOTREXATE SOD
23490588900, METHOTREXATE, METHOTREXATE SOD
00054855010, METHOTREXATE, METHOTREXATE SOD
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54868382604, METHOTREXATE, METHOTREXATE SOD
51079067001, METHOTREXATE, METHOTREXATE SOD
51079067005, METHOTREXATE, METHOTREXATE SOD
55289092430, METHOTREXATE, METHOTREXATE SOD
67253032036, METHOTREXATE, METHOTREXATE SOD
00555057235, METHOTREXATE, METHOTREXATE SOD
62701094036, METHOTREXATE, METHOTREXATE SOD
00781107636, METHOTREXATE, METHOTREXATE SOD
00182153995, METHOTREXATE, METHOTREXATE SOD
00904174973, METHOTREXATE, METHOTREXATE SOD
00364249936, METHOTREXATE, METHOTREXATE SOD
00536399836, METHOTREXATE, METHOTREXATE SOD
00054455015, METHOTREXATE, METHOTREXATE SOD
54868382606, METHOTREXATE, METHOTREXATE SOD
00378001450, METHOTREXATE, METHOTREXATE SOD
54569181800, METHOTREXATE, METHOTREXATE SOD
00555057245, METHOTREXATE, METHOTREXATE SOD
00054855003, METHOTREXATE, METHOTREXATE SOD
63323012250, METHOTREXATE, METHOTREXATE SOD
66479013929, METHOTREXATE, METHOTREXATE SOD
55390014301, METHOTREXATE, METHOTREXATE SOD
58406067301, METHOTREXATE, METHOTREXATE SOD
66479013721, METHOTREXATE, METHOTREXATE SOD
00205532618, METHOTREXATE, METHOTREXATE SOD
54569452500, METHOTREXATE, METHOTREXATE SOD
61703040732, METHOTREXATE, METHOTREXATE SOD
58406068117, METHOTREXATE, METHOTREXATE SOD
66479013509, METHOTREXATE, METHOTREXATE SOD
00469288030, METHOTREXATE, METHOTREXATE SOD
10019094101, METHOTREXATE, METHOTREXATE SOD
61703035038, METHOTREXATE, METHOTREXATE SOD
61703040832, METHOTREXATE, METHOTREXATE SOD
61703040813, METHOTREXATE, METHOTREXATE SOD
63323012140, METHOTREXATE, METHOTREXATE SOD
63323012104, METHOTREXATE, METHOTREXATE SOD
63323012108, METHOTREXATE, METHOTREXATE SOD
63323012110, METHOTREXATE, METHOTREXATE SOD
63323012310, METHOTREXATE, METHOTREXATE SOD
54868471600, METHOTREXATE, METHOTREXATE SOD
10139006210, METHOTREXATE, METHOTREXATE SOD
53905003410, METHOTREXATE, METHOTREXATE SOD
55390003410, METHOTREXATE, METHOTREXATE SOD
66758004008, METHOTREXATE, METHOTREXATE SOD
66758004001, METHOTREXATE, METHOTREXATE SOD
10139006202, METHOTREXATE, METHOTREXATE SOD
66479013501, METHOTREXATE, METHOTREXATE SOD
61703040707, METHOTREXATE, METHOTREXATE SOD
00205455626, METHOTREXATE, METHOTREXATE SOD
58406068114, METHOTREXATE, METHOTREXATE SOD
10019094001, METHOTREXATE, METHOTREXATE SOD
53905003110, METHOTREXATE, METHOTREXATE SOD
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55390003110, METHOTREXATE, METHOTREXATE SOD
66758004002, METHOTREXATE, METHOTREXATE SOD
61703040822, METHOTREXATE, METHOTREXATE SOD
66758004101, METHOTREXATE, METHOTREXATE SOD
10139006240, METHOTREXATE, METHOTREXATE SOD
61703040841, METHOTREXATE, METHOTREXATE SOD
10019094002, METHOTREXATE, METHOTREXATE SOD
55390003210, METHOTREXATE, METHOTREXATE SOD
61703040858, METHOTREXATE, METHOTREXATE SOD
55390003310, METHOTREXATE, METHOTREXATE SOD
00205933792, METHOTREXATE, METHOTREXATE SOD
63323012102, METHOTREXATE, METHOTREXATE SOD
63323012302, METHOTREXATE, METHOTREXATE SOD
54868479600, METHOTREXATE, METHOTREXATE SOD
54868017301, METHOTREXATE, METHOTREXATE SOD
00186142212, METHOTREXATE, METHOTREXATE SOD
00186142013, METHOTREXATE, METHOTREXATE SOD
00186142113, METHOTREXATE, METHOTREXATE SOD
62991154503, MITOMYCIN, MITOMYCIN
51927364200, MITOMYCIN, MITOMYCIN
38779055307, MITOMYCIN, MITOMYCIN
16729010811, MITOMYCIN, MITOMYCIN
55390025201, MITOMYCIN, MITOMYCIN
61703030650, MITOMYCIN, MITOMYCIN
55390045201, MITOMYCIN, MITOMYCIN
55390025301, MITOMYCIN, MITOMYCIN
55390045301, MITOMYCIN, MITOMYCIN
62701001001, MITOMYCIN, MITOMYCIN
16729011505, MITOMYCIN, MITOMYCIN
55390025101, MITOMYCIN, MITOMYCIN
55390045101, MITOMYCIN, MITOMYCIN
63323019140, MITOMYCIN, MITOMYCIN
63323019120, MITOMYCIN, MITOMYCIN
63323019020, MITOMYCIN, MITOMYCIN
49452478502, Mitomycin, MITOMYCIN
00015300222, MITOMYCIN, MUTAMYCIN
00015300220, MITOMYCIN, MUTAMYCIN
00015305920, MITOMYCIN, MUTAMYCIN
00015300120, MITOMYCIN, MUTAMYCIN
50419048858, SORAFENIB, NEXAVAR
00026848858, SORAFENIB, NEXAVAR
00172375675, PACLITAXEL, ONXOL
00172375377, PACLITAXEL, ONXOL
00172375473, PACLITAXEL, ONXOL
63323017650, OXALIPLATIN, OXALIPLATIN
41616017840, OXALIPLATIN, OXALIPLATIN
41616017640, OXALIPLATIN, OXALIPLATIN
66758005302, OXALIPLATIN, OXALIPLATIN
61703036322, OXALIPLATIN, OXALIPLATIN
63323065020, OXALIPLATIN, OXALIPLATIN
00703398601, OXALIPLATIN, OXALIPLATIN
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66758005301, OXALIPLATIN, OXALIPLATIN
61703036318, OXALIPLATIN, OXALIPLATIN
00703398501, OXALIPLATIN, OXALIPLATIN
55390011420, PACLITAXEL, PACLITAXEL
61703034222, PACLITAXEL, PACLITAXEL
00074433502, PACLITAXEL, PACLITAXEL
51079096201, PACLITAXEL, PACLITAXEL
00703476601, PACLITAXEL, PACLITAXEL
00555198414, PACLITAXEL, PACLITAXEL
55390030420, PACLITAXEL, PACLITAXEL
55390031420, PACLITAXEL, PACLITAXEL
55390051420, PACLITAXEL, PACLITAXEL
66758004302, PACLITAXEL, PACLITAXEL
10518010208, PACLITAXEL, PACLITAXEL
63323076316, PACLITAXEL, PACLITAXEL
00703476701, PACLITAXEL, PACLITAXEL
66758004303, PACLITAXEL, PACLITAXEL
55390011450, PACLITAXEL, PACLITAXEL
61703034250, PACLITAXEL, PACLITAXEL
00074433504, PACLITAXEL, PACLITAXEL
10518010209, PACLITAXEL, PACLITAXEL
63323076350, PACLITAXEL, PACLITAXEL
51079096301, PACLITAXEL, PACLITAXEL
00703476801, PACLITAXEL, PACLITAXEL
00555198514, PACLITAXEL, PACLITAXEL
55390030450, PACLITAXEL, PACLITAXEL
55390031450, PACLITAXEL, PACLITAXEL
55390051450, PACLITAXEL, PACLITAXEL
00172375396, PACLITAXEL, PACLITAXEL
66758004301, PACLITAXEL, PACLITAXEL
55390011405, PACLITAXEL, PACLITAXEL
00074433501, PACLITAXEL, PACLITAXEL
61703034209, PACLITAXEL, PACLITAXEL
10518010207, PACLITAXEL, PACLITAXEL
63323076305, PACLITAXEL, PACLITAXEL
51079096101, PACLITAXEL, PACLITAXEL
00703476401, PACLITAXEL, PACLITAXEL
55390030405, PACLITAXEL, PACLITAXEL
55390031405, PACLITAXEL, PACLITAXEL
55390051405, PACLITAXEL, PACLITAXEL
00172375494, PACLITAXEL, PACLITAXEL
00015321430, CARBOPLATIN, PARAPLATIN
00015321530, CARBOPLATIN, PARAPLATIN
00015321330, CARBOPLATIN, PARAPLATIN
00015321630, CARBOPLATIN, PARAPLATIN
00015321130, CARBOPLATIN, PARAPLATIN
00015321230, CARBOPLATIN, PARAPLATIN
00015321030, CARBOPLATIN, PARAPLATIN
00015321076, CARBOPLATIN, PARAPLATIN
00015322122, CISPLATIN, PLATINOL AQ
00015322097, CISPLATIN, PLATINOL AQ
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00015322022, CISPLATIN, PLATINOL AQ
67253058042, METHOTREXATE, RHEUMATREX
00005450704, METHOTREXATE, RHEUMATREX
67253058043, METHOTREXATE, RHEUMATREX
00005450705, METHOTREXATE, RHEUMATREX
67253058044, METHOTREXATE, RHEUMATREX
00005450707, METHOTREXATE, RHEUMATREX
67253058045, METHOTREXATE, RHEUMATREX
00005450709, METHOTREXATE, RHEUMATREX
00005450791, METHOTREXATE, RHEUMATREX
67253058046, METHOTREXATE, RHEUMATREX
00015335222, DOXORUBICIN, RUBEX
00069055038, SUNITINIB, SUTENT
00069055030, SUNITINIB, SUTENT
00069077038, SUNITINIB, SUTENT
00069077030, SUNITINIB, SUTENT
00069098038, SUNITINIB, SUTENT
00069098030, SUNITINIB, SUTENT
50242006301, ERLOTINIB, TARCEVA
54868547400, ERLOTINIB, TARCEVA
50242006401, ERLOTINIB, TARCEVA
54868544700, ERLOTINIB, TARCEVA
50242006201, ERLOTINIB, TARCEVA
00015347630, PACLITAXEL, TAXOL SEMI-SYN
00015347620, PACLITAXEL, TAXOL SEMI-SYN
00015347911, PACLITAXEL, TAXOL SEMI-SYN
00015347530, PACLITAXEL, TAXOL SEMI-SYN
00015347520, PACLITAXEL, TAXOL SEMI-SYN
00015347627, PACLITAXEL, TAXOL SEMI-SYN
00015347527, PACLITAXEL, TAXOL SEMI-SYN
00075800120, DOCETAXEL, TAXOTERE
00075800301, DOCETAXEL, TAXOTERE
00075800180, DOCETAXEL, TAXOTERE
00075800404, DOCETAXEL, TAXOTERE
00013733691, ETOPOSIDE, TOPOSAR
51285036801, METHOTREXATE, TREXALL
00555092901, METHOTREXATE, TREXALL
51285036901, METHOTREXATE, TREXALL
00555094501, METHOTREXATE, TREXALL
51285036601, METHOTREXATE, TREXALL
00555092701, METHOTREXATE, TREXALL
51285036701, METHOTREXATE, TREXALL
00555092801, METHOTREXATE, TREXALL
00015309145, ETOPOSIDE, VEPESID
00015309520, ETOPOSIDE, VEPESID
00015309595, ETOPOSIDE, VEPESID
00015308420, ETOPOSIDE, VEPESID
00015306220, ETOPOSIDE, VEPESID
00015306120, ETOPOSIDE, VEPESID
00173080409, PAZOPANIB, VOTRIENT
00173063225, LEUCOVORIN, WELLCOVORIN
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00173063155, LEUCOVORIN, WELLCOVORIN
00081063120, LEUCOVORIN, WELLCOVORIN
00173063120, LEUCOVORIN, WELLCOVORIN
54868414301, CAPECITABINE, XELODA
00004110051, CAPECITABINE, XELODA
00004110020, CAPECITABINE, XELODA
54868414300, CAPECITABINE, XELODA
68258903601, CAPECITABINE, XELODA
00004110175, CAPECITABINE, XELODA
00004110150, CAPECITABINE, XELODA
54868526002, CAPECITABINE, XELODA
54569571700, CAPECITABINE, XELODA
54868526004, CAPECITABINE, XELODA
54868526009, CAPECITABINE, XELODA
00004110116, CAPECITABINE, XELODA
54868526005, CAPECITABINE, XELODA
54868526000, CAPECITABINE, XELODA
54868526006, CAPECITABINE, XELODA
54868526001, CAPECITABINE, XELODA
54868526007, CAPECITABINE, XELODA
54868526008, CAPECITABINE, XELODA
54868526003, CAPECITABINE, XELODA
Any
immunotherapy

ICD-9-CM diagnosis code V58.12; ICD-9-CM procedure codes 00.15, 99.28;
HCPCS codes indicating immunotherapy J9015, J9214;
NDC codes in the Durable Medical Equipment or prescription drug event data files
indicating immunotherapy drugs :
NDC Code, Generic Name, Brand Name
00078049561, ALDESLEUKIN, PROLEUKIN
00085012002, INTERFERON ALFA 2B, INTRON-A
00085012003, INTERFERON ALFA 2B, INTRON-A
00085012004, INTERFERON ALFA 2B, INTRON-A
00085012005, INTERFERON ALFA 2B, INTRON-A
00085028502, INTERFERON ALFA 2B, INTRON-A
00085053901, INTERFERON ALFA 2B, INTRON-A
00085057102, INTERFERON ALFA 2B, INTRON-A
00085057106, INTERFERON ALFA 2B, INTRON-A
00085064703, INTERFERON ALFA 2B, INTRON-A
00085064704, INTERFERON ALFA 2B, INTRON-A
00085064705, INTERFERON ALFA 2B, INTRON-A
00085068901, INTERFERON ALFA 2B, INTRON-A
00085076901, INTERFERON ALFA 2B, INTRON-A
00085095301, INTERFERON ALFA 2B, INTRON-A
00085111001, INTERFERON ALFA 2B, INTRON-A
00085113301, INTERFERON ALFA 2B, INTRON-A
00085116801, INTERFERON ALFA 2B, INTRON-A
00085117901, INTERFERON ALFA 2B, INTRON-A
00085117902, INTERFERON ALFA 2B, INTRON-A
00085118401, INTERFERON ALFA 2B, INTRON-A
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00085118402, INTERFERON ALFA 2B, INTRON-A
00085119101, INTERFERON ALFA 2B, INTRON-A
00085119102, INTERFERON ALFA 2B, INTRON-A
00085123501, INTERFERON ALFA 2B, INTRON-A
00085124201, INTERFERON ALFA 2B, INTRON-A
00085125401, INTERFERON ALFA 2B, INTRON-A
00339650099, INTERFERON ALFA 2B, INTRON-A
00339650199, INTERFERON ALFA 2B, INTRON-A
00339650299, INTERFERON ALFA 2B, INTRON-A
00339650399, INTERFERON ALFA 2B, INTRON-A
00339651199, INTERFERON ALFA 2B, INTRON-A
00339651299, INTERFERON ALFA 2B, INTRON-A
53905099101, ALDESLEUKIN, PROLEUKIN
54868334100, INTERFERON ALFA 2B, INTRON-A
65483011607, ALDESLEUKIN, PROLEUKIN
ICD-9-CM procedure codes (55.4, 55.5, 55.51, 55.52, 55.53, 55.54) and Current
Procedural Terminology (CPT) procedure codes (50220, 50225, 50230, 50234,
50236, 50240, 50320, 50545, 50543, 50546).
ICD-9-CM diagnosis codes 250.xx
ICD-9-CM diagnosis codes 440.xx, 441.xx, 442.xx, 443.89, 444.xx, and 445.xx.
ICD-9-CM diagnosis codes 454, 454.0, 454.1, 454.2, 454.8, 454.9.
ICD-9-CM procedure codes (35.x, 36.x, 37.1x, 37.24, 37.25, 37.3x, 37.4x, 37.6x,
37.9x, 38.0x, 38.1x, 38.3x, 38.4x, 38.6x, 38.7x, 39.0x, 39.2x, 39.4x, 39.5x, 39.7x);
CPT codes 32160, 32658 – 3266, 33015, 33020, 33025, 33030, 33031, 33050,
33120, 33130, 33140, 33141, 33200 – 33203, 33206 – 33208, 33210 – 33218,
33220, 33222 – 33226, 33233 – 33238, 33240 – 33247, 33249 – 33251, 33253 –
33256, 33261, 33300, 33305, 33310, 33315, 33320 – 33322, 33330, 33332, 33335,
33400, 33401, 33403- 33406, 33410 – 33417, 33420, 33422, 33425 – 33427,
33430, 33460, 33463 – 33465, 33468, 33470 – 33472, 33474 – 33476, 33478,
33496, 33500 – 33508, 33510 – 33514, 33516 – 33519, 33521 – 33523, 33530,
33533 – 33536, 33542, 33545, 33548, 33572, 33600, 33602, 33606, 33608, 33610 33612, 33615, 33617, 33619, 33641, 33645, 33647, 33660, 33665, 33670, 33675 33677, 33681, 33684, 33688, 33690, 33692, 33694, 33697, 33702, 33710, 33720,
33722, 33724, 33726, 33730, 33732, 33735 - 33737, 33750, 33755, 33762, 33764,
33766 - 33768, 33770, 33771, 33774 - 33781, 33786, 33788, 33800, 33802, 33803,
33813, 33814, 33820, 33822, 33824, 33840, 33845, 33851 - 33853, 33860, 33861,
33863, 33870, 33875, 33877, 33880, 33881, 33883, 33884, 33886, 33889, 33891,
33910, 33915 - 33920, 33922, 33924 - 33926, 33940, 33960, 33961, 33967, 33968,
33970, 33971, 33973 - 33980, 33999, 34001, 34051, 34101, 34111, 34151, 34201,
34203, 34401, 34421, 34451, 34471, 34490, 34501, 34502, 34510, 34520, 34530,
34800, 34802 - 34805, 34808, 34812, 34813, 34820, 34825, 34826, 34830 - 34834,
34900, 35001, 35002, 35005, 35011, 35013, 35021, 35022, 35045, 35081, 35082,
35091, 35092, 35102, 35103, 35111, 35112, 35121, 35122, 35131, 35132, 35141,
35142, 35151, 35152, 35161, 35162, 35180, 35182, 35184, 35188, 35189, 35190,
35201, 35206, 35207, 35211, 35216, 35221, 35226, 35231, 35236, 35241, 35246,
35251, 35256, 35261, 35266, 35271, 35276, 35281, 35286, 35301, 35311, 35321,
35331, 35341, 35351, 35355, 35361, 35363, 35371, 35372, 35381, 35390, 35450,
35452, 35454, 35456, 35458, 35459, 35460, 35470 - 35476, 35480 - 35485, 35490 35495, 35500, 35501, 35506 - 35512, 35515, 35516, 35518, 35521, 35526, 35531,
35533, 35536, 35541, 35546, 35548, 35549, 35551, 35556, 35558, 35560, 35563,
35565, 35566, 35571, 35572, 35582, 35583, 35585, 35587, 35600, 35601, 35606,
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Placement of a
CVC
Kidney disease

Coding Definitions
35612, 35616, 35621, 35623, 35626, 35631, 35636, 35637, 35638, 35641, 35642,
35645, 35646, 35647, 35650, 35651, 35654, 35656, 35661, 35663, 35665, 35666,
35671, 35681 - 35683, 35685, 35686, 35691, 35693, 35694, 35695, 35700, 35701,
35721, 35741, 35761, 35800, 35820, 35840, 35860, 35870, 35875, 35876, 35879,
35881, 35883, 35884, 35900, 35901, 35903, 35905, 35907, 35910, 36260, 36261,
36262, 36470, 36471, 36800, 36810, 36815, 36818 - 36822, 36825, 36830 - 36835,
36860, 36861, 36870, 37140, 37145, 37160, 37180 - 37188, 37190, 37204 - 37208,
37500, 37565, 37600, 37605 - 37607, 37609, 37615 - 37618, 37620, 37650, 37660,
37788, 37790, 37799, 50100, 60600, 60605, 61609 - 61613, 61623, 61624, 61626,
61630, 61635, 61640 - 61642, 61680, 61682, 61684, 61686, 61690, 61692, 61697,
61698, 61700, 61702, 61703, 61705, 61708, 61710, 61711, 92961, 92970, 92971,
92975, 92977, 92986, 92987, 92990, 92992, 92993, 93536, 93580, 93581; and
HCPCS codes 0001T, 0002T, 0005T, 0033T, 0034T, 0035T, 0036T, 0037T,
G0269, G0297, G0298, G0299, G0300, G0365, M0301, S2130, S2131, S2204,
S2205, S2206, S2207, S2208, S2209.
HCPCS or CPT codes C1751, S5520, S5522, 36488, 36489, 36490, 36491, 36493,
36530, 36531, 36532, 36536, 36537, 36555, 36556, 36557, 36558, 36560, 36561,
36563, 36565, 36566, 36568, 36569, 36570, 36571, 36575, 36576, 36578, 36580,
36581, 36582, 36583, 36584, 36585, 36589, 36590, 36595, 36596, 36597, 75998
ICD-9-CM diagnosis codes 403, 403.0, 403.00, 403.01, 403.1, 403.10, 403.11,
403.9, 403.90, 403.91, 404, 404.0, 404.00, 404.01, 404.02, 404.03, 404.1, 404.10,
404.11, 404.12, 404.13, 404.9, 404.90 , 404.91 , 404.92, 404.93, 582 , 582.0, 582.1,
582.2, 582.4, 582.8, 582.81, 582.89, 582.9, 584, 584.5, 584.6, 584.7, 584.8, 584.9,
585, 585.1, 585.2, 585.3, 585.4 , 585.5, 585.6, 585.9, 586.
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Appendix C. Adapted Charlson Comorbidity Index
Note. Based on publically-available code retrieved from
http://www.appliedresearch.cancer.gov/seermedicare/program/charlson.comorbidity.macr
o.txt
Condition
Weight Codes
Diagnoses
Myocardial Infarction
Old Myocardial Infarction
Congestive Heart Failure
Peripheral Vascular Disease
Cerebrovascular Disease
Chronic Obstructive
Pulmonary Disease
Dementia
Paralysis
Diabetes
Diabetes with Sequelae
Chronic Renal Failure

1
1
1
1
1
1

Various Cirrhodites
Moderate to Severe Liver
Disease
Ulcers

1
3

Rheumatoid Arthritis

1

AIDS

6

Peripheral Vascular Disease

1

1
2
1
2
2

1

ICD-9-CM Diagnosis Codes
410 – 410.9
412
428 – 428.9
441-441.9, 443.9, 785.4, V43.4
430 – 437.9, 438
490 – 496.9, 500 – 505.9, 506.4
290-290.9
342-342.9, 344.1
250, 250.0-250.3, 250.7
250.4-250.6, 250.8-250.9
582-582.9, 583-583.9, 585, 586, 588588.9
571.2, 571.4, 571.5, 571.6
572.2-572.8, 456.0-456.1, 456.2, 456.20,
456.21
531-531.9, 532-532.9, 533-533.9, 534534.9
710.0, 710.1, 710.4 , 714.0-714.2, 714.81,
725
042.0 – 044.9

Procedures
ICD-9-CM Procedure codes:
381.3 , 381.4, 381.6, 381.8, 383.3, 383.4,
383.6, 383.8, 384.3, 384.4, 384.6, 384.8,
392.2-392.6, 392.8, 392.9
HCPCS:
'35011', '35013', '35045', '35081', '35082',
'35091', '35092', '35102', '35103', '35111',
'35112', '35121', '35122', '35131', '35132',
'35141', '35142', '35151', '35152', '35153',
'35311', '35321', '35331', '35341', '35351',
'35506', '35507', '35511', '35516', '35518',
'35521', '35526', '35531', '35533', '35536',
'35541', '35546', '35548', '35549',
'35551','35556', '35558', '35560', '35563',
'35565', '35566', '35571','35582', '35583',
'35585', '35587', '35601', '35606',
'35612','35616', '35621', '35623', '35626',
'35631', '35636', '35641','35646', '35650',
'35651', '35654', '35656', '35661',
'35663','35665', '35666', '35671', '35694',
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Cerebrovascular Disease

Moderate to Severe Liver
Disease

1

3

'35695', and '35355' to '35381'
ICD-9-CM Procedure codes:
381.2, 384.2
HCPCS:
'35301', '35001', '35002', '35005', '35501',
'35508', '35509', '35515', '35642', '35645',
'35691', '35693'
ICD-9-CM Procedure codes:
391, 429.1
HCPCS:
'37140', '37145', '37160', '37180', '37181',
'75885', '75887', '43204', '43205'
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Appendix D. Code to Calculate the Charlson Comorbidity Score Weights
Note. Publically available code retrieved from
http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html
/**********************************************************************
Changes have been made to the remove.ruleout.dxcodes.macro.txt on
July 22, 2010 to remove code (below) that made a selection
on HCPCS. Now all the claims are looked at for conditions.
if (&FILETYPE='M') or
('00100' <= &HCPCS <= '01999' or '10021' <= &HCPCS <= '69979' or
'77261' <= &HCPCS <= '79999' or
'90918' <= &HCPCS <= '91299' or '92950' <= &HCPCS <= '99199');
Please make sure you use the current remove.ruleout.dxcodes.macro.txt
before running this macro.
*****************************************************************
This SAS macro uses a dataset of claim records to calculate a
comorbidity index for a patient with respect to cancer. This code
reflects the Deyo adaptation of the Charlson comorbidity index, with
several procedure codes that reflect the Romano adaptation.
(NOTE: since cancer is the disease of interest, it is not included
in the comorbidity index given below.) The dataset must contain
lists of diagnosis and surgery codes. There are other specific
variables needed to complete this task.
In order to use this program:
1. Include this file in your SAS program
%include '/directory path/charlson.comorbidity.macro.sas';
2. Create a clean file of claim records to send to the macro.
If you wish to remove diagnoses for procedures done for
'rule out' purposes, you must do so externally to this macro.
(SEE remove.ruleout.dxcodes.macro.sas from SEER-Medicare web site)
You may include claim information from any file, including
MEDPAR, Outpatient SAF and Physicial/Supplier (NCH). All claim
records of interest should be included into the same file.
You must sort the claim records by your person identifier.
3. After setting up your data file, call the macro COMORB:
COMORB(ClmData, RegCase, Ind_Pri, LOS, dx01-dx10, 10, surg01-surg10, 10, HCPCS, Source)
would send the data set 'ClmData', sorted by the person
identifier 'RegCase' to the macro. The variable 'Ind_Pri'
must be set on each record as either index (I) or Prior event (P)
with respect to the cancer of interest. The number of
days for a hospital stay is found in the variable 'LOS'.
There are 10 diagnosis codes in the array variables 'dx01-dx10'.
Similarly, there are 10 surgery codes in the array variables
'surg01-surg10'. Diagnosis and surgery codes are in ICD-9 format.
HCPCS are the procedure codes from the SAF and NCH files. Only CPT-4
codes are used in this program. The file source of each claim
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record is found in the variable 'Source' (M=Medpar, O=Outpatient,
N=NCH).
This returns the data set COMORB which contains 1 record for each person
that had at least one claim record. The variables included in this data set are
the person identifier (in the example, RegCase), Charlson scores for
prior conditions, index conditions and prior+index conditions, and the
condition indicator flags for prior and for index time frames.
NCI usually uses PCHRLSON calculated using claims from
(Date of Diagnosis - 12 months) through (Date of DX - 1 month)
**********************************************************************/
/* internal macro to set indicators */
%MACRO FLAGSET(VAR,FLAG,NFLAGS,POSISHN);
&FLAG = &POSISHN;
&NFLAGS = &NFLAGS + 1;
&VAR = 1;
%MEND;
/* Main macro COMORB */
%MACRO
COMORB(SETIN,PATID,IDXPRI,DAYS,DXVARSTR,NDXVAR,SXVARSTR,NSXVAR,HCPCS,FILE
TYPE);
/**********************************************************************
SETIN: Dataset name: a dataset that contains the following:
PATID: Variable name: Unique ID for each patient. &SETIN must be
sorted by &PATID. There may be more than 1 record per patient.
IDXPRI: Variable name: indicates for each record if the Dx and Surg
codes are Index 'I' or Prior 'P' to the event of interest.
If the variable does not equal I or P, the record will not be
used. This variable should be set by the calling program.
DAYS: Variable name: contains the length of stay for hospital visits.
DXVARSTR: Variable names: the diagnosis codes in ICD-9, ie 'DX01-DX10'
NDXVAR: Number: the actual number of diagnosis codes in DXVARSTR
SXVARSTR: Variable names: the surgery codes in ICD-9, ie 'SURG01-SURG10'
NSXVAR: Number: the actual number of surgery codes in SXVARSTR
HCPCS: Variable name: the SAF and NCH file procedure codes in CPT-4.
FILETYPE: Variable name: the source of the claim record. Only important
value is 'M' for MEDPAR (inpatient hospital records). If this
is 'M', the check for Acute MI will include &DAYS > 2.
**********************************************************************/
DATA COMORB;
RETAIN CVPRIO01-CVPRIO18
CVINDX01-CVINDX18;
LENGTH DEFAULT=3;
SET &SETIN;
BY &PATID;
/* Flag arrays, diagnosis and surgery code arrays */
ARRAY CLPRIO (18) CVPRIO01-CVPRIO18;
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ARRAY CLINDX (18) CVINDX01-CVINDX18;
ARRAY COVAR (18) ACUTEMI OLDMI CHF VASCUL1 VASCUL2 CVD
PULMON1 DEMENTIA PARALYS DIABET1 DIABET3 RENAL1
LIVER1 LIVER2 ULCER1 ULCER2 RHEUM AIDS;
ARRAY FLAGS (*) FLAG01-FLAG18;
ARRAY DX (&NDXVAR) $ &DXVARSTR;
ARRAY SX (&NSXVAR) $ &SXVARSTR;
/* Initialization */
IF FIRST.&PATID THEN DO;
DO M=1 TO 18;
CLPRIO(M)=0;
CLINDX(M)=0;
END;
END;
DO M=1 TO 18;
COVAR(M)=0;
FLAGS(M)=0;
END;
NFLAGS=0;
/* Diagnosis code loop */
DO K=1 TO &NDXVAR;
dx_4 = substr(dx(k),1,4);
dx_3 = substr(dx(k),1,3);
/********** MYOCARDIAL INFARCTION WEIGHT = 1 ****************/
IF ACUTEMI=0 THEN DO;
IF dx_3 = '410' then do;
/* 410 thru 4109 */
IF ((&FILETYPE='M') & (&DAYS > 2)) | NOT (&FILETYPE='M') THEN DO;
%FLAGSET(ACUTEMI,FLAGS(NFLAGS+1),NFLAGS,1);
END;
END;
END;
IF OLDMI=0 THEN DO;
IF DX(K) = '412 ' then do;
%FLAGSET(OLDMI,FLAGS(NFLAGS+1),NFLAGS,2);
END;
END;
/********** CHF ***** WEIGHT = 1 ****************************/
IF CHF=0 THEN DO;
IF dx_3 = '428' then do;
/* 428 thru 4289 */
%FLAGSET(CHF,FLAGS(NFLAGS+1),NFLAGS,3);
END;
END;
/*********** PERIPHERAL VASCULAR DISEASE ******* WEIGHT = 1**/
IF VASCUL1=0 THEN DO;
/* 441 thru 4419 */

243
IF dx_3 = '441' | dx_4 in ('4439', '7854', 'V434', 'v434') then do;
%FLAGSET(VASCUL1,FLAGS(NFLAGS+1),NFLAGS,4);
END;
END;
/********* CEREBROVASCULAR DISEASE ******* WEIGHT = 1 *******/
IF CVD=0 THEN DO;
/* 430 thru 4379 */
IF '430' <= dx_3 <= '437' | DX(K)= '438 ' then do;
%FLAGSET(CVD,FLAGS(NFLAGS+1),NFLAGS,6);
END;
END;
/*********** COPD *********************** WEIGHT = 1 ********/
IF PULMON1=0 THEN DO;
IF '490' <= dx_3 <= '496' | '500' <= dx_3 <= '505' |
dx_4 = '5064' THEN DO;
%FLAGSET(PULMON1,FLAGS(NFLAGS+1),NFLAGS,7);
END;
END;
/******** DEMENTIA ****** WEIGHT = 1 ***********************/
IF DEMENTIA=0 THEN DO;
IF dx_3 = '290' then do;
/* 290 thru 2909 */
%FLAGSET(DEMENTIA,FLAGS(NFLAGS+1),NFLAGS,8);
END;
END;
/********* PARALYSIS **************** WEIGHT = 2 ************/
IF PARALYS=0 THEN DO;
IF dx_3 = '342' | dx_4 = '3441' then do;
/* 342 thru 3429 */
%FLAGSET(PARALYS,FLAGS(NFLAGS+1),NFLAGS,9);
END;
END;
/******** DIABETES ************* WEIGHT = 1 *****************/
IF DIABET1=0 THEN DO;
IF DX(K)= '250 ' | dx_4 = '2507' | '2500' <= dx_4 <= '2503' then do;
%FLAGSET(DIABET1,FLAGS(NFLAGS+1),NFLAGS,10);
END;
END;
/********* DIABETES WITH SEQUELAE ****** WEIGHT = 2 *********/
IF DIABET3=0 THEN DO;
IF ('2504' <= dx_4 <= '2506') | ('2508' <= dx_4 <= '2509') THEN DO;
%FLAGSET(DIABET3,FLAGS(NFLAGS+1),NFLAGS,11);
END;
END;
/********* CHRONIC RENAL FAILURE ******* WEIGHT = 2 *********/
IF RENAL1=0 THEN DO;
/* 582 - 5829; 583 - 5839, 588 - 5889 */
IF dx_3 in ('582', '583', '585', '586', '588') then do;
%FLAGSET(RENAL1,FLAGS(NFLAGS+1),NFLAGS,12);
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END;
END;
/************** VARIOUS CIRRHODITES ******** WEIGHT = 1 *****/
IF LIVER1=0 THEN DO;
/* includes 5714x ICD-9-CM codes */
IF dx_4 in ('5712', '5714', '5715', '5716') then do;
%FLAGSET(LIVER1,FLAGS(NFLAGS+1),NFLAGS,13);
END;
END;
/************** MODERATE-SEVERE LIVER DISEASE *** WEIGHT = 3*/
IF LIVER2=0 THEN DO;
IF ('5722' <= dx_4 <= '5728') | ('4560' <= dx_4 <= '4561') |
DX(K) in ('4562 ', '45620', '45621') THEN DO;
%FLAGSET(LIVER2,FLAGS(NFLAGS+1),NFLAGS,14);
END;
END;
/*************** ULCERS ********** WEIGHT = 1 ***************/
IF ULCER1=0 THEN DO;
IF '5310' <= dx_4 <= '5313' | '5320' <= dx_4 <= '5323' |
'5330' <= dx_4 <= '5333' | '5340' <= dx_4 <= '5343' |
dx_4 in ('531 ', '5319', '532 ', '5329', '533 ', '5339',
'534 ', '5349') THEN DO;
%FLAGSET(ULCER1,FLAGS(NFLAGS+1),NFLAGS,15);
END;
END;
IF ULCER2=0 THEN DO;
IF '5314' <= dx_4 <= '5317' | '5324' <= dx_4 <= '5327' |
'5334' <= dx_4 <= '5337' | '5344' <= dx_4 <= '5347' THEN DO;
%FLAGSET(ULCER2,FLAGS(NFLAGS+1),NFLAGS,16);
END;
END;
/*************** RHEUM ********** WEIGHT = 1 ***************/
IF RHEUM=0 THEN DO;
IF DX(K) in ('71481', '725 ', '7100 ', '7101 ', '7104 ') |
'7140' <= dx_4 <= '7142' THEN DO;
%FLAGSET(RHEUM,FLAGS(NFLAGS+1),NFLAGS,17);
END;
END;
/*************** AIDS ********** WEIGHT = 6 ***************/
IF AIDS=0 THEN DO;
IF '042' <= dx_3 <= '044' then do;
/* 042 thru 0449 */
%FLAGSET(AIDS,FLAGS(NFLAGS+1),NFLAGS,18);
END;
END;
END; /* end of Diagnosis code loop */
/* Surgery code loop */
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DO J=1 TO &NSXVAR;
/*********** PERIPHERAL VASCULAR DISEASE ******* WEIGHT = 1**/
IF VASCUL2=0 THEN DO;
IF SX(J) = '3813' | SX(J) = '3814' | SX(J) = '3816' |
SX(J) = '3818' | SX(J) = '3843' | SX(J) = '3844' |
SX(J) = '3846' | SX(J) = '3848' | SX(J) = '3833' |
SX(J) = '3834' | SX(J) = '3836' | SX(J) = '3838' |
'3922' <=SX(J)<= '3929' & SX(J) ^= '3927' THEN DO;
%FLAGSET(VASCUL2,FLAGS(NFLAGS+1),NFLAGS,5);
END;
END;
/********* CEREBROVASCULAR DISEASE ******* WEIGHT = 1 *******/
IF CVD=0 THEN DO;
IF SX(J) = '3812' | SX(J) = '3842' THEN DO;
%FLAGSET(CVD,FLAGS(NFLAGS+1),NFLAGS,6);
END;
END;
/************** MODERATE-SEVERE LIVER DISEASE *** WEIGHT = 3*/
IF LIVER2=0 THEN DO;
IF SX(J) = '391 ' | SX(J) = '4291' THEN DO;
%FLAGSET(LIVER2,FLAGS(NFLAGS+1),NFLAGS,14);
END;
END;
END; /* end of Surgery code loop */
/* HCPCS procedure code */
/*********** PERIPHERAL VASCULAR DISEASE ******* WEIGHT = 1**/
IF VASCUL2=0 THEN DO;
IF &HCPCS IN ('35011', '35013', '35045', '35081', '35082',
'35091', '35092', '35102', '35103', '35111', '35112', '35121',
'35122', '35131', '35132', '35141', '35142', '35151', '35152',
'35153', '35311', '35321', '35331', '35341', '35351', '35506',
'35507', '35511', '35516', '35518', '35521', '35526', '35531',
'35533', '35536', '35541', '35546', '35548', '35549', '35551',
'35556', '35558', '35560', '35563', '35565', '35566', '35571',
'35582', '35583', '35585', '35587', '35601', '35606', '35612',
'35616', '35621', '35623', '35626', '35631', '35636', '35641',
'35646', '35650', '35651', '35654', '35656', '35661', '35663',
'35665', '35666', '35671', '35694', '35695') OR
'35355' <= &HCPCS <= '35381'
THEN DO;
%FLAGSET(VASCUL2,FLAGS(NFLAGS+1),NFLAGS,5);
END;
END;
/********* CEREBROVASCULAR DISEASE ******* WEIGHT = 1 *******/
IF CVD=0 THEN DO;
IF &HCPCS IN ('35301', '35001', '35002', '35005', '35501', '35508',
'35509', '35515', '35642', '35645', '35691', '35693') THEN DO;
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%FLAGSET(CVD,FLAGS(NFLAGS+1),NFLAGS,6);
END;
END;
/************** MODERATE-SEVERE LIVER DISEASE *** WEIGHT = 3*/
IF LIVER2=0 THEN DO;
IF &HCPCS IN ('37140', '37145', '37160', '37180', '37181', '75885',
'75887', '43204', '43205') THEN DO;
%FLAGSET(LIVER2,FLAGS(NFLAGS+1),NFLAGS,14);
END;
END;
/* end HCPCS procedure code */
/* Use general indicators to turn on Prior and Index indicators */
IF NFLAGS > 0 THEN DO;
DO M=1 TO NFLAGS;
I=FLAGS(M);
IF COVAR(I) THEN DO;
IF &IDXPRI = 'P' THEN CLPRIO(I)=1;
ELSE IF &IDXPRI = 'I' THEN CLINDX(I)=1;
END;
END;
END;
IF LAST.&PATID THEN DO;
/* CALCULATE THE COEFFICIENT FOR PRIOR CONDITIONS ONLY */
PCHRLSON = (CVPRIO01 | CVPRIO02) +
(CVPRIO03) +
(CVPRIO04 | CVPRIO05) +
(CVPRIO06) +
(CVPRIO07) +
(CVPRIO08) +
((CVPRIO10) & ^(CVPRIO11)) +
((CVPRIO13) & ^(CVPRIO14)) +
(CVPRIO15 | CVPRIO16) +
(CVPRIO17) +
((CVPRIO09) * 2) +
((CVPRIO12) * 2) +
((CVPRIO11) * 2) +
((CVPRIO14) * 3) +
((CVPRIO18) * 6);
/* CALCULATE THE COEFFICIENT FOR PRIOR AND INDEX COND */
CHRLSON = (CVPRIO01 | CVPRIO02 | CVINDX02) +
(CVPRIO03) +
(CVPRIO04 | CVINDX04 | CVPRIO05 | CVINDX05) +
(CVPRIO06) +
(CVPRIO07 | CVINDX07) +
(CVPRIO08 | CVINDX08) +
((CVPRIO10 | CVINDX10) & ^(CVPRIO11 | CVINDX11)) +
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((CVPRIO13 | CVINDX13) & ^(CVPRIO14 | CVINDX14)) +
(CVPRIO15) +
((CVPRIO09) * 2) +
((CVPRIO12 | CVINDX12) * 2) +
((CVPRIO11 | CVINDX11) * 2) +
((CVPRIO14 | CVINDX14) * 3);
/* CALCULATE THE COEFFICIENT FOR INDEX CONDITIONS ONLY */
XCHRLSON = (CVINDX02) +
(CVINDX04 | CVINDX05) +
(CVINDX07) +
(CVINDX08) +
((CVINDX10) &^ (CVINDX11)) +
((CVINDX13) &^ (CVINDX14)) +
((CVINDX12) * 2) +
((CVINDX11) * 2) +
((CVINDX14) * 3);
OUTPUT;
END;
KEEP &PATID PCHRLSON CHRLSON XCHRLSON CVPRIO01-CVPRIO18 CVINDX01CVINDX18;
Label PCHRLSON = 'Prior Charlson comorbidity score'
CHRLSON = 'Prior+Index Charlson comorbidity score'
XCHRLSON = 'Index Charlson comorbidity score'
CVPRIO01 = 'Prior: MYOCARDIAL INFARCTION (1)'
CVPRIO02 = 'Prior: OLD MYOCARDIAL INFARCTION (1)'
CVPRIO03 = 'Prior: CHF (1)'
CVPRIO04 = 'Prior: PERIPHERAL VASCULAR DISEASE (DX, 1)'
CVPRIO05 = 'Prior: PERIPHERAL VASCULAR DISEASE (SURG, 1)'
CVPRIO06 = 'Prior: CEREBROVASCULAR DISEASE (1)'
CVPRIO07 = 'Prior: COPD (1)'
CVPRIO08 = 'Prior: DEMENTIA (1)'
CVPRIO09 = 'Prior: PARALYSIS (2)'
CVPRIO10 = 'Prior: DIABETES (1)'
CVPRIO11 = 'Prior: DIABETES WITH SEQUELAE (2)'
CVPRIO12 = 'Prior: CHRONIC RENAL FAILURE (2)'
CVPRIO13 = 'Prior: VARIOUS CIRRHODITES (1)'
CVPRIO14 = 'Prior: MODERATE-SEVERE LIVER DISEASE (3)'
CVPRIO15 = 'Prior: ULCERS1 (1)'
CVPRIO16 = 'Prior: ULCERS2 (1)'
CVPRIO17 = 'Prior: RHEUM (1)'
CVPRIO18 = 'Prior: AIDS (6)'
CVINDX01 = 'Index: MYOCARDIAL INFARCTION (1)'
CVINDX02 = 'Index: OLD MYOCARDIAL INFARCTION (1)'
CVINDX03 = 'Index: CHF (1)'
CVINDX04 = 'Index: PERIPHERAL VASCULAR DISEASE (DX, 1)'
CVINDX05 = 'Index: PERIPHERAL VASCULAR DISEASE (SURG, 1)'
CVINDX06 = 'Index: CEREBROVASCULAR DISEASE (1)'
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CVINDX07 = 'Index: COPD (1)'
CVINDX08 = 'Index: DEMENTIA (1)'
CVINDX09 = 'Index: PARALYSIS (2)'
CVINDX10 = 'Index: DIABETES (1)'
CVINDX11 = 'Index: DIABETES WITH SEQUELAE (2)'
CVINDX12 = 'Index: CHRONIC RENAL FAILURE (2)'
CVINDX13 = 'Index: VARIOUS CIRRHODITES (1)'
CVINDX14 = 'Index: MODERATE-SEVERE LIVER DISEASE (3)'
CVINDX15 = 'Index: ULCERS1 (1)'
CVINDX16 = 'Index: ULCERS2 (1)'
CVINDX17 = 'Index: RHEUM (1)'
CVINDX18 = 'Index: AIDS (6)'
;
run;
%MEND;
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Appendix E: Unadjusted Kaplan-Meier Survival Curves

Figure E1. Time to Any VTE in the year prior to index date by exposure status. Any ATE
= any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI =
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE
= venous thromboembolic event.
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Figure E2. Time to DVT in the year prior to index date by exposure status. Any ATE = any arterial
thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = myocardial
infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE = venous
thromboembolic event.
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Figure E3. Time to PE in the year prior to index date by exposure status. Any ATE = any
arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI =
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE
= venous thromboembolic event.
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Figure E4. Time to Other VTE in the year prior to index date by exposure status. Any ATE
= any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI =
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE
= venous thromboembolic event.
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Figure E5. Time to Any ATE in the year prior to index date by exposure status. Any ATE
= any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI =
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE
= venous thromboembolic event.
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Figure E6. Time to MI in the year prior to index date by exposure status. Any ATE = any
arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI =
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE
= venous thromboembolic event.
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Figure E7. Time to IS in the year prior to index date by exposure status. Any ATE = any
arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI =
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE
= venous thromboembolic event.
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Figure E8. Time to Any VTE in the follow-up period after index date by exposure status.
Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic
stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary
embolism; VTE = venous thromboembolic event.
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Figure E9. Time to DVT in the follow-up period after index date by exposure status. Any
ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke;
MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism;
VTE = venous thromboembolic event.
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Figure E10. Time to PE in the follow-up period after index date by exposure status. Any
ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke;
MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism;
VTE = venous thromboembolic event.
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Figure E11. Time to Other VTE in the follow-up period after index date by exposure
status. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E12. Time to Any ATE in the follow-up period after index date by exposure
status. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E13. Time to MI in the follow-up period after index date by exposure status. Any ATE = any arterial
thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = myocardial
infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE = venous
thromboembolic event.
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Figure E14. Time to IS in the follow-up period after index date by exposure status. Any
ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke;
MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism;
VTE = venous thromboembolic event.
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Figure E15. Time to Any VTE in kidney cancer patients in the follow-up period after index date by
histology group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis;
IS = ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E16. Time to DVT in kidney cancer patients in the follow-up period after index date by histology
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E17. Time to PE in kidney cancer patients in the follow-up period after index date by histology
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E18. Time to Other VTE in kidney cancer patients in the follow-up period after index date by
histology group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis;
IS = ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E19. Time to Any ATE in kidney cancer patients in the follow-up period after index date by
histology group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis;
IS = ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.

268

Figure E20. Time to MI in kidney cancer patients in the follow-up period after index date by histology
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.
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Figure E21. Time to IS in kidney cancer patients in the follow-up period after index date by histology
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS =
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE =
pulmonary embolism; VTE = venous thromboembolic event.

